2017 AES Annual Meeting Program Book by American Epilepsy Society

AES Program2017-Cover.qxp_Layout 1 10/31/17 10:25 AM Page 1

71ST ANNUAL MEETING | WALTER E. WASHINGTON CONVENTION CENTER

PROGRAM BOOK aesnet.org

FINE TUNED FOR THE NEXT GENERATION Envision the future for your patients at the

NEUROSPHERE

VISIT BOOTH #705 AES // DEC 1-5

Please note that this is a promotional, non-CME program and no CME credits will be given for attendance.

SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co. Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752 Â©2017 Sunovion Pharmaceuticals Inc. All rights reserved. 09/17 APT349-17

WHEN WOULD YOUR PATIENTS WANT A FULL THERAPEUTIC DOSE? NOW APPROVED AS

MONOTHERAPY

FOR PARTIAL-ONSET SEIZURES

BRIVIACT® (brivaracetam) CV THE ONE THAT STARTS DAY ONE. BRIVIACT® (brivaracetam) is indicated for the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. BRIVIACT® is now approved for monotherapy and adjunctive therapy dosing without titration. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS • Suicidal Behavior and Ideation: Antiepileptic drugs, including BRIVIACT, increase the risk of suicidal behavior and ideation. Monitor patients taking BRIVIACT for the emergence or worsening of depression; unusual changes in mood or behavior; or suicidal thoughts, behavior, or self-harm. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider. • Neurological Adverse Reactions: BRIVIACT causes somnolence, fatigue, dizziness, and disturbance in coordination. Somnolence and fatigue-related adverse reactions were reported in 25% of patients taking at least 50 mg per day of BRIVIACT compared to 14% of patients taking placebo. Dizziness and disturbance in gait and coordination were reported in 16% of patients taking at least 50 mg per day of BRIVIACT compared to 10% of patients taking placebo. The risk is greatest early in treatment but can occur at any time. Monitor patients for these signs and symptoms and advise them not to drive or operate machinery until they have gained sufficient experience on BRIVIACT. • Psychiatric Adverse Reactions: BRIVIACT causes psychiatric adverse reactions, including non-psychotic and psychotic symptoms. These events were reported in approximately 13% of patients taking at least 50 mg per day of BRIVIACT compared to 8% of patients taking placebo. A total of 1.7% of adult patients taking BRIVIACT discontinued treatment due to psychiatric reactions compared to 1.3% of patients taking placebo. Advise patients to report these symptoms immediately to a healthcare provider.

• Hypersensitivity: BRIVIACT can cause hypersensitivity reactions. Bronchospasm and angioedema have been reported. Discontinue BRIVIACT if a patient develops a hypersensitivity reaction after treatment. BRIVIACT is contraindicated in patients with a prior hypersensitivity reaction to brivaracetam or any of the inactive ingredients. • Withdrawal of Antiepileptic Drugs: As with all antiepileptic drugs, BRIVIACT should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. DOSING CONSIDERATIONS • Dose adjustments are recommended for patients with all stages of hepatic impairment. • When BRIVIACT is co-administered with rifampin, an increase in the BRIVIACT dose is recommended. ADVERSE REACTIONS The most common adverse reactions (at least 5% for BRIVIACT and at least 2% more frequently than placebo) are somnolence and sedation, dizziness, fatigue, and nausea and vomiting symptoms. BRIVIACT is a Schedule V controlled substance.

Please refer to the Brief Summary on the following pages, and visit www.BRIVIACTHCP.com to learn more.

52080_ucbbu_0041_AES_prg_ad_fa.indd 1

10/5/17 2:53 PM

The relative risk for suicidal thoughts or behavior was higher in clinical trials in patients with epilepsy than in clinical trials in patients with psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing BRIVIACT or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

BRIVIACT速 (brivaracetam) tablets, for oral use, BRIVIACT速 (brivaracetam) oral solution, BRIVIACT速 (brivaracetam) injection, for intravenous use, Brief Summary of Full Prescribing Information (See Package Insert for Full Prescribing Information) Rx Only

INDICATIONS AND USAGE

BRIVIACT速 (brivaracetam) is indicated for the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.

CONTRAINDICATIONS

Hypersensitivity to brivaracetam or any of the inactive ingredients in BRIVIACT (bronchospasm and angioedema have occurred) [see Warnings and Precautions].

WARNINGS AND PRECAUTIONS

Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including BRIVIACT, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (monoand adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drugtreated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 1 shows absolute and relative risk by indication for all evaluated AEDs. Table 1: Risk of Suicidal Thoughts or Behaviors by Indication for Antiepileptic Drugs in the Pooled Analysis Indication

Placebo Patients with Events Per 1000 Patients

Drug Patients with Events Per 1000 Patients

Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients

Risk Difference: Additional Drug Patients with Events Per 1000 Patients 2.4

Epilepsy

1.0

3.4

3.5

Psychiatric

5.7

8.5

1.5

2.9

Other

1.0

1.8

1.9

0.9

Total

2.4

4.3

1.8

1.9

52080_ucbbu_0041_AES_prg_ad_fa.indd 2

Neurological Adverse Reactions BRIVIACT causes somnolence, fatigue, dizziness, and disturbance in coordination. Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on BRIVIACT to gauge whether it adversely affects their ability to drive or operate machinery. Somnolence and Fatigue BRIVIACT causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy) [see Adverse Reactions]. In the Phase 3 controlled adjunctive epilepsy trials, these events were reported in 25% of patients randomized to receive BRIVIACT at least 50 mg/day (20% at 50 mg/day, 26% at 100 mg/day, and 27% at 200 mg/day) compared to 14% of patients who received placebo. The risk is greatest early in treatment but can occur at any time. Dizziness and Disturbance in Gait and Coordination BRIVIACT causes adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, vertigo, balance disorder, ataxia, nystagmus, gait disturbance, and abnormal coordination) [see Adverse Reactions]. In the Phase 3 controlled adjunctive epilepsy trials, these events were reported in 16% of patients randomized to receive BRIVIACT at least 50 mg/day compared to 10% of patients who received placebo. The risk is greatest early in treatment but can occur at any time. Psychiatric Adverse Reactions BRIVIACT causes psychiatric adverse reactions. In the Phase 3 controlled adjunctive epilepsy trials, psychiatric adverse reactions were reported in approximately 13% of patients who received BRIVIACT (at least 50 mg/day) compared to 8% of patients who received placebo. Psychiatric events included both non-psychotic symptoms (irritability, anxiety, nervousness, aggression, belligerence, anger, agitation, restlessness, depression, depressed mood, tearfulness, apathy, altered mood, mood swings, affect lability, psychomotor hyperactivity, abnormal behavior, and adjustment disorder) and psychotic symptoms (psychotic disorder along with hallucination, paranoia, acute psychosis, and psychotic behavior). A total of 1.7% of adult patients treated with BRIVIACT discontinued treatment because of psychiatric reactions compared to 1.3% of patients who received placebo. Hypersensitivity: Bronchospasm and Angioedema BRIVIACT can cause hypersensitivity reactions. Bronchospasm and angioedema have been reported in patients taking BRIVIACT. If a patient develops hypersensitivity reactions after treatment with BRIVIACT, the drug should be discontinued. BRIVIACT is contraindicated in patients with a prior hypersensitivity reaction to brivaracetam or any of the inactive ingredients [see Contraindications]. Withdrawal of Antiepileptic Drugs As with most antiepileptic drugs, BRIVIACT should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus [see Dosage and Administration and Clinical Studies]. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

10/5/17 2:53 PM

ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in labeling: • Suicidal Behavior and Ideation [see Warnings and Precautions] • Neurological Adverse Reactions [see Warnings and Precautions] • Psychiatric Adverse Reactions [see Warnings and Precautions] • Hypersensitivity: Bronchospasm and Angioedema [see Warnings and Precautions] • Withdrawal of Antiepileptic Drugs [see Warnings and Precautions] Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In all controlled and uncontrolled trials performed in adult epilepsy patients, BRIVIACT was administered as adjunctive therapy to 2437 patients. Of these patients, 1929 were treated for at least 6 months, 1500 for at least 12 months, 1056 for at least 24 months, and 758 for at least 36 months. A total of 1558 patients (1099 patients treated with BRIVIACT and 459 patients treated with placebo) constituted the safety population in the pooled analysis of Phase 3 placebo-controlled studies in patients with partial-onset seizures (Studies 1, 2, and 3) [see Clinical Studies]. The adverse reactions presented in Table 2 are based on this safety population; the median length of treatment in these studies was 12 weeks. Of the patients in those studies, approximately 51% were male, 74% were Caucasian, and the mean age was 38 years. In the Phase 3 controlled epilepsy studies, adverse events occurred in 68% of patients treated with BRIVIACT and 62% treated with placebo. The most common adverse reactions occurring at a frequency of at least 5% in patients treated with BRIVIACT doses of at least 50 mg/day and greater than placebo were somnolence and sedation (16%), dizziness (12%), fatigue (9%), and nausea and vomiting symptoms (5%). The discontinuation rates due to adverse events were 5%, 8%, and 7% for patients randomized to receive BRIVIACT at the recommended doses of 50 mg, 100 mg, and 200 mg/day, respectively, compared to 4% in patients randomized to receive placebo. Table 2 lists adverse reactions for BRIVIACT that occurred at least 2% more frequently for BRIVIACT doses of at least 50 mg/day than placebo. Table 2: Adverse Reactions in Pooled Placebo-Controlled Adjunctive Therapy Studies in Patients with Partial-Onset Seizures (BRIVIACT 50 mg/day, 100 mg/day, and 200 mg/day)

BRIVIACT (N=803) %

Placebo (N=459) %

Gastrointestinal disorders Nausea/vomiting symptoms

Constipation

Somnolence and sedation

Dizziness

Fatigue

Cerebellar coordination and balance disturbances*

Adverse Reactions

Nervous system disorders

Psychiatric disorders Irritability

*Cerebellar coordination and balance disturbances includes ataxia, balance disorder, coordination abnormal, and nystagmus. There was no apparent dose-dependent increase in adverse reactions listed in Table 2 with the exception of somnolence and sedation.

52080_ucbbu_0041_AES_prg_ad_fa.indd 3

Hematologic Abnormalities BRIVIACT can cause hematologic abnormalities. In the Phase 3 controlled adjunctive epilepsy studies, a total of 1.8% of BRIVIACTtreated patients and 1.1% of placebo-treated patients had at least one clinically significant decreased white blood cell count (<3.0 x 109/L), and 0.3% of BRIVIACT-treated patients and 0% of placebo-treated patients had at least one clinically significant decreased neutrophil count (<1.0 x 109/L). Adverse Reactions with BRIVIACT Injection Adverse reactions with BRIVIACT injection were generally similar to those observed with BRIVIACT tablets. Other adverse events that occurred in at least 3% of patients who received BRIVIACT injection included dysgeusia, euphoric mood, feeling drunk, and infusion site pain. Comparison by Sex There were no significant differences by sex in the incidence of adverse reactions.

DRUG INTERACTIONS

Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction [see Clinical Pharmacology]. Prescribers should increase the BRIVIACT dose by up to 100% (i.e., double the dosage) in patients while receiving concomitant treatment with rifampin [see Dosage and Administration]. Carbamazepine Co-administration with carbamazepine may increase exposure to carbamazepine-epoxide, the active metabolite of carbamazepine. Though available data did not reveal any safety concerns, if tolerability issues arise when co-administered, carbamazepine dose reduction should be considered [see Clinical Pharmacology]. Phenytoin Because BRIVIACT can increase plasma concentrations of phenytoin, phenytoin levels should be monitored in patients when concomitant BRIVIACT is added to or discontinued from ongoing phenytoin therapy [see Clinical Pharmacology]. Levetiracetam BRIVIACT provided no added therapeutic benefit to levetiracetam when the two drugs were co-administered [see Clinical Studies].

USE IN SPECIFIC POPULATIONS

Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as BRIVIACT, during pregnancy. Encourage patients who are taking BRIVIACT during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. Risk Summary There are no adequate data on the developmental risks associated with use of BRIVIACT in pregnant women. In animal studies, brivaracetam produced evidence of developmental toxicity (increased embryofetal mortality and decreased fetal body weights in rabbits; decreased growth, delayed sexual maturation, and long-term neurobehavioral changes in rat offspring) at maternal plasma exposures greater than clinical exposures [see Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data Oral administration of brivaracetam (0, 150, 300, or 600 mg/kg/ day) to pregnant rats during the period of organogenesis did not produce any significant maternal or embryofetal toxicity. The highest dose tested was associated with maternal plasma exposures (AUC) approximately 30 times exposures in humans at the maximum recommended dose (MRD) of 200 mg/day.

10/5/17 2:53 PM

Oral administration of brivaracetam (0, 30, 60, 120, or 240 mg/kg/ day) to pregnant rabbits during the period of organogenesis resulted in embryofetal mortality and decreased fetal body weights at the highest dose tested, which was also maternally toxic. The highest no-effect dose (120 mg/kg/day) was associated with maternal plasma exposures approximately 4 times human exposures at the MRD. When brivaracetam (0, 150, 300, or 600 mg/kg/day) was orally administered to rats throughout pregnancy and lactation, decreased growth, delayed sexual maturation (female), and long-term neurobehavioral changes were observed in the offspring at the highest dose. The highest no-effect dose (300 mg/kg/day) was associated with maternal plasma exposures approximately 7 times human exposures at the MRD. Brivaracetam was shown to readily cross the placenta in pregnant rats after a single oral (5 mg/kg) dose of 14C-brivaracetam. From 1 hour post dose, radioactivity levels in fetuses, amniotic fluid, and placenta were similar to those measured in maternal blood. Lactation Risk Summary No data are available regarding the presence of brivaracetam in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Studies in lactating rats have shown excretion of brivaracetam or metabolites in milk [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BRIVIACT and any potential adverse effects on the breastfed infant from BRIVIACT or from the underlying maternal condition. Data Animal Data Following a single oral (5 mg/kg) dose of 14C-brivaracetam to lactating rats, radioactivity was secreted in milk and rapidly reached levels similar to those in plasma. Pediatric Use Safety and effectiveness in adolescents 16 years of age have been established [see Clinical Studies]. Safety and effectiveness in pediatric patients below the age of 16 years have not been established. The potential adverse effects of brivaracetam on postnatal growth and development were investigated in juvenile rats and dogs. Oral administration (0, 150, 300, or 600 mg/kg/day) to rats during the neonatal and juvenile periods of development resulted in increased mortality, decreased body weight gain, delayed male sexual maturation, and adverse neurobehavioral effects at the highest dose tested and decreased brain size and weight at all doses. Therefore, a no-effect dose was not established; the lowest dose tested in juvenile rats was associated with plasma exposures (AUC) approximately 2 times those in adult humans at the maximum recommended dose (MRD) of 200 mg/day. In dogs, oral administration (0, 15, 30, or 100 mg/kg/day) throughout the neonatal and juvenile periods of development induced liver changes similar to those observed in adult animals at the highest dose but produced no adverse effects on growth, bone density or strength, neurological testing, or neuropathology evaluation. The overall no-effect dose (30 mg/kg/day) and the no-effect dose for adverse effects on developmental parameters (100 mg/kg/day) were associated with plasma exposures approximately equal to and 4 times, respectively, adult human exposures at the MRD.

Hepatic Impairment Because of increases in BRIVIACT exposure, dosage adjustment is recommended for all stages of hepatic impairment [see Dosage and Administration and Clinical Pharmacology].

DRUG ABUSE AND DEPENDENCE

Controlled Substance BRIVIACT contains brivaracetam and is listed as a Schedule V controlled substance. Abuse In a human abuse potential study, single doses of BRIVIACT at therapeutic and supratherapeutic doses were compared to alprazolam (C-IV) (1.5 mg and 3 mg). BRIVIACT at the recommended single dose (50 mg) caused fewer sedative and euphoric effects than alprazolam; however, BRIVIACT at supratherapeutic single doses (200 mg and 1000 mg) was similar to alprazolam on other measures of abuse. Dependence There was no evidence of physical dependence potential or a withdrawal syndrome with BRIVIACT in a pooled review of placebo-controlled adjunctive therapy studies [see Warnings and Precautions].

OVERDOSAGE

There is limited clinical experience with BRIVIACT overdose in humans. Somnolence and dizziness were reported in a patient taking a single dose of 1400 mg (14 times the highest recommended single dose) of BRIVIACT. The following adverse reactions were reported with BRIVIACT overdose: vertigo, balance disorder, fatigue, nausea, diplopia, anxiety, and bradycardia. In general, the adverse reactions associated with BRIVIACT overdose were consistent with the known adverse reactions. There is no specific antidote for overdose with BRIVIACT. In the event of overdose, standard medical practice for the management of any overdose should be used. An adequate airway, oxygenation, and ventilation should be ensured; monitoring of cardiac rate and rhythm and vital signs is recommended. A certified poison control center should be contacted for updated information on the management of overdose with BRIVIACT. There are no data on the removal of brivaracetam using hemodialysis, but because less than 10% of brivaracetam is excreted in urine, hemodialysis is not expected to enhance BRIVIACT clearance.

PATIENT COUNSELING INFORMATION

See Patient Counseling Information section and FDA-approved patient labeling (Medication Guide) in the Full Prescribing Information. BRIVIACT Tablets, BRIVIACT Oral Solution, and BRIVIACT Injection manufactured for UCB, Inc., Smyrna, GA 30080

Geriatric Use There were insufficient numbers of patients 65 years of age and older in the double-blind, placebo-controlled epilepsy trials (n=38) to allow adequate assessment of the effectiveness of BRIVIACT in this population. In general, dose selection for an elderly patient should be judicious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Clinical Pharmacology]. Renal Impairment Dose adjustments are not required for patients with impaired renal function. There are no data in patients with end-stage renal disease undergoing dialysis, and use of BRIVIACT is not recommended in this patient population [see Clinical Pharmacology].

52080_ucbbu_0041_AES_prg_ad_fa.indd 4

10/5/17 2:53 PM

VISIT SUPERNUS PHARMACEUTICALS AT BOOTH #327

Not actual test result, artist interpretation only

Come see what we're rolling out at booth #327... Get into the holiday spirit and join Supernus Pharmaceuticals in supporting the Epilepsy Foundation Get your Passport to Prizes stamped at booth #327 each day of the convention to be eligible for the daily prize drawing Supernus Pharmaceuticals will donate $10 to the Epilepsy Foundation for each cookie sticker pasted on our Holiday Cookie Wall For more information about Oxtellar XR®, visit www.OxtellarXR.com For more information about Trokendi XR®, visit www.TrokendiXR.com

Proudly supports the American Epilepsy Society 2017 Annual Meeting Trokendi XR and Oxtellar XR are registered trademarks of Supernus Pharmaceuticals, Inc. ©2017 Supernus Pharmaceuticals, Inc. All rights reserved. SPN.2017-0051

SPN2017-0051 AES GuideAd 2017.M01.indd 1

10/6/17 2:41 PM

WE DIDN’T DEVELOP AN AD FOR THIS PROGRAM BOOK. We are SK life science and we’ve been busy pursuing our passion— to unlock the mysteries of the brain. Visit Booth 815 to learn more about our commitment

to making life better for those affected by CNS diseases.

TUZI17CDPR6414_AES_Program_Book_Ad_r5.indd 1

www.SKlifescienceinc.com

10/2/17 11:15 AM

THE ONLY 100% EXTENDED-RELEASE BEAD FORMULATION OF TOPIRAMATE1,2

HELP PATIENTS

START, STAY SAVE! AND

ON QUDEXY® XR THERAPY

Simple to Prescribe Access Pathways offers co-pay assistance and administrative support to help your patients start, stay and save on Qudexy® XR therapy. You determine which patients are right for Qudexy® XR, and we’ll help with the rest. TM

Get Your Patients Started on Qudexy® XR Today! Visit hcp.QudexyXR.com/patient-support-savings or call 1-855-282-4887 Qudexy and Access Pathways are trademarks of Upsher-Smith Laboratories, LLC. References: 1. Qudexy® XR [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; March 2017. 2. Data on file. Maple Grove MN: Upsher-Smith Laboratories, LLC; 2017. © 2017 Upsher-Smith Laboratories, LLC, 6701 Evenstad Drive, Maple Grove, MN 55369 112575.01

112575-01-QXR-ReminderAd-AES-gray.indd 2

9/28/17 9:29 AM

AES 2017 Ad_8.5x11 rev 3.qxp_Layout 1 10/24/17 4:30 PM Page 1

Join us for a CME Dinner Symposium being held during the American Epilepsy Society (AES) 71st Annual Meeting 2017

DRAVET SYNDROME Emerging Insights, New Treatment Approaches

SUNDAY, DECEMBER 3, 2017 6:00 PM â&#x20AC;&#x201C; 8:00 PM Walter E. Washington Convention Center

Salon C, Street Level

PROGRAM CHAIR

PROGRAM OVERVIEW

PRE-REGISTER

Linda C. Laux, MD

Several investigational therapies of Dravet syndrome (DS) are in late-stage development with the potential to provide new treatment options to address the serious medical needs for patients with DS.

https://courses.elseviercme.com/aes2017

Medical Director Comprehensive Epilepsy Center Assistant Professor of Pediatrics Northwestern University Feinberg School of medicine Chicago, Illinois

Pre-registration does not guarantee seating. On-site registration may be available, space permitting. Fee Information There is no fee for attending this educational activity.

This activity has been approved for AMA PRA Category 1 Credit Tm.

Jointly provided by the Elsevier Office of Continuing medical Education and miller medical Communications, LLC. This live activity is supported by an independent educational grant from Zogenix, Inc. Opinions presented during Satellite CmE Symposia are those of the speakers and the ACCmE-accredited provider and are not a reflection of American Epilepsy Society (AES) opinions, nor are they supported, sponsored, or endorsed by the AES.

TABLE OF CONTENTS MEETING INFORMATION

MONDAY, DECEMBER 4

Welcome ............................................................................................10 General Information ......................................................................12 Schedule at a Glance ....................................................................18 AES Partner Events and Satellite Symposia ....................22 Maps and Floor Plans ..................................................................23 Special Interest Group Schedules..........................................28 Scientific Exhibits Schedules ..................................................30 Awards and Recognitions..........................................................32 Supporter Recognition Summary ........................................39 Education Credits..........................................................................42

Special Interest Groups ..............................................................69 Poster Session 3 ............................................................................70 Scientific Exhibits............................................................................71 Translational Research Symposium ..................................71 Special Interest Groups ..............................................................72 Lennox and Lombroso Lecture ............................................74 Pediatric Epilepsy Highlights Session..................................74 IOM/NASEM Epilepsy Updates ............................................74 Investigators Workshops............................................................75 Platform Sessions ..........................................................................76 Epilepsy Therapies Symposium ..........................................77

FRIDAY, DECEMBER 1 TUESDAY, DECEMBER 5

Epilepsy Specialist Symposium..............................................44 31st Annual Advances in the Management of Epilepsy and the Epilepsy Clinic ..................................44 Infantile Spasms Action Network (ISAN) Meeting........45 Annual Fundamentals Symposium ......................................45 Epilepsy Fellowship Program Directors Meeting ..........46 Special Interest Groups ..............................................................46 Career Pathways ............................................................................47 Spanish Symposium ....................................................................48 15th Judith Hoyer Lecture in Epilepsy ................................48 What AES Can Do for You: Professional Development Session....................................49 Basic Science Skills Workshop ..............................................49 Special Interest Groups ..............................................................50 Satellite Symposium ......................................................................51

Special Interest Groups ..............................................................78 Merritt-Putnam Symposium ................................................79 Pediatric State of the Art Symposium............................80 Skills Workshops ............................................................................81

EXHIBITORS Exhibitor Locations ......................................................................85 Exhibit Hall Map ............................................................................86 Epilepsy Resource Area..............................................................87 Innovation Pavilions......................................................................87 Exhibitors ..........................................................................................88 Exhibitors by Category ............................................................104

RECOGNITION Supporter Recognition ............................................................106 AES Research Funding Partners............................................121

SATURDAY, DECEMBER 2 Special Interest Groups ..............................................................52 Junior Investigators Roundtable Discussions ..................53 Presidential Symposium ............................................................54 Poster Session 1 ..............................................................................55 Epilepsy Foundation—Community of Practice ..............56 Scientific Symposium..............................................................56 Investigators Workshop..............................................................57 Hot Topics Symposium ..........................................................57 Interprofessional Care Symposium ......................................58

APPENDIX: MEETING REFERENCE Resources ........................................................................................122 Faculty Ready Room, Press Room, First Aid, Mother’s Room, Quiet Room, Coat and Luggage Check, SAE Zone, Lost and Found, Business Centers Guidelines and Policies..............................................................123 New day and time for 2017

SUNDAY, DECEMBER 3 AES Annual Business Meeting ................................................59 Scientific Exhibits ..........................................................................59 Annual Course ................................................................................59 Investigators Workshops ............................................................61 Investigators Workshops - Poster Session........................63 Poster Session 2 ............................................................................66 Special Interest Groups ..............................................................66 Satellite Symposia ........................................................................68 AES Attendee Reception ..........................................................68 AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

PRESIDENT’S WELCOME LETTER

On behalf of the AES Board of Directors, Annual Meeting and Scientific Program Committees, and staff, I am pleased to welcome you to our 71st Annual Meeting! Gathered together, here, in Washington, D.C., will be an extraordinary cross-section of our epilepsy community—clinicians, scientists, researchers, patient advocates, industry—all focused on the same goal: improving the treatment, care, and quality of life for people with epilepsy. The AES Annual Meeting is unique in convening such a diverse group, ranging from those early in their careers to the most seasoned of us, and in doing so fostering the formal and informal connections that will advance our collective efforts. I urge you to take advantage of the scheduled education, networking, and discussion opportunities, as well as the serendipitous hallway conversations and social interactions that build collaboration. As always, our symposia are central to the meeting, and will cover a range of advances and challenges. It is my privilege to convene the Presidential Symposium on Saturday morning. An outstanding panel will examine complex issues in epilepsy beyond seizure management, including transition from pediatric to adult care, potential cognitive decline following surgery, management of epilepsy during pregnancy, mood disorders and self-management, and overlapping mechanisms and therapies in epilepsy and neurodegenerative disorders like Alzheimer’s. See the welcome from our meeting chairs on the next page for additional details on the other symposia offered during the meeting. To round-out your Annual Meeting experience, take advantage of more than 30 special interest group (SIG) sessions featuring lively conversation on a variety of niche topics, 15 investigators workshops, and finally the skills workshops occurring on the last day of the meeting. Don't forget to make time for poster sessions, walking tours, and platform sessions, where you will be exposed to the most current epilepsy research. Finally, I urge you to make a new connection at the meeting this year—be it a peer who can answer a difficult clinical question, an up-and-coming young investigator eager to share new ideas, a patient advocate with a unique perspective on our shared goals, or a fellow attendee you have not met before. It's the personal connections that make this meeting special, and we're proud to offer professionals in our field the place and the opportunity to network and collaborate. I look forward to seeing you.

2017 BOARD OF DIRECTORS PRESIDENT Eli M. Mizrahi, M.D. FIRST VICE PRESIDENT Shlomo Shinnar, M.D., Ph.D. SECOND VICE PRESIDENT Page B. Pennell, M.D. TREASURER William H. Theodore, M.D. PRESIDENT EMERITUS Michael D. Privitera, M.D. BOARD MEMBERS Anne E. Anderson, M.D. Gregory K. Bergey, M.D. Douglas A. Coulter, Ph.D. Howard Goodkin, M.D., Ph.D. Robert Edward Hogan, M.D. Georgette (Gigi) Smith, Ph.D., RN, CPNP-PC EX-OFFICIO Eileen M. Murray, M.M., CAE Executive Director Barbara Dworetzky, M.D. Council on Clinical Activities Joseph I. Sirven, M.D. Council on Communications Elinor Ben-Menachem, M.D., Ph.D. Council on Education Amy Brooks-Kayal, M.D. Development Council Andres M. Kanner, M.D., FANA, FAAN Epilepsy Currents Cynthia L. Harden, M.D. Research and Training Council

Sincerely,

Sheryl Haut, M.D. North American Commission/ILAE

Eli M. Mizrahi, M.D. President

STAFF LIAISON Janice M. Mackovitch

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

WELCOME FROM THE CHAIRS

Welcome to Washington, D.C. for the 71st Annual Meeting of the American Epilepsy Society. The schedule of topics and activities presented at this year's Annual Meeting are the product of the suggestions from AES membership ... this truly is your meeting. We strive to make this a valuable forum for all constituencies that AES serves. The diversity of professionals in the Society makes our community unique. Washington, D.C. was founded with the intention of providing a capital city for all states, just as this meeting is convened with one common goal: to bring together individuals from every discipline in epilepsy and move toward eradicating the disease all together.

ABOUT AES Dedicated to eradicating epilepsy and its consequences. The American Epilepsy Society is a medical and scientific society whose members are engaged in research and clinical care for people with epilepsy. For more than 75 years, AES has provided a dynamic global

This meeting will offer many opportunities for scientific exchange, clinical education, increase of knowledge, and shared community.

forum where professionals from

Here are some highlights of the meeting:

industry can learn, share, and

Symposia: In addition to the Presidential Symposium highlighted on the previous page, other symposia will engage attendees in investigation of seizures originating in the insula, genetic testing in epilepsy, translational perspectives on sex differences in the neurobiology of epilepsy, new tools for diagnosis and treatment, interprofessional approaches to quality of life assessment and improvement for persons with epilepsy, diagnostic and treatment options across the lifespan, innovations in treatment options, examination of perspectives on efficient and effective translational research, epilepsy and it comorbidities, and clinical research advances for infantile spasms. Special Interest Groups and Investigators Workshops: Exchange thoughtprovoking ideas in open discussions and debate at the Special Interest Groups that span from global health to clinical epilepsy, or take a deep dive into everything from mechanisms to novel therapeutic strategies to computational modeling and genetics in the one of the Investigators Workshops. Poster Sessions: Donâ&#x20AC;&#x2122;t forget to come by for new and exciting research at the poster sessions! Your next big project may be rooted in a casual conversation. The always popular poster walking tours will be available Saturday, Sunday, and Monday.

academia, private practice, notfor-profit, government, and grow.

aesnet.org Executive Office 135 South LaSalle Street Suite 2850 Chicago, IL 60603 Tel: 312-883-3800

Career Development: There will be roundtables for junior investigators, sessions about career pathways in epilepsy care for fellows and other trainees, and sessions for professional development. Skills Workshops in Basic and Clinical Science: Increase your clinical and practical skills in one of these hands-on workshops! We sincerely hope you enjoy the meeting. Fred Lado, M.D., Ph.D. Annual Meeting Committee Chair Barbara C. Jobst, M.D., Ph.D. Annual Meeting Committee Vice Chair

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

GENERAL INFORMATION

The Annual Course encourages in-depth exploration of important topics related to epilepsy and focused on clinical care, including review of the science underlying the topics, clinical research, and discussion of the associated clinical implications. The Annual Course includes a mixture of educational lectures, clinical vignettes, and panel discussions.

Location The AES Annual Meeting will be held at the Walter E. Washington Convention Center.

Language The official language of the Annual Meeting is English.

Program Changes

Investigators Workshops highlight exciting developments in basic, translational, and clinical epilepsy research in a format promoting interactive discussion. Speakers include established and junior epilepsy investigators, as well as researchers from other fields.

AES cannot assume liability for any changes in the program due to external or unforeseen circumstances. For the most recent program information, visit the online Schedule At-A-Glance.

Skills Workshops deliver hands-on and interactive learning opportunities in focused clinical areas or basic science research skills. Attendance at each workshop is limited to a small number of participants to allow optimal interaction. Advanced registration and an additional fee are required.

About the Annual Meeting Sessions The AES Annual Meeting offers high-quality educational programming across diverse work settings, professional roles, and experience levels. Whether you are just starting out with the specialty, have a limited background in epilepsy, or are highly fluent with complex topics, you will find sessions and content relevant to your needs and interests.

The AES meeting offers many more opportunities for education and networking. Don’t miss sessions like the platform presentations poster sessions and other events from AES partners.

Symposia provide the major educational activities at the meeting. Topics range from clinically-oriented presentations, reviewing common issues in epilepsy, to more complex topics combining basic sciences and clinical neurology. While target audiences differ, all symposia include discussion of clinically-relevant information.

Target Audience Neurologists, epileptologists, pediatric neurologists, nurses, psychologists, neuropsychologists, nurse practitioners, physician assistants, pharmacists

Content Categories

• Symposia Handouts Handout materials for the educational symposia are available at aesnet.org/handouts. • Audience Response System AES uses an Audience Response System (ARS) in several of the symposia to increase the educational impact of these sessions. Faculty will have ARS questions throughout their presentations with multiple choice answers. Instructions will be provided during the sessions. Special Interest Groups (SIGs) offer information and networking for attendees with similar interests, in sessions organized by AES members. Although the sizes of SIG sessions vary, all lend themselves to active participation and dialogue.

The AES Annual Meeting offers high-quality educational content across diverse work settings, professional roles, and experience levels. Basic: Those new to epilepsy treatment or whose background in the specialty is limited, e.g. students, residents, general physicians, general neurologists and neurosurgeons, other professionals in epilepsy care, administrators Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons, and other providers with experience in epilepsy care (e.g. advanced practice nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic and translational researchers Advanced: Address highly technical or complex topics (e.g. neurophysiology, advanced imaging techniques, or advanced treatment modalities — including surgery)

Special Lectures recognize the accomplishments of distinguished leaders in clinical epilepsy and research. The Judith Hoyer Lecture in Epilepsy is delivered by an AES President Emeritus and the Lennox and Lombroso Lecture is given by an invited member who has greatly advanced the collective understanding of epilepsy.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

GENERAL INFORMATION

Making the Most of AES 2017

Wi-Fi Access Basic, complimentary wireless access is offered in several seating areas throughout the convention center. Visit the complimentary "Convention Center Connect" Lounges in the Grand Lobby, Concourse A, Concourse B, Metro Entrance, L Street Entrance near rooms 156 and 140 (across from 143C), Uptown Cafe and Downtown Cafe, 2nd and 3rd floor Wing seating areas.

Discover the Latest Research at Poster Sessions Providing a forum for the latest research, poster sessions feature accepted abstracts, encouraging interaction between presenters and attendees. First authors will be present each day from 12:00 (noon) – 2:00 PM.

Find Valuable Resources in the Exhibit Hall The Exhibit Hall is an integral part of the AES Annual Meeting experience, highlighting the latest and greatest in pharmaceuticals, publications, scientific equipment, and technology relevant to the field of epilepsy. Don't miss the grand opening celebration at noon on Saturday, supported by Sunovion Pharmaceuticals Inc.

Camera, Mobile Phone, and Video Recording Policies Annual Meeting attendees are strictly prohibited from photographing, filming, or recording educational sessions or posters at the meeting. Violation of this policy will result in removal from sessions and equipment will be confiscated.

To ensure safety and security, no children under 12 years of age, strollers, carriages, wheeled luggage, or wheeled briefcases are allowed in the Exhibit Hall during exhibit hours.

Material presented at the AES Annual Meeting is not to be reproduced in any format without the express written consent of AES. Attendees acknowledge and agree that commercial or promotional distribution, including publication or exploitation of speaker sessions, content, or materials from the AES Annual Meeting, is strictly prohibited unless you have received the express prior written permission from AES or the otherwise applicable rights holder.

Visit the Epilepsy Resource Area in the Exhibit Hall Members of the Epilepsy Leadership Council and other non-profit organizations doing important work in advocacy, patient outreach, and research will be exhibiting at the AES Exhibit Hall. Visit their booths or find their tables in the Epilepsy Resource Area near Innovation Pavilion F. Attend one of the mini-workshops in the new Discovery Center (Booth #1221—across from the AES Membership Booth) to network and hear about important developments, programs, and resources. A schedule will be posted near the entrance of that booth highlighting daily events.

In Memoriam

Attend the Scientific Exhibits AES has approved guidelines for industry-sponsored scientific exhibits at the Annual Meeting. Scientific exhibits differ from traditional poster presentations in that a broad range of material can be presented as a collection of topics, such as results of various clinical trials or a thematic presentation of one aspect of drug development.

Debra L. Gist, MPH, FACEHP 1953 - 2017 As you participate in the rich variety of medical education offered by AES this week, please pause to remember a leader and colleague who did so much to make this meeting a success.

Network with Your Colleagues Peer-to-peer networking is a longstanding tradition at the AES Annual Meeting. The meeting provides a unique forum for all professionals advancing research and patient care in epilepsy, a place to readily exchange ideas, practices, and experiences. Attendees often cite interacting with other professionals as a key benefit of attending the meeting.

Deb Gist served as the AES Director of Clinical Activities and Education until her untimely passing on October 3, 2017. We were extraordinarily privileged to work with someone who had earned such respect and stature in the medical education community. Deb took a wise and practical approach to juggling the demands of accreditation requirements with delivery of excellent educational content, and she was driven by a strong vision of the value of medical education in supporting improved patient care.

Get Connected at the Cyber Café The Cyber Café, supported by Sunovion Pharmaceuticals Inc., is located on the Exhibit Hall floor in the seating area, convenient to the food and beverage station near Booth #236. It is open during Exhibit Hall hours. The Café provides computers for complimentary access to email and the Internet, plus a printer for your convenience.

AES ANNUAL MEETING | meeting.aesnet.org

Deb admired all that each of you do every day as clinicians, and felt honored to support your efforts. We are deeply saddened and will miss her tremendously.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

GENERAL INFORMATION Exhibit Hall Events and Hours Refer to page 86 for a map of the Exhibit Hall.

Saturday, December 2, 12:00 PM – 6:00 PM Convention Center, Hall B 12:00 PM ......................................Grand Opening 12:00 PM – 6:00 PM................Cyber Café 12:00 PM – 6:00 PM................Selfie Station 12:00 PM – 1:00 PM ................Lunch 2:30 PM – 3:30 PM ..................Beverage Break 4:30 PM – 5:30 PM..................Symposia Break 5:00 PM..........................................Passport to Prizes Drawing

ENTER TO WIN GIFT CARDS, ELECTRONICS, AND MORE WITH PASSPORT TO PRIZES

Sunday, December 3, 10:00 AM – 4:00 PM

H Pick up your passport at the Registration Desk

Convention Center, Hall B

H Visit participating exhibitors and get your passport stamped

10:00 AM – 4:00 PM ..............Cyber Café 10:00 AM – 4:00 PM ..............Selfie Station 10:00 AM – 11:00 AM..............Beverage Break 12:00 PM – 1:00 PM ................Lunch 3:00 PM – 4:00 PM ................Beverage Break 3:00 PM..........................................Passport to Prizes Drawing

H Drop your completed passport at Eisai Inc., Booth #301

All prizes provided by AES

Eisai Inc. is the premier sponsor of the 2017 PASSPORT TO PRIZES.

Monday, December 4, 10:00 AM – 2:00 PM Convention Center, Hall B

You’re Invited

10:00 AM – 2:00 PM ..............Cyber Café 10:00 AM – 2:00 PM ..............Selfie Station 10:00 AM – 11:00 AM..............Beverage Break 12:00 PM – 1:00 PM ................Lunch 1:30 PM............................................Passport to Prizes Drawing

AES 6th Annual Wine Tasting And Silent Auction Sample extraordinary wines and delicious hors d'oeuvres. All proceeds benefit the Lennox and Lombroso Trust and the Susan S. Spencer Fund, which support AES research programs. Supported by LivaNova Saturday, December 2 7:00 PM - 10:00 PM Bobby Van’s Grill 1201 New York Avenue, N.W. $175 per ticket Tickets available at the AES meeting registration desk. Space is limited!

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

Your Guide

Your Way

Get the most up-to-date meeting information.

Customize your agenda by bookmarking sessions.

Find speakers, sessions, and posters with a quick search.

Access handouts, abstracts, and authors.

Locate meeting rooms, events, and exhibitors easily.

Network with colleagues, share photos, and rate programs.

Download the AES Annual Meeting App

AESnet.org/app App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google Inc.

Epilepsy Faces A Shortage Of Researchers It takes well-trained researchers to advance the understanding and treatment of epilepsy. Top-notch epilepsy researchers don’t just happen. The American Epilepsy Society provides grants, fellowships, training, and mentoring to encourage the best and brightest to study epilepsy. You can help us fill the epilepsy talent pipeline with scientists who are determined to find epilepsy answers. Today’s AES early career research and training program is an investment in tomorrow’s leading epilepsy researchers — and the game-changing discoveries they will make for people with epilepsy.

aesnet.org/research

135 S. LaSalle St., Suite 2850, Chicago, IL 60603

The Epilepsy Leadership Council (ELC) is a coalition of professional, governmental, and non-profit organizations representing patients with epilepsy and their families. The ELC is working collaboratively to support research and advocacy in order to improve the lives of individuals with epilepsy. Learn more at epilepsyleadershipcouncil.org

Centers for Disease Control and Prevention (CDC)

CSWS Epilepsy and Landau Kleffner Syndrome (ESES) Foundation

ÂŽ

National Institute of Neurological Disorders and Stroke (NINDS)

SCHEDULE AT A GLANCE THURSDAY, NOVEMBER 30 REGISTRATION

Convention Center Concourse B, Concourse Level

5:00 PM - 7:00 PM

FRIDAY, DECEMBER 1 REGISTRATION

Convention Center Concourse B, Concourse Level

7:00 AM - 5:00 PM 7:00 AM

8:00 AM

9:00 AM

10:00 AM

Epilepsy Specialist Symposium Convention Center, Ballroom A/B, Level 3 Details on page 44

11:00 AM

Noon

1:00 PM

2:00 PM

Annual Fundamentals Symposium Convention Center, Ballroom A/B, Level 3 Details on page 45

Epilepsy Fellowship Program Directors Meeting Convention Center, Room 202 A/B, Level 2 Details on page 46

3:00 PM

Special Interest Groups (concurrent) Convention Center, Concourse B, Concourse Level Details on page 46

Career Pathways 4:00 PM

5:00 PM

(concurrent) Details on page 47

Spanish Symposium Convention Center, Room 207 A/B, Level 2 Details on page 48

15th Judith Hoyer Lecture in Epilepsy Convention Center, Ballroom A/B, Level 3 Details on page 48

6:00 PM

What AES Can Do for You Basic Science Skills Workshops

7:00 PM

(concurrent) Details on page 49

Special Interest Groups (concurrent) Details on page 50

Convention Center, Room 201, Level 2, Details on page 49

8:00 PM

9:00 PM SYMBOL LEGEND Changed in 2017 â&#x20AC;&#x201C; Look for this symbol which indicates a program change (new day or time)

CME and CE credit

CME credit only

Additional fee to register

Session and event locations are subject to change. Please refer to the AES meeting app (aesnet.org/app) for the most up-to-date information and change notifications. Information current as of October 30, 2017.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SCHEDULE AT A GLANCE SATURDAY, DECEMBER 2 REGISTRATION

Convention Center Concourse B, Concourse Level

7:00 AM - 5:00 PM 7:00 AM

8:00 AM

Special Interest Groups

Junior Investigators Roundtable Discussions

(concurrent) Details on page 52

Convention Center, Salon B, Street Level Details on page 53

9:00 AM

10:00 AM

11:00 AM

Presidential Symposium Convention Center, Ballroom A/B, Level 3 Details on page 54

Noon

First Authors Present

1:00 PM

Details on page 55

2:00 PM

3:00 PM

4:00 PM

Exhibit Hall Open Scientific Symposium

Investigators Workshop

Convention Center, Ballroom A/B, Level 3 Details on page 56

Convention Center, Room 207 A/B, Level 2 Details on page 57

Interprofessional Care Symposium

Hot Topics Symposium

Poster Session 1 Convention Center, Hall B, Lower Level Details on page 55

Convention Center, Hall B, Lower Level Exhibitor information on page 85

5:00 PM

6:00 PM

7:00 PM

Convention Center, Ballroom C, Level 3 Details on page 58

Convention Center, Ballroom A/B, Level 3 Details on page 57

8:00 PM

9:00 PM

6th Annual AES Wine Tasting and Silent Auction Details on page 14

10:00 PM SYMBOL LEGEND Changed in 2017 â&#x20AC;&#x201C; Look for this symbol which indicates a program change (new day or time)

CME and CE credit

CME credit only

Additional fee to register

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SCHEDULE AT A GLANCE SUNDAY, DECEMBER 3 REGISTRATION

Convention Center Concourse B, Concourse Level

7:00 AM - 5:00 PM 7:00 AM

8:00 AM

AES Annual Business Mtg Details on page 59

9:00 AM

Annual Course 10:00 AM

Convention Center, Ballroom A/B, Level 3 Details on page 59

Poster Session 2 Convention Center, Hall B, Lower Level Details on page 66

11:00 AM

Investigators Workshops and Poster Session

Noon

(concurrent) Details on page 61

1:00 PM

Exhibit Hall Open First Authors Present Details on page 66

Convention Center, Hall B, Lower Level Exhibitor information on page 85

Scientific Exhibits Convention Center, Street Level (Concurrent) Details on page 59

2:00 PM

3:00 PM

4:00 PM

Annual Course, cont. Convention Center, Ballroom A/B, Level 3 Details on page 59

5:00 PM

6:00 PM

Special Interest Groups 7:00 PM

(Concurrent) Details on page 66

8:00 PM

9:00 PM

10:00 PM

Attendee Reception Details on page 68

11:00 PM SYMBOL LEGEND Changed in 2017 â&#x20AC;&#x201C; Look for this symbol which indicates a program change (new day or time)

CME and CE credit

CME credit only

Additional fee to register

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SCHEDULE AT A GLANCE MONDAY, DECEMBER 4 REGISTRATION

Convention Center Concourse B, Concourse Level

7:00 AM - 5:00 PM 7:00 AM

Special Interest Groups (Concurrent) Details on page 69

8:00 AM

Scientific Exhibits

9:00 AM

Special Interest Groups 10:00 AM

Translational Research Symposium

11:00 AM

Convention Center, Ballroom A/B, Level 3 Details on page 71

(Concurrent) Details on page 72

Convention Center, Street Level (Concurrent) Details on page 71

Poster Session 3 Convention Center, Hall B, Lower Level Details on page 70

Exhibit Hall Open Convention Center, Hall B, Lower Level Exhibitor information on page 85

Noon

First Authors Present

1:00 PM

Details on page 73 2:00 PM

3:00 PM

Lennox and Lombroso Lecture Convention Center, Ballroom A/B, Level 3, Details on page 74

4:00 PM

IOM/NASEM Epilepsy Update

5:00 PM

Convention Center, Ballroom C, Level 3 Details on page 74

Investigators Workshops (Concurrent) Details on page 75

Pediatric Epilepsy Highlights Session Convention Center, Room 147 A/B, Street Level Details on page 74

Platform Sessions (Concurrent) Details on page 76

6:00 PM

Epilepsy Therapies Symposium 7:00 PM

Convention Center, Ballroom A/B, Level 3 Details on page 77

8:00 PM

9:00 PM

10:00 PM SYMBOL LEGEND Changed in 2017 â&#x20AC;&#x201C; Look for this symbol which indicates a program change (new day or time)

CME and CE credit

CME credit only

Additional fee to register

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SCHEDULE AT A GLANCE TUESDAY, DECEMBER 5 REGISTRATION

Convention Center Concourse B, Concourse Level

7:00 AM - 1:15 PM 7:00 AM

Special Interest Groups (Concurrent) Details on page 78

8:00 AM

9:00 AM

Pediatric State of the Art Symposium

Merritt-Putnam Symposium

10:00 AM

Convention Center, Room 146, Street Level Details on page 80

Convention Center, Ballroom C, Level 3 Details on page 79

11:00 AM

Skills Workshops Session 1 Noon

1:00 PM

(Concurrent) Details on page 81

Skills Workshops Session 2 (Concurrent) Details on page 83

2:00 PM SYMBOL LEGEND Changed in 2017 – Look for this symbol which indicates a program change (new day or time)

CME and CE credit

CME credit only

Additional fee to register

AES PARTNER EVENTS AND SATELLITE SYMPOSIA See full details in daily listings. FRIDAY, DECEMBER 1

SATURDAY, DECEMBER 2

31st Annual Advances in the Management of Epilepsy and the Epilepsy Clinic 9:00 AM - 4:00 PM Marriott Marquis, Liberty Ballroom, Salons I-L, Level M4 Separate registration required.

Epilepsy Foundation—Community of Practice 2:00 PM - 6:00 PM Location to be posted in the mobile app By invitation only. SUNDAY, DECEMBER 3

Infantile Spasms Action Network (ISAN) Meeting 12:00 PM - 2:00 PM Location to be posted in the mobile app

Satellite Symposium Dravet Syndrome: Emerging Insights, New Treatment Approaches 6:00 PM - 8:00 PM Convention Center, Salon C, Street Level Separate registration required, dinner provided.

Satellite Symposium Looking Beyond the Seizure: Harnessing Recent Advances to Expedite Diagnosis and Optimize Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis—New Science & Encouraging Stories 6:00 PM - 8:00 PM Convention Center, Room 147, Street Level Separate registration required, dinner provided.

AES ANNUAL MEETING | meeting.aesnet.org

Satellite Symposium Patient and Caregiver Perspectives in Pediatric Epilepsy: Established Strategies and Emerging Approaches for Focal Seizures 6:00 PM - 8:00 PM Convention Center, Room 147, Street Level Separate registration required, dinner provided. 22

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

HOTEL AND EVENT MAP

HQ Hotel

1 H

Convention Center

The White House

Union Station

200 m

Marriott Marquis Washington, D.C. 901 Massachusetts Ave. N.W.

Cambria Hotel & Suites Washington, D.C. 899 O St. N.W.

Washington Marriott at Metro Center 775 12th St. N.W.

Morris-Clark Historic Hotel 1011 L St. N.W.

Renaissance Washington, D.C. Downtown 999 9th St. N.W.

Grand Hyatt Washington 1000 H St. N.W.

Hampton Inn Washington, D.C. Convention Center 901 6th St. N.W.

AES ANNUAL MEETING | meeting.aesnet.org

H 6th Annual AES Wine-Tasting and Silent Auction Bobby Van's Grill 1201 New York Ave. N.W.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

WALTER E. WASHINGTON CONVENTION CENTER

L STREET, ABOVE

Concourse (Level C) 7TH STREET, ABOVE

HALL B Exhibit Hall & Poster Sessions

Down to Hall B

MOUNT VERNON PLACE, ABOVE

M STREET, ABOVE

Exhibit Hall B Registration

HALL A

Entrance

M STREET, ABOVE

REGISTRATION Concourse B

Connector to Marriott Marquis Rotunda B

9TH STREET, ABOVE

Up to: • Coat and Luggage Check • Grand Lobby • Scientific Exhibits • Session Rooms

Up to: • Coat and Luggage Check • Scientific Exhibits • Session Rooms

Street Level (Level 1)

ROOM 101

ROOM 102 A&B

ROOM 145A

GRAND LOBBY

TO RENAISSANCE HOTEL

DOWN TO HALL B AND MARRIOTT

BUSINESS CENTER

COMPASS COFFEE

TO HALL B VIA CONCOURSE

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

ROOM 145B

MOUNT VERNON PLACE

ROOM 147 A&B

SALONS D, E, F

SALONS A, B, C COAT CHECK

Business Center Coat and Luggage Check Quiet Room Scientific Exhibits Session Rooms

WALTER E. WASHINGTON CONVENTION CENTER 7TH STREET, BELOW

Level Two (Level 2)

ROOM FIRST AID MOTHERS ROOM 205

East Overlook Faculty Ready Room 208 Meeting Rooms 201-210

L STREET BRIDGE

MOUNT VERNON PLACE, BELOW

EAST OVERLOOK

ELEVATORS

FACULTY READY ROOM

ROOM 208A

ELEVATORS

9TH STREET, BELOW

Level Three

ROOM 301

(Level 3) PRESS ROOM

Ballroom A/B General Sessions Ballroom C Meeting Rooms 301-306 Press Room 301 SAE Zone Room 306

ELEVATORS

Ballroom C

MOUNT VERNON PLACE, BELOW

Ballroom A/B General Sessions

ELEVATORS

SAE ZONE ROOM 306

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MARRIOTT MARQUIS WASHINGTON D.C. Meeting Level Two (M2) (Two levels below lobby) Access to concourse to convention center

SALON 7

SALON 4

MARQUIS BALLROOM

SALON 3

SALON 8 SALON 5

SALON 6

SALON 11

ESCALATOR, ELEVATOR AND STAIRWAY ACCESS TO THE CONCOURSE TO WALTER E. WASHINGTON CONVENTION CENTER

SALON 9

SALON 2

SALON 10

SALON 1 M

ELEVATORS

ESCALATORS

SALON 12

SALON 13

SALON 14

SALON 15

SALON 16

SALON 17

Meeting Level Three (M3) (Three levels below lobby) Up one floor to Meeting Level Two (M2) and access to convention center ANACOSTIA

ADAMS MORGAN CAPITOL HILL

DUPONT CIRCLE

EASTERN MARKET

GALLERY PLACE

Lâ&#x20AC;&#x2122;ENFANT PLAZA

AES ANNUAL MEETING | meeting.aesnet.org

ELEVATORS

LEDROIT PARK

JUDICIARY SQUARE

ESCALATORS

SHAW W

PENN QUARTER

WOODLEY PARK

ELEVATORS

FARRAGUT NORTH

MOUNT VERNON SQUARE

CHINATOWN

UNION STATION

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MARRIOTT MARQUIS WASHINGTON D.C. Meeting Level Four (M4) (Four levels below lobby) Up two floors to Meeting Level Three (M3) and access to convention center

SUPREME COURT

SALON P

SENATE

SALON O

MONUMENT

SALON N

SALON H

SALON G

SALON F

SALON M

SALON E

LIBERTY BALLROOM

INDEPENDENCE BALLROOM

SALON L

SALON D

SALON K

SALON J

SALON I

SALON C

SALON B

SALON A M

F D

ELEVATORS

PENTAGON

CONGRESS

CAPITOL

MINT

ESCALATORS

TREASURY

ARCHIVES

F D

W F D

AES ANNUAL MEETING | meeting.aesnet.org

W F D

F D

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SPECIAL INTEREST GROUP SCHEDULES Friday, December 1, 1:30 PM – 3:00 PM

Monday, December 4, 7:00 AM – 8:30 AM

Details available on page 46

Details available on page 69

Critical Care Epilepsy Convention Center, Room 146 B, Street Level

Basic Mechanisms and Neuroscience Convention Center, Salon C, Street Level

Data Science in Epilepsy Convention Center, Room 204 A/B, Level 2

Ictal Semiology Convention Center, Room 146 B/C, Street Level

Genetics Convention Center, Room 102 B, Street Level

Neonatal Seizures Convention Center, Room 202 A, Level 2

Private Practice Epilepsy Convention Center, Room 102 A, Street Level

Psychosocial Comorbidities Convention Center, Room 146 A, Street Level

Quality, Value, and Safety in Epilepsy Convention Center, Room 101, Street Level

Seizures and Cerebrovascular Disease Convention Center, Room 202 B, Level 2 Temporal Lobe Club Convention Center, Room 147 A/B, Street Level

Friday, December 1, 6:00 PM – 7:30 PM Details available on page 50

Monday, December 4, 9:00 AM – 10:30 AM

Epilepsy Education Convention Center, Room 101, Street Level

Details available on page 72

NIH and Non-Profit Research Resources/Junior Investigator Workshop Convention Center, Room 102 B, Street Level

Engineering and Neurostimulation Convention Center, Room 146 B/C, Street Level Global Pregnancy Registry Outcomes Convention Center, Room 204 A/B, Level 2

Pediatric Epilepsy Case Discussions Convention Center, Room 146 A, Street Level

Neuropharmacology Convention Center, Salon C, Street Level

Psychogenic Non-epileptic Seizures (PNES) Convention Center, Salon C, Street Level

Neuropsychology Convention Center, Room 147 A/B, Street Level

Sleep and Epilepsy Convention Center, Room 146 B/C, Street Level

Nursing Convention Center, Room 204 C, Level 2

Saturday, December 2, 7:00 AM – 8:30 AM

Scientific Publishing Convention Center, Room 202 B, Level 2

Details available on page 52 Epidemiology Convention Center, Room 102 B, Street Level

Tuesday, December 5, 7:00 AM – 8:30 AM

Global Health Convention Center, Room 101, Street Level

Details available on page 78 Children's Hour Convention Center, Salon C, Street Level

MEG / MSI Convention Center, Salon C, Street Level

Dietary Therapies Convention Center, Room 101, Street Level

Practice Management Convention Center, Room 204 A/B, Level 2

Frontal Lobe Epilepsy Convention Center, Room 102 B, Street Level

SUDEP Convention Center, Room 146 B/C, Street Level

Neuroendocrinology Convention Center, Room 204 A/B, Level 2

Tuberous Sclerosis Convention Center, Room 147 A/B, Street Level

Neuroimaging Convention Center, Room 147 A/B, Street Level

Sunday, December 3, 6:00 PM – 7:30 PM Details available on page 66 Cognitive and Behavioral Treatment Convention Center, Room 201, Level 2 EEG Convention Center, Room 146 A, Street Level Epilepsy and Aging Convention Center, Room 202 A, Level 2 Epilepsy Surgery Convention Center, Room 146 B/C, Street Level Tumor-Related Epilepsy Convention Center, Room 202 B, Level 2 AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

Poster Walking Tours Saturday, Sunday, and Monday 12:15 PM to 1:45 PM

Annual Meeting Abstracts Database

Convention Center, Hall B, Lower Level Join leading experts as they spotlight interesting posters and facilitate discussion with authors, gaining new and different perspectives on the data presented.

Find all the 2017 poster session abstracts online â&#x20AC;&#x201D; searching by authors, topic, title, and more.

To join a walking tour, gather at the poster information table near booth #1305 and poster board #001. A schedule of topics and tour leaders will be available.

Plus, the AES online abstract database includes an archive going back to 2007.

POSTER SESSION 1: SATURDAY, DECEMBER 2 Tour Leaders: Jean Gotman, Ph.D., Ilo Leppik, M.D., Andres M. Kanner, M.D., FANA, FAAN, and Elaine Wirrell, M.D.

Get started at a e s n e t .o rg /a b st ra c t s

POSTER SESSION 2: SUNDAY, DECEMBER 3 Tour Leaders: Peter Crino, M.D., Jacqueline A. French, M.D., Bruce Hermann, Ph.D., and Paul Van Ness, M.D.

Abstract search for the 2017 meeting is supported by Greenwichâ&#x201E;˘ Biosciences.

POSTER SESSION 3: MONDAY, DECEMBER 4 Tour Leaders: Anne Anderson, M.D., Greg Bergey, M.D., Eric Kossoff, M.D., Kimford Meador, M.D., and Dennis Spencer, M.D. Please note: Poster tour leaders are subject to change.

2017- 2018 AES Fellows Program The AES Fellows Program welcomes 100 clinical fellows and fields such as nursing, pharmacology, pharmacy, psychology, and

The 2017-2018 AES Fellows Program is supported in part by educational grants from:

basic sciences to the 2017 Annual Meeting.

Eisai Inc.

Participants will:

Lundbeck

postdoctoral research fellows and trainees with advanced degrees in

> Learn about advances in epilepsy care and research

Upsher-Smith Laboratories, Inc.

> Engage with expert mentors and peers

Greenwich Biosciences, Inc.

> Attend sessions highlighting career paths

Sage Therapeutics

> Participate in educational sessions

Sunovion Pharmaceuticals Inc.

To learn more about the program and the application process, visit aesnet.org

AES ANNUAL MEETING | meeting.aesnet.org

Supernus Pharmaceuticals, Inc.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SCIENTIFIC EXHIBITS SCHEDULES These exhibits provide meeting attendees an opportunity stay current on the latest epilepsy research. Authors will be present throughout the entire exhibit window. Convention Center, Rooms 101, 102 B, Salon A, and Salon B, Street Level

Sunday, December 3, 8:00 AM - 11:00 AM

Sunday, December 3, 2:00 PM - 5:00 PM

Research Updates for Epilepsy Eisai Inc. Convention Center, Salon B, Street Level

Aptiom® (eslicarbazepine acetate) Scientific Exhibit Sunovion Pharmaceuticals Inc. Convention Center, Salon B, Street Level

Supporting Adult and Pediatric Epilepsy Care: Research Updates from Lundbeck Lundbeck Convention Center, Salon A, Street Level

UCB Epilepsy Heritage UCB, Inc. Convention Center, 101, Street Level

Monday, December 4, 8:00 AM - 11:00 AM Sunday, December 3, 8:00 AM - 5:00 PM Advancing Cannabidiol as a Treatment for Epilepsy: GWPCARE Phase III Trials and Long-term Results Greenwich Biosciences, Inc. Convention Center, Salon B, Street Level

Low-Dose Fenfluramine: An Update on Mechanisms, Efficacy, and Safety in the Treatment of Epileptic Encephalopathies Zogenix, Inc. Convention Center, 102 B, Street Level

UCB Commitment to Science UCB, Inc. Convention Center, Salon A, Street Level

Interact and Learn at AES Discovery Center With lively talks and networking, the AES Discovery Center directly connects you with experts, advocates, and colleagues. The interaction all takes place at Booth #1221, across from the AES Membership Booth. DYNAMIC TALKS

SPEED NETWORKING

Join half-hour interactive talks with pharmaceutical and patient advocacy experts. Presenting organizations include: • Lundbeck • NINDS, Division of Translational Research • Rare Epilepsy Network • Citizens United for Research in Epilepsy (CURE) • TESS Foundation • EpiNet Study Group • Glut1 Deficiency Foundation • Tuberous Sclerosis Alliance • International Foundation for CDKL5 Research • Seizure Tracker • Epilepsy Foundation • VA Epilepsy Centers of Excellence • Child Neurology Foundation • Managing Epilepsy Well Network

Supported by Eisai Inc. Participate in these fun and quickly-moving networking events. And leave with new friends, fresh ideas, and important professional contacts. Pick the session that best fits your interests: Saturday, 3:00 – 4:00 PM Career Development and Transition Sunday, 11:00 AM – 12:00 PM Translating Discovery to Delivery Sunday, 2:00 – 3:00 PM Exploratory Research and Innovation Arrive early as space is limited. First come, first served.

Get the complete schedule with times and topics at the AES booth, on signs in Booth #1221, and in your mobile app.

Open during Exhibit Hall hours. These events do not include CME credits.

Booth #1221 in the Exhibit Hall AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AWARD RECIPIENTS AES selects recipients for the following travel awards based on the scientific merit of submitted abstracts. Congratulations to this yearâ&#x20AC;&#x2122;s travel award winners.

Suzanne and Peter Berry International Travel Awardees This award recognizes and honors two young investigators conducting clinical neuroscience research related to epilepsy in Asia, Africa, Oceania, the Middle East, or Latin America. Awardees receive $1,000 travel stipend along with complimentary meeting registration. Contact Author

Abstract Title

Mistuyoshi Nakatani, M.D.

Electric cortical stimulation inhibits interictal epileptiform discharge and related high frequency activity in human epileptic focus

Poster/Platform

Genevieve Rayner, M.Psych., Ph.D.

MRI-negative TLE is not cognitively benign: looking beyond lesions for causes of neuropsychological impairment

1.124

1.354

Grass Travel Awardees This award recognizes and honors outstanding young investigators conducting research in basic or clinical neuroscience related to epilepsy. The Grass Foundation and AES combine resources to provide awardees with a $1,000 travel stipend and complimentary meeting registration. Contact Author

Abstract Title

Poster/Platform

Joseph Symonds, B.Sc., MBChB. MRCPCH

Scottish whole population based prospective genetic and autoimmune testing in new onset epilepsy and complex febrile seizures in children <3 years: diagnostic and clinical utility

2.386|A.07

Cristina Reschke, B.Sc., PharmD., M.Sc., Ph.D. Potent disease-modifying effects of systemicallydelivered microRNA inhibitor in experimental epilepsy

3.027

Antonella Pirone, Ph.D.

Altered cortical-striatal circuits in a new genetically modified mouse model of infantile spasms and seizures

3.031

Adam Kney, M.D.

Epileptiform activity on follow up EEG at the time of successful treatment is associated with relapse in infantile spasms: Prospective study

1.210

Lin Li, Ph.D.

Propagation and development of ictal discharges generated in an acute experimental epileptic focus

3.032

Krithiga Sekar, M.D., Ph.D.

Favorable outcome in patients with spontaneous burst suppression after cardiac arrest

1.097

Matea Rados, M.D.

Comparison of subdural grid electrodes and stereoelectroencephalography in patients with refractory epilepsy in three large European centers

2.354

Richard Burman, BMedSci

The role of excitatory GABAergic signaling on benzodiazepine efficacy during prolonged seizure activity

3.026

Young Investigator Award This award recognizes young investigators conducting basic, translational, or clinical epilepsy research. Awardees receive a $1,200 travel stipend. The AES Young Investigator Awards are supported in part by a charitable grant from Medtronic. Contact Author

Abstract Title

Amir Al-Bakri, Ph.D.

Detection of rhythmic high frequency oscillations on surface EEG in patients with refractory epilepsy

3.017

Chase Carver, Ph.D.

Significance of M-type potassium channels in the dentate gyrus in contribution to neuronal excitability and seizure

1.007

AES ANNUAL MEETING | meeting.aesnet.org

Poster/Platform

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AWARD RECIPIENTS Contact Author

Abstract Title

Gemma Carvill, Ph.D.

A recurrent missense variant in the transcription factor and upper layer neuronal marker, CUX2, causes developmental and epileptic encephalopathy

2.375

Wu Chen, Ph.D.

Stxbp1 haploinsufficient mice recapitulate many features of STXBP1 encephalopathy

1.039

Marian Galovic, M.D.

NMDA-receptor activation measured with [18F]GE-179 PET lateralizes and localizes the epileptic focus

1.244

Akshay Gupta, M.D.

Developmental trajectory of tonic GABA currents contribute to maturation of membrane properties in dentate semilunar granule cells

Jacob Hull, B.S.

Axonal and somatic sodium current defects in a cell type specific and development independent model of SCN1B-linked Dravet Syndrome

3.011|B.05

Nikola Jancovski, Ph.D.

Mouse model of myoclonus epilepsy and ataxia due to potassium channel mutation

1.138

Harper Kaye, B.A.

Cortical maturation metrics obtained by neuronavigated transcranial magnetic stimulation (nTMS) in patients with intractable focal epilepsy

3.110|B.08

Hyun Yong Koh, M.D., Ph.D.

BRAF somatic mutation in developing neurons underlies the intrinsic REST mediated epileptogenicity in long-term epilepsy-associated tumors (LEATs)

1.013

Zachery Koneval, B.S.

Lamotrigine-resistant corneal kindled mice: a model of pharmacoresistant partial seizures for moderatethroughput drug discovery

1.037

William Nobis, M.D., Ph.D.

Breathing and the amygdala: potential implications for SUDEP

1.056

Ahyuda Oh, DDS, MBA, DrPH

Independent role of neonatal seizures in developing epilepsy and neurocognitive disorders

1.405

Mangor Pedersen, Ph.D.

Patient-specific brain abnormalities in refractory focal epilepsy: Adjusted Local Connectivity (ALC)

Christina Pressl, M.D., M.S.

Resting state functional connectivity patterns are associated with pharmacological response in temporal lobe epilepsy

1.247

Karim ReFaey, M.D.

Effect of intraoperative high-density-ECoG on surgical outcome after awake craniotomies

3.112|B.09

Ashley Reynolds (Helseth), M.D., Ph.D.

A mouse model of a human ATP1A3 mutation emulates the most severe phenotype of alternating hemiplegia of childhood: characterization and response to therapy

3.035

Tristan Sands, M.D., Ph.D.

Autism with benzodiazepine-responsive electrical status epilepticus in sleep (ESES) caused by KCNQ3 gain-of-function variants

2.380

Ahmet Tanritanir, M.D.

Electrophysiological and clinical biomarkers of ACTH (Acthar gel) treatment

1.104

Kiyohide Usami, M.D., Ph.D.

Sleep exerts a change in network effective connectivity â&#x20AC;&#x201D; Causality analysis of human brain network evoked by single-pulse electrical stimulation

1.122

AES ANNUAL MEETING | meeting.aesnet.org

Poster/Platform

1.141

1.251|C.05

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AWARD RECIPIENTS

Nurse Travel Awardees This award recognizes and honors outstanding young investigators with nursing degrees who are conducting epilepsy research. Awardees receive a $1,000 travel stipend. Contact Author

Abstract Title

Poster/Platform

Marissa Bragdon, BSN, RN, CPN

Standardized seizure education in an outpatient pediatric neurology clinic reduces emergency room admissions

1.075

Patricia Bruno, RN, BSN

Efficacy of cannabidiol in patients with refractory epilepsy relative to concomitant use of clobazam

3.181

Kelly Frost, RN, MSN, CPNP

Higher yield studies in a pediatric epilepsy monitoring unit: Intravenous midazolam versus intravenous lorazepam as first line therapy for status epilepticus

3.064

Lindsay Schommer, MSN, ANP-BC, WHNP-BC Longitudinal assessment of suicidality in epilepsy

2.253

T. Brooke Schultz, DNP

2.078

Time for EMU 2.0: Surveys of patients and epileptologists suggest need for a new design concept for EMU rooms

John (Jack) M. Pellock Award in Pediatric Excellence The 2016 John (Jack) M. Pellock Award for Pediatric Excellence recognizes and honors outstanding young investigators conducting clinical research in pediatrics related to epilepsy. Awardees will receive a $1,000 travel stipend and complimentary meeting registration. Contact Author

Abstract Title

Poster/Platform

Juan Piantino, M.D., and Marina GaĂnza-Lein (co-awardees)

Long-term outcomes in pediatric refractory status epilepticus (the pSERG cohort)

Erica Weiss, Ph.D.

Memory function following febrile status epilepticus: Results of the Febstat Study

1.214 2.368

Rebecca Goldberg Kaufman Honor The Rebecca Goldberg Kaufman Ethical Neuropsychiatry Fund works to advance a better understanding of the psychiatric aspects of epilepsy care and treatment. The Kaufman Honor is awarded to the highest-ranking abstract in the comorbidities topic category and is presented during Platform B.11. The abstract honored is selected by the Scientific Program Committee from more than 1,300 submitted abstracts. Contact Author

Abstract Title

Annie Richard

The 'epileptic personality' revisited: Is the broader autism phenoype more frequent in people with seizures?

Poster/Platform

1.257|B.11

Kimford J. Meador Research in Women with Epilepsy Award This award recognizes an AES member who has done important and recently published research which advances the care of women with epilepsy. Awardee(s) receives a $1,000 travel stipend. This award is sponsored by My Epilepsy Story. Contact Author

Abstract Title

Michael O. Kinney, BSc, MB, BCh, BAO, MRCP

Changing anti-epileptic drug prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations

AES ANNUAL MEETING | meeting.aesnet.org

Poster/Platform

3.203

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AWARDS AND RECOGNITION

Distinguished Service Award

William G. Lennox Award

Established in 1993, this award recognizes outstanding service by an AES member in the field of epilepsy (including non-educational and non-scientific) with emphasis on exemplary contributions to advancing the mission of the American Epilepsy Society and service to its members. The award includes a $1,000 honorarium.

This award, established in 1966, recognizes AES members who have a record of lifetime contributions and accomplishments related to epilepsy. The award is funded by the Lennox and Lombroso Trust Fund, which was established in 1962 to advance and disseminate knowledge concerning epilepsy in all of its aspects— biological, clinical, and social—and to promote better care and treatment for persons with epilepsy. The award includes a $10,000 honorarium.

Friday, December 1, 4:00 PM Preceding the 15th Judith Hoyer Lecture in Epilepsy Convention Center, Ballroom A/B, Level 3

Saturday, December 2, 8:30 AM Preceding the Presidential Symposium

Jose Cavazos, M.D., Ph.D. Dr. José Enrique Cavazos was born in Monterrey, Mexico, where he later attended medical school. He graduated as a physician and surgeon with honors from the Instituto Tecnológico de Monterrey, and then pursued a Ph.D. in neuroscience at the University of Wisconsin-Madison under the guidance of Dr. Thomas Sutula. He completed a neurology residency and a clinical neurophysiology/ epilepsy fellowship at Duke University Medical Center.

Convention Center, Ballroom A/B, Level 3

Jacqueline A. French, M.D. Dr. Jacqueline French is a professor in the Department of Neurology at NYU, in the Comprehensive Epilepsy Center, and founder/director of the Epilepsy Study Consortium. Dr. French trained in neurology at Mount Sinai Hospital, and did her fellowship training in EEG and epilepsy at Mount Sinai and Yale University. Dr. French’s research efforts are focused on development of new therapeutics for epilepsy and new methodologies for clinical trials.

He has performed extensive professional service to the epilepsy community as a member of NIH Study Sections and Panels for more than 15 years — helping to draft the law that created the VA Epilepsy Centers of Excellence, participating in FDA panels for epilepsy drugs and devices, serving as an editorial board member of Epilepsy Research and Epilepsy and Behavior, and chair of the AES committees for Student and Resident Education, Technology and Web Content, and the 2010 Scientific Meeting in San Antonio. He created and funded the Partnering Epilepsy Centers in the Americas (PECA) project with more than 35 partnerships between epilepsy centers in Latin America, the Caribbean, and North America. He has also served as ILAE's treasurer for the North American Commission for the most recent quadrennium.

AES ANNUAL MEETING | meeting.aesnet.org

Dr. French is active in creating guidelines and classifications for the American Academy of Neurology and the International League Against Epilepsy. She chaired an AAN/AES committee that produced two widely quoted guidelines on the use of new antiepileptic drugs. She served as chair of the ILAE North American Regional Commission, and Commission on Therapeutic Strategies. Dr. French is a past president of AES and is the 2005 recipient of the AES Service Award and the 2013 Epilepsy Foundation Hero award.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AWARDS AND RECOGNITION

Fritz E. Dreifuss Lecture

Lennox and Lombroso Lecturer

The Fritz E. Dreifuss lecture honors the memory of Dr. Dreifuss, a leading clinical epilepsy specialist, clinical investigator and former President of the American Epilepsy Society and the International League Against Epilepsy. Founder of the Comprehensive Epilepsy Program at the University of Virginia and mentor to a generation of epilepsy researchers, Dr. Dreifuss was devoted to mentoring those in clinical epilepsy research.

The Lennox and Lombroso Lecture is given each year by a clinician or scientist who is considered to be an outstanding investigator in the field of epilepsy research. The Lennox and Lombroso Lecturer is selected in collaboration with the AES President, Annual Meeting Chair, and Scientific Program Committee Chair. This year’s Lennox and Lombroso Lecturer will mark the 50th lecture in this series.

Supported by the AES Fritz Dreifuss Fund, the lecture promotes clinical epilepsy research and outstanding patient care and includes a $1,000 honorarium.

Lennox and Lombroso Lecture Monday, December 4, 2:15 PM Convention Center, Ballroom A/B, Level 3

Saturday, December 2, 8:30 AM During the Presidential Symposium Convention Center, Ballroom A/B, Level 3

Helen E. Scharfman, Ph.D. Dr. Scharfman received a B.A. in Biopsychology from Vassar College in 1977, a Ph.D. in Pharmacology from the Uniformed Services University of Health Sciences in 1986, and conducted postdoctoral training at the University of Washington in the laboratory of Phillip Schwartzkroin and then Paul Adams at SUNY Stony Brook. She began her independent research program at Columbia University and Helen Hayes Hospital and became the director of the Center for Neural Recovery and Regeneration Research at Helen Hayes Hospital. She is currently a professor in the departments of child psychiatry, neuroscience and physiology, and adult psychiatry at New York University's Langone Medical Center, an Investigator at the New York University Neuroscience Institute, and Senior Scientist in the Center for Dementia Research at The Nathan Kline Institute of Psychiatric Research of the New York State Office of Mental Health.

Rebecca J. Schultz Ph.D., RN, CPNP Dr. Rebecca Schultz is an assistant professor of pediatric neurology and developmental medicine at Baylor College of Medicine and the principal pediatric nurse practitioner in the Comprehensive Epilepsy Program, Blue Bird Circle Clinic for Pediatric Neurology at Texas Children’s Hospital. Dr. Schultz is a nurse scientist and pediatric nurse practitioner with more than 25 years of experience caring for youth with neurological conditions and their families. Her research interests include the psycho-social aspects of epilepsy in youth, efficacy and side effects of the ketogenic diet, and the transition of adolescents with epilepsy from pediatric to adult care. She also serves as the medical advisor for the Epilepsy Foundation Houston HRSA grant, Strategic Approaches to Improving Access to Quality Health Care for Children and Youth with Epilepsy, which addresses transition of care of youth with epilepsy. Additionally, she is an integral member of the Child Neurology Foundation's Transition Project Advisory Committee.

The focus of her research is mechanisms of neuronal excitability and plasticity in the hippocampus both in the normal brain as well as in epilepsy. She has received continuous funding from the National Institutes of Health and has either served on the advisory boards or reviewed research proposals for many national and international organizations. She has been an active participant in training of students and postgraduates, currently acting as director of training at the Nathan Kline Institute.

Dr. Schultz’s awards include the 2017 Nurse Practitioner Excellence in Child Neurology Nurses award, the Excellence in Nursing Practice Award from Sigma Theta Tau in 2014, Texas Nurses Association Outstanding Nurse of 2008 Award, and the Kiffen Penry Top Scholar award in 2003.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AWARDS AND RECOGNITION

J. Kiffin Penry Award for Excellence In Epilepsy Care This award, originally funded by Abbott Laboratories and supported now by the AES J. Kiffin Penry Fund, was established in 1997 in honor of Dr. Penry’s lifelong focus on and genuine concern for the patient with epilepsy. It recognizes individuals whose work has had a major impact on patient care and improved the quality of life for persons with epilepsy. The award includes a $3,000 honorarium.

2017 J. Kiffin Penry Award Monday, December 4, 5:45 PM Preceding the Epilepsy Therapies Symposium Convention Center, Ballroom A/B, Level 3

James Cloyd, PharmD

Dr. Cloyd’s academic activities are based in the Center for Orphan Drug Research, whose mission is the development of drugs for rare pediatric neurological disorders. His recent research has focused on new therapies for seizure emergencies.

Dr. Cloyd received a BS in pharmacy from Purdue University and subsequently completed the combined PharmD/hospital pharmacy residency program at the University of Kentucky in 1976. He joined the University of Minnesota College of Pharmacy that same year, where he established a clinical practice in an epilepsy clinic, designed and taught a neurotherapeutics course, and established a research program in clinical neuropharmacology with a focus on epilepsy.

Dr. Cloyd is a member of the NeuroNext DSMB and formerly a member of the FDA clinical pharmacology advisory committee and the AES Board of Directors. He is also a member of the UMN Academy of Distinguished Teachers, has received the Outstanding Mentoring and Advising Award from the UMN Graduate and Professional Student Association, and the UMN Clinical and Translational Science Institute Mentor of the Year Award. He is the recipient of the Rho Chi Lecture Award and the Summer J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics bestowed by the Pediatric Pharmacotherapy Advocacy Group.

AES Research Funds The American Epilepsy Society is the leading non-profit in support for early career epilepsy researchers with fellowships, travel grants, training, and mentorship. We are committed to funding and supporting research from exploratory mechanistic science through clinical advances to identify and deliver answers to treat and cure epilepsy. AES has established several funds targeting specific research and programmatic needs in epilepsy research, including these opportunities: • Susan S. Spencer Fund for Clinical Research and Education • Jack M. Pellock Pediatric Travel Fund • Suzanne and Peter Berry International Travel Award

• Rebecca Goldberg-Kaufman Ethical Neuropsychiatry Award Fund • Lennox and Lombroso Trust for Research and Training • J. Kiffin Penry Fund • Fritz Dreifuss Epilepsy Fund

To make a gift supporting research, visit the AES website at: aesnet.org/research-at-work

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AWARDS AND RECOGNITION

Research Awards The American Epilepsy Society Research and Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research. These individuals are recognized for their extraordinary professional excellence and their distinguished contributions to research for the improved understanding and treatment of epilepsy. These awards include a $10,000 honorarium.

The 2017 Basic Science Research Award

The 2017 Clinical Science Research Award

Saturday, December 2, 8:30 AM Preceding the Presidential Symposium

Convention Center, Ballroom A/B, Level 3

Prof. Dr. Heinz Beck

Hal Blumenfeld, M.D., Ph.D.

Heinz Beck is a professor of experimental epileptology and cognition research at the University of Bonn in Germany and the head of the NeuroCognition Translational Research Unit at the Life & Brain Institute. Dr. Beck studied medicine in Cologne, and received a degree summa cum laude for his doctoral thesis with Prof. U. Heinemann. He was a Heisenberg Fellow of the DFG at the Department of Epileptology in Bonn from 2001-2004, before becoming a full professor in 2004.

Dr. Blumenfeld studied philosophy and bioelectrical engineering as an undergraduate at Harvard, completed an M.D./Ph.D. at Columbia in the laboratories of Steven Siegelbaum and Eric Kandel, did neurology residency at Massachusetts General Hospital, and then entered the field of epilepsy through fellowships at Yale. He is the Mark Loughridge and Michele Williams professor of neurology, neuroscience, and neurosurgery, director of the Yale Clinical Neuroscience Imaging Center (CNIC) and a member of the Yale Comprehensive Epilepsy Center.

His work has explored changes in intrinsic excitability and neuronal integration in epilepsy, and has made contributions to understanding the mechanisms of anticonvulsant drug actions and mechanisms of pharmacoresistance in human and experimental epilepsy. His group has a research interest in neuronal integration and the function and dysfunction of neuronal networks in the intact brain.

The main goal of Dr. Blumenfeldâ&#x20AC;&#x2122;s career has been to understand the mechanisms of impaired consciousness in seizures and to improve the lives of people living with epilepsy. Combining neuroimaging, electrophysiology, and behavioral testing in patients, with translational work in animal models, his work has greatly advanced current knowledge, with important therapeutic benefits.

Dr. Beck is a past president of the German Epilepsy Society, is the chair of the integrated research program SFB1089 of the German Research Council, and is founder of numerous educational programs at the University of Bonn. He has been the recipient of the International Michael Prize, the Alfred Hauptmann Prize for Epilepsy Research, the Bennigsen-Foerder Prize, and a Cure Frontiers in Research Lectureship.

AES ANNUAL MEETING | meeting.aesnet.org

Dr. Blumenfeld has received the Francis Gilman Blake and Graduate Mentor awards and served for nine years as director of medical studies in clinical neuroscience at Yale. He has participated in numerous committees including the AES Scientific Programming Committee and Clinical Investigator Workshop Committee. Prior research awards include the AAN Dreifuss-Penry Epilepsy Research Award and the NINDS Javits Neuroscience Investigator Award.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION SUMMARY

71st Annual Meeting AES recognizes the following companies for supporting AES and the 2017 Annual Meeting.

BENEFACTOR | $500,000+ Sunovion Pharmaceuticals Inc. Eisai Inc.

LEADER | $250,000 - $499,999 UCB Inc. Lundbeck

PARTNER | $100,000 - $249,999 LivaNova Upsher-Smith Laboratories, LLC Greenwich Biosciences, Inc. Supernus Pharmaceuticals, Inc.

SUPPORTER | $50,000 - $99,999 AbbVie SK Life Science Nihon Kohden America, Inc. BioMarin Pharmaceutical Inc. Zogenix, Inc.

CONTRIBUTOR | $25,000 - $49,999 Mallinckrodt Pharmaceuticals Ricoh USA, Inc. NeuroPace Medtronic

ADVOCATE | $10,000 - $24,999 Sage Therapeutics Rhythmlink International, LLC Persyst Development Corporation Neuralynx, Inc. Texas Children's Hospital Natus Neuro Validus Pharmaceuticals LLC

Cadwell Industries, Inc. Compumedics Neuroscan Inc. Elekta Zimmer Biomet SUN Neurosciences Lifelines Neurodiagnostic Systems, Inc. Prasco

PATRON | $5,000 - $9,999 Child Neurology Foundation Electrical Geodesics, Inc. University of Maryland Medical Center Tuberous Sclerosis Alliance Cleveland Clinic Empatica Micromed LLC Renishaw Healthcare Inc York Instruments

Ad-Tech Medical Instrument Corporation GeneDx Monteris Medical Moberg ICU Solutions PMT Corporation Mayo Medical Laboratories Brain Sentinel, Inc. MNG Laboratories

Status as of 10/27/2017. See supporter signs at the Annual Meeting for updated recognition levels.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

In Just One Minute You Can Support AES Research and Education Programs

THANK YOU! Many thanks to AES members and our colleagues who further the Societyâ&#x20AC;&#x2122;s mission through their philanthropic support. AES recognizes and deeply appreciates the generosity of all donors and contributors.

PLANNED GIFTS

ENDOWED FUNDS

ANNUAL FUND

Make a lasting impact during and beyond your lifetime

Support fellowships, research grants, and travel awards

Put your dollars to work today where the need is greatest

TEXT 56512

Three Easy Steps 1. Take out your phone and text 56512. 2. Enter your info as noted below:

Learn more and donate at a e s n e t .o r g /d o n a t e

EPILEPSY [space] Your Gift Amount [space] Your name Example: EPILEPSY 100 Jane Doe 3. Hit SEND. You will receive a secure link back to finish your donation by credit card. Questions? Contact Susan Oliver at soliver@aesnet.org

EEG MACHINE BECOMES RESEARCH DOLLARS FOR AMERICAN EPILEPSY SOCIETY For nine years Nihon Kohden has generously supported a unique giving program it pioneered. Each year it has auctioned off its EEG-1200 machine and donated 100% of the proceeds to the Lennox and Lombroso Trust for Research and Training and the Susan S. Spencer Fund for Clinical Education and Research. This year, Greenville Health System of Greenville, South Carolina is the EEG-1200 auction winner at $26,702.16. Nihon Kohden executives will present a check to the American Epilepsy Society on Saturday, December 2 at 2:00 PM on the floor of the Exhibit Hall. AES deeply appreciates the support of Nihon Kohden America, Inc. Thank you!

Booth #919

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

Experience AES AES member benefits include: • Substantial discounts to meetings and programs, including the AES Annual Meeting • Epilepsia, research journal of the International League Against Epilepsy* • Epilepsy Currents, a commentary and literature review journal from AES • Listing in Find-A-Doctor online directory*

Join our dynamic community — more than 4,000 professionals working together to treat and cure epilepsy. To eradicate epilepsy and its consequences — that’s the vision of the American Epilepsy Society. AES provides continuing

• AES Connections email newsletter • Research funding opportunities • Scholarships and awards • AES Connect, our online, members-only community for networking and exchange

education resources for members, is a champion of research, and serves as home to the brightest minds in the field of epilepsy. Find out more about AES Membership.

ONSITE Exhibit Hall

Satellite Booth

Booth #1119

Registration Area

ONLINE aesnet.org/membership

*Benefit of select member categories

EDUCATION CREDITS If you have any questions about this CE activity relative to nursing and/or pharmacy CE, please contact AKH, Inc. at service@akhcme.com.

Accreditation The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Maintenance of Certification The American Board of Psychiatry and Neurology has reviewed the 71st Annual Meeting—American Epilepsy Society and has approved this program as part of a comprehensive epilepsy program, which is mandated by the ABMS as a necessary component of maintenance of certification.

AMA Credit Designation Statement The American Epilepsy Society designates this live activity for a maximum of 26.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming CME Credit and CME Certificates

International Credits: The American Medical Association has determined that non-U.S. licensed physicians who participate in this CME activity are eligible for a maximum of 26.5 AMA PRA Category 1 Credits™.

Attendees who registered in the following categories may claim CME or CE for the meeting: physician, health care provider, trainee, one-day, and two-day. Meeting registration includes credit claiming. There is no separate fee to claim CME/CE.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 26.5 hours of Category 1 credit for completing this program.

Attendees will receive an emailed notification to access the online evaluation and credit claim system. The evaluation and credit claim system will remain open through Tuesday, February 27, 2018. Evaluations and credit claims must be completed by this date in order to record and receive your CME/CE certificate.

Continuing Education for Nurses and Pharmacists

Attendance Certificate/International Attendees

Jointly provided by AKH, Inc., Advancing Knowledge in Healthcare, and the American Epilepsy Society.

A meeting attendance certificate will be available at the registration desk for international meeting attendees on Tuesday, December 5, 2017.

Nurses: Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is awarded 26.5 contact hours.

Resolution of Conflicts of Interest It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, AES implemented the mechanism of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Pharmacists: Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Select portions of this Annual Meeting are approved for pharmacy CE credit. Specific hours of credit for approved presentations and the Universal Activity Numbers assigned to those presentations are found elsewhere in the program materials. Criteria for success: credit is based on documented program attendance and online completion of a program evaluation/ assessment.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

EDUCATION CREDITS

Unapproved Use Disclosure

Disclaimer

AES requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDAapproved uses and any off-label, investigational, and/or experimental uses.

Self Assessment in Epilepsy VOLUMES 1-4

Continuing Education in Epilepsy

Created by fellow epileptologists and neurologistsâ&#x20AC;&#x201D; members of AESâ&#x20AC;&#x201D;these self-assessment activities provide continuing medical education, lifelong learning, and career development. Also use these activities to fulfill Maintenance of Certification (MOC) requirements.

Access continuing education and professional resources from AES all year long, including: Webinars Online courses Handouts Self-Assessment

Visit the SAE Zone during the meeting to take advantage of meeting discounts for self-assessment activities. Details on page 121.

Learn more at a es ne t.o rg/p ro fe ss iona l_ ed ucati on

Get details at a e s n e t . o r g /s a e

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

FRIDAY, DECEMBER 1

FRIDAY, DECEMBER 1 Functional Mapping of the Insula: Index Case Invasive Evaluation Jean Isnard, M.D., Ph.D.

8:30 AM - 11:30 AM

Epilepsy Specialist Symposium | The Insula and Its Epilepsies

Debate: Treatment: Should the Insular be Resected? Chengyuan Wu, M.D., M.S.Bm.E., and Jorge GonzalezMartinez, M.D., Ph.D.

Convention Center, Ballroom A/B, Level 3 OVERVIEW

Conclusion and Index Case Conclusion Fred Lado, M.D., Ph.D.

The symposium focuses on seizures originating in the insula and presents information on the best strategy to investigate such seizures with both non-invasive and invasive methods. It will inform about surgical and minimally invasive approaches and outcomes of epilepsy surgery in the insula. The symposium will be rich in case presentations to educate about clinical manifestations of insular seizures. The function of the insula and possible consequences such as SUDEP will also be discussed.

EDUCATION CREDIT

3.0 CME credits Nurses may claim up to 3.0 contact hours for this session. Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 3.0 contact hours (0.3 CEUs). UAN 0077-9999-17-040L01-P. Initial Release Date: 12/1/17.

LEARNING OBJECTIVES COMMERCIAL SUPPORT ACKNOWLEDGEMENT

Following participation in this activity, learners should be able to:

This educational activity is supported in part by an educational grant from Medtronic.

• Recognize intracranial EEG patterns of insular epilepsy

9:00 AM - 4:00 PM

• Identify the ictal and interictal semiology of insular seizures

31st Annual Advances in the Management of Epilepsy and the Epilepsy Clinic

• Delineate the appropriate invasive and non-invasive diagnostic work-ups for insular epilepsy

Separate registration required.

• Draw the functional anatomy of the insula

Marriott Marquis Liberty Ballroom, Salons I-L, Level M4

• Describe surgical approaches to insular epilepsy and restate their outcome(s)

This intensive one-day conference is designed for professionals who participate in the care of persons with epilepsy. The overall purpose is to improve services to individuals and families affected by epilepsy. The conference is presented by the Epilepsy Information Service of Wake Forest University School of Medicine, Winston-Salem, North Carolina, through an unrestricted grant committed to the education of health professionals, in an effort to promote the comprehensive care of those with epilepsy and their families.

TARGET AUDIENCE

Neurologists, epileptologists, pediatric neurologists, nurses, psychologists/neuropsychologists, nurse practitioners/physician assistants PROGRAM

Co-chairs: Barbara Jobst, M.D., Ph.D., FAAN, and Fred Lado, M.D., Ph.D. Introduction and Index Case History Barbara Jobst, M.D., Ph,D., FAAN

Pre-registration through Wake Forest School of Medicine ended on Friday, November 24. Please call 800-642-0500 with questions.

Semiology of Insular Epilepsy Andreas Alexopoulos, M.D. Non-invasive Investigation of the Insula Dang Nguyen, M.D.

This activity has been approved for 5.0 AMA PRA Category 1 Credits™. Wake Forest is the accrediting entity.

Is SUDEP Increased in Insular Epilepsy? Index Case Non-invasive Evaluation Samden Lhatoo, M.D. Onset and Propagation Patterns on Intracranial EEG Philippe Kahane, M.D., Ph.D.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

• Restate the developmental and epileptic encephalopathies with a focus on the sodium channelopathies such as Dravet syndrome (previously called Severe Myoclonic Epilepsy of Infancy), and which treatments are recommended to be used vs. those to be avoided

12:00 PM - 2:00 PM

AES Partner Event | Infantile Spasms Action Network (ISAN) Meeting More information available in the mobile app. The Infantile Spasms Action Network (ISAN), led by the Child Neurology Foundation, is a collaborative network of more than 20 national and international entities focused on raising awareness for infantile spasms.

• List the genes implicated in the focal epilepsies and discuss their association with malformations such as focal cortical dysplasia • Discuss the promise of precision medicine and describe the clinician’s responsibility to critically evaluate each patient’s data and available data regarding treatments

This program is not accredited for continuing education credits.

TARGET AUDIENCE

12:30 PM - 3:00 PM

Neurologists, epileptologists, pediatric neurologists, nurses, psychologists/neuropsychologists, nurse practitioners/physician assistants, genetic counselors

Annual Fundamentals Symposium | Epilepsy Genetics: Transforming Clinical Practice Convention Center, Ballroom A/B, Level 3

PROGRAM

OVERVIEW

Co-chairs: Annapurna Poduri, M.D. and Ingrid Scheffer, M.B.B.S., Ph.D.

This symposium will address the current state of genetic testing in epilepsy. We will review which populations of patients with epilepsy warrant genetic testing based on high yield of a genetic diagnosis, as well as potential for treatment modification. We will discuss which types of tests can and should be sent, as well as factors important for clinicians to know to inform pre- and posttest discussions with patients (or their parents). Two speakers will delve into some of the pediatric developmental epilepsies as well as focal epilepsies as examples to illustrate the above concepts. The final talk will discuss the promise of precision medicine with a word of caution that we must carefully weigh available evidence and consider risks and benefits of all treatments.

Introduction Annapurna Poduri, M.D. The When, What, and Why of Genetic Testing in Epilepsy Sameer Zuberi, M.D. Why You Need Genetic Counseling for Genetic Testing in Epilepsy Beth Sheidley, M.S., CGC Developmental and Epileptic Encephalopathies Ingrid Scheffer, M.B.B.S., Ph.D. Focal Epilepsies — Is it Time for Genetic Testing? Douglas Crompton, M.D., Ph.D. Precision Medicine — N of 1 Experience vs. Clinical Trials Saul Mullen, M.B.B.S., Ph.D.

LEARNING OBJECTIVES

Following participation in this activity, learners should be able to:

EDUCATION CREDIT

• Recognize which patients with epilepsy should undergo genetic testing

2.5 CME credits Nurses may claim up to 2.5 contact hours for this session.

• Distinguish which tests evaluate for which types of genetic abnormalities

Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-17-041L01-P. Initial Release Date: 12/1/17.

• Identify when patients should be referred for consultation to others with particular knowledge and expertise in genetics and neurogenetics, including genetic counselors

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

This educational activity is supported in part by an educational grant from Greenwich Biosciences, Inc.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

FRIDAY, DECEMBER 1

1:00 PM - 3:00 PM

1:30 PM - 3:00 PM

Epilepsy Fellowship Program Directors Meeting

Special Interest Groups

Convention Center, Room 202 A/B, Level 2

These programs are not accredited for continuing education credits.

OVERVIEW

Chair: David Ficker, M.D.

Critical Care Epilepsy | Uncommon Causes and Uncommon Treatments of Status Epilepticus

Speakers: Jennifer Hopp, M.D., Heidi M. Munger Clary, M.D., M.P.H., Imran I. Ali, M.D., FAAN, Joseph Drazkowski, M.D., FAAN This session is intended for current epilepsy fellowship directors, clinical neurophysiology program directors, and those interested in starting an ACGME-accredited epilepsy fellowship. Participation in this session will meet ACGME program requirement II.A.4, which advises program directors to attend one program director meeting per year. The objective of this session is to provide a forum for program directors to address challenges encountered in running a program and in meeting accreditation requirements. A “flipped classroom” model will be described, and session participants will consider how to incorporate this instructional method into their fellowship programs.

Convention Center, Room 146 B, Street Level Coordinators: Cecil Hahn, M.D., Nicolas Gaspard, M.D., Ph.D. Speakers: To be announced OVERVIEW

This year's Critical Care Epilepsy SIG will focus on uncommon causes and treatments of status epilepticus. The session will highlight important new discoveries and research advances through a series of brief interactive presentations by authors of important research studies completed in the past year, and by trainee members presenting important new abstracts related to critical care epilepsy at the meeting.

LEARNING OBJECTIVES

TARGET AUDIENCE

Following participation in this activity, program directors should be able to: • Support AES future activities for fellowship education • Incorporate methods and techniques to convert clinical neurophysiology fellowships to epilepsy fellowships • Implement the current and upcoming ACGME requirements for fellowships • Determine whether and how to incorporate a flipped classroom model into fellowship programs

Clinicians, scientists, nurses, technicians, fellows, trainees

Data Science in Epilepsy | Data Science Applied to Electrophysiology, Imaging and Seizure Diaries Convention Center, Room 204 A/B, Level 2 Coordinators: Daniel Goldenholz, M.D., Ph.D., Brian Litt, M.D. Speakers: Daniel Goldenholz, M.D., Ph.D., Mark Cook, M.B.B.S., M.D., Andrea Bernasconi, M.D.

TARGET AUDIENCE OVERVIEW

Current epilepsy fellowship directors, clinical neurophysiology program directors, and those interested in starting an ACGME-accredited epilepsy fellowship

The convergence of newly-acquired, massive datasets with advances in machine learning as well as the development of newer statistical frameworks have brought the old idea of data science once again to the forefront of scientific discovery and inquiry. This SIG will explore aspects of data science ranging from seizure detection/prediction to artificial intelligence-enhanced medical imaging, to data-driven methodology for clinical trial improvement.

PROGRAM

Business Meeting David Ficker, M.D. How To Practically Convert Your Fellowship From Clinical Neurophysiology to Epilepsy Jennifer Hopp, M.D., and Heidi Munger Clary, M.D., M.P.H. Update from the ACGME Imran I. Ali, M.D., FAAN Educational Value of the Flipped Classroom Model Joseph Drazkowski, M.D., FAAN Discussion David Ficker, M.D.

TARGET AUDIENCE

Scientists

EDUCATION CREDIT

2.0 CME Credits AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

OVERVIEW

Genetics | Making Sense of Genetic Data in Epilepsy - Consensus and Controversy in 2017

This session will be comprised of three brief presentations and active discussion.

Convention Center, Room 102 B, Street Level Coordinators: Ingo Helbig, M.D., Circa Quintero Hernandez, M.D., Ph.D.

Speakers: Heather Mefford, M.D., Ph.D., Katherine Helbig, M.S., CGC, Mark Fitzgerald, M.D., Ph.D.

Outcome measure or process measure? Challenges with utilizing outcome measures for provider performance. Challenges in linking expert consensus with high level outcome evidence

2. Reducing epilepsy related emergency visits associated with increased documentation of seizure frequency at each visit (an established AAN epilepsy quality measure)

OVERVIEW

Understanding results of genetic testing is the key to making these findings actionable in clinical practice. Over the last 12 months, interpretation guidelines have advanced significantly. In this session, selected speakers from the epilepsy neurogenetics and variant interpretation fields will provide an updated 2017 overview of the genetic complexity observed in patients with epilepsy, which usually confound interpretation in molecular diagnostics. A focus on the concerns, considerations, and approaches used to translate this information into clinical risk prediction and treatment will be explored. Following up from the successful SIGs in 2015 and 2016, this SIG will explore the state-of-the art of variant analysis in 2017 and the epilepsy genetic community will be invited to submit cases for consideration and discussion. A full 60 minutes of the session will be designated for discussion and conversation among the attendees.

3. Quality of life as an outcome—could this be used as a performance indicator? TARGET AUDIENCE

Clinicians, scientists, nurses, behavioral health providers, technicians, fellows, trainees 3:15 PM - 4:00 PM

Career Pathways in Epilepsy Care and Research #1 – Research Panel Convention Center, Salon B, Street Level

Career Pathways in Epilepsy Care and Research #2 – Clinical Care Panel Convention Center, Salon C, Street Level

TARGET AUDIENCE

OVERVIEW

Clinicians, scientists, fellows, trainees

These sessions will highlight a variety of career paths, featuring concurrent panels focused on clinician career paths with emphasis on clinical care and research opportunities; and scientist and clinician career paths with emphasis on research and related fields. Participants will self-select and may go between sessions in adjacent rooms. Each panel will represent career options in different sectors, such as private practice, academia, industry, government, and nonprofit organizations. Panelists will describe their work, provide advice, and answer questions from the audience.

Private Practice Epilepsy | Building an Independent Free-standing EMU Convention Center, Room 102 A, Street Level Coordinators: Eric Segal, M.D., Ro Elgavish, M.D., Ph.D. Speakers: Ahmed Sadek, M.D., Robert Nahouraii, M.D. OVERVIEW

The epilepsy monitoring unit is an essential component of an epilepsy practice. Speakers will discuss experiences creating an EMU within affiliated hospitals as well as independent of medical centers.

TARGET AUDIENCE

Quality, Value, and Safety in Epilepsy | Towards Outcome Measures of Provider Performance

Open to all meeting attendees, but may be of particular interest to residents, fellows and others at an early career stage or considering a transition.

Convention Center, Room 101, Street Level Coordinator: Gabriel Martz, M.D. Speakers: Anup Patel, M.D., Amir Arain, M.D., Mary Jo Puch, Ph.D., RN

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

FRIDAY, DECEMBER 1

PROGRAM

Co-Chairs: Susan Herman, M.D., and Karen Wilcox, Ph.D.

Co-chairs: David King-Stephens, M.D., and Mario A. Alonso-Vanegas, M.D.

Career Pathways Research Panelists: Laura Lubbers, Ph.D., Esther Krook-Magnuson, Ph.D., Stephen D. Collins, M.D., Ph.D., Rachel Lane, Ph.D., and Carl Stafstrom M.D., Ph.D.

Introduction David King-Stephens, M.D. Non-epileptic Paroxysmal Events Horacio Senties-Madrid, M.D.

Career Pathways Clinical Care Panelists: Adam Hartman, M.D., Sara Inati, M.D., Zachary Grinspan, M.D., O’Neil D’Cruz, M.D., M.B.A., and Nicholas Abend, M.D., M.S.C.E.

Ketogenic Diet for Adults Adriana Tanner, M.D.

This program is not accredited for continuing education credits.

Neuromodulation Ana L. Velasco-Monroy, M.D., Ph.D., and Damian Consalvo, M.D., Ph.D.

3:30 PM - 6:00 PM

Roundtable Panel Discussion

Spanish Symposium | What to Do When the Patient Does Not Respond to Medical Treatment and Is Not a Candidate for Surgery

EDUCATION CREDIT

2.5 CME credits Nurses may claim up to 2.5 contact hours for this session.

Convention Center, Room 207 A/B, Level 2

Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-17-042L01-P. Initial Release Date: 12/1/17.

This symposium is presented entirely in Spanish. OVERVIEW

This symposium focuses on the importance of the early differentiation of paroxysmal non-epileptic events and epilepsy so that treatment for epilepsy is not delayed. In cases of refractory epilepsy, referral considerations for epilepsy surgery evaluation will be discussed, as will the challenging situation in which said evaluation concludes that the person with epilepsy is not a candidate for surgery. In this case, as well as in situations where epilepsy surgery is unavailable, the appropriate role and evidence for the remaining therapies, vagus nerve stimulation, brain stimulation, and the ketogenic diet will be presented and patient selection criteria presented.

4:00 PM - 5:30 PM

15th Judith Hoyer Lecture in Epilepsy | Epilepsy at the Cutting Edge: Using Novel Models and Innovative Approaches for Therapeutic Advances Convention Center, Ballroom A/B, Level 3 AES Award Presentation: Distinquished Service Award NINDS Director’s Update Walter Koroshetz, M.D., will provide an update from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health.

LEARNING OBJECTIVES

Following participation in this activity, learners should be able to:

Hoyer Lecture Amy Brooks-Kayal, M.D., will present Epilepsy at the Cutting Edge: Using Novel Models and Innovative Approaches for Therapeutic Advances

• Differentiate epilepsy from paroxysmal non-epileptic events • Appropriately select patients for the ketogenic diet • Identify the criteria for selection of candidates for vagus nerve stimulation (VNS) vs. other types of neuromodulation

OVERVIEW

Sixty-five million people worldwide have epilepsy, and despite the existence of over 40 anti-seizure medications, one third of people with epilepsy have seizures that are not controlled with available therapies.

TARGET AUDIENCE

Neurologists, epileptologists, pediatric neurologists, nurse practitioners, physician assistants, nurses

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

All current medications for epilepsy symptomatically treat seizures only; none treat the underlying cause of epilepsy, specifically target mechanisms unique to certain epilepsy syndromes, or target “non-ictal” symptoms of epilepsy such as depression, anxiety, or cognitive and memory dysfunction. All current medical therapies impact every cell all the time (not just during seizures), and result in unacceptable side-effects in many patients. None change the course of the disease, prevent/reduce progression or reduce the risk of epilepsy in patients at risk. In other words, we have no precision or disease modifying therapies for epilepsy … yet.

6:00 PM - 7:30 PM

Basic Science Skills Workshops Imaging the Behaving Brain with Miniscopes Convention Center, Room 206, Level 2 Speaker: Tristan Shuman, Ph.D. OVERVIEW

This interactive workshop for basic scientists will demonstrate a new generation of head-mounted fluorescent microscopes (miniscopes) developed at UCLA on a low-cost, open-source platform that enables calcium imaging in freely behaving animals. It will include information about how to build and use miniscopes, perform necessary surgeries, collect and analyze data, as well as discuss new innovations to this technology that are currently under development.

Translational therapies on the horizon for people with epilepsy will do more than symptomatically treat seizures. Epilepsy researchers are using novel preclinical models and innovative approaches to develop new therapies that are precise, targeted, and diseasemodifying. They target cognitive and neurobehavioral co-morbidities as well as seizures. Most importantly, they have the potential to transform the lives of people with epilepsy.

Modeling and Studying Epilepsy in the Age of Genomics and CRISPR Convention Center, Room 201, Level 2 Speakers: Yu Wang, M.D., Ph.D., Andrew Tidball, Ph.D.

This program is not accredited for continuing education credits.

OVERVIEW

This interactive workshop for basic scientists will include CRISPR design strategies for gene-editing humaninduced pluripotent stem cells. Particular emphasis will be given to critical conceptual and technical information to begin making your own "virtual" patient or isogenic control iPSC lines. Examples will be presented and discussed from ongoing projects modeling genetic epileptic encephalopathies with CRISPR gene-edited iPSC lines.

Co-sponsored with National Institute of Neurological Disorders and Stroke (NINDS). COMMERCIAL SUPPORT ACKNOWLEDGEMENT

This educational activity is supported in part by an educational grant from Upsher-Smith Laboratories, Inc. 5:30 PM - 6:30 PM

What AES Can Do for You | Professional Development Session

Topics include: 1) In vivo CRISPR design, delivery, and validation

Convention Center, Room 201, Level 2 2) Case studies: focal cortical dysplasia, and epileptic encephalopathies

OVERVIEW

Learn more about how the American Epilepsy Society supports you in your career with research funding, mentoring, educational programming, and online communities. Those who are new to AES and the Annual Meeting are especially encouraged to attend. TARGET AUDIENCE

Open to all attendees. New and prospective members are especially encouraged to attend, as are those in the early stages of their careers. This program is not accredited for continuing education credits.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

FRIDAY, DECEMBER 1

grant-writing for junior investigators followed by an indepth Q&A session.

6:00 PM - 7:30 PM

Special Interest Groups

TARGET AUDIENCE

These programs are not accredited for continuing education credits.

Scientists, fellows, trainees

Pediatric Epilepsy Case Discussions | Diagnostic and Treatment Challenges in Pediatric Epilepsy

Epilepsy Education | Comparison of Resident Epilepsy Curricula

Convention Center, Room 146 A, Street Level Coordinators: Ahsan Moosa Naduvil Valappil, M.D., Ajay Gupta, M.D.

Convention Center, Room 101, Street Level Coordinators: Daniel Weber, D.O., Mackenzie Cervenka, M.D. Speakers: Jun Park, M.D., David Burkholder, M.D., Susan Herman, M.D., Howard Goodkin, M.D., Ph.D.

Speakers: Elaine Wyllie, M.D., Linda Laux, M.D., Ingo Helbig, M.D., Nicholas Abend, M.D., Ahsan Moosa Naduvil Valappil, M.D.

OVERVIEW

This new SIG begins with an introduction to the role of the clinician-educator in epilepsy training. This will be followed by four brief talks from leaders in neurology education from different academic institutions discussing the structure of their programs and how they became clinician-educators. This session will conclude with a 25-minute panel discussion/Q&A session on the strengths and weaknesses of these curricula. Look forward to a vibrant discussion on how best to become a clinician-educator and teach this information to our residents and fellows.

For more than 20 years, this session has provided a rare platform for sharing complex challenges in the management of pediatric epilepsy. Young and seasoned epileptologists from both academic and private centers worldwide have an opportunity to present an interesting case from their practice. Cases are selected in such a way that a wide range of topics in pediatric epilepsy will be covered. Recent cases discussed in this SIG include: refractory absence epilepsy, epilepsy surgery with stereo EEG guidance, autoimmune epilepsy, super refractory status epilepticus, ESES, treatable metabolic causes of epilepsy. By offering this annual opportunity to share illustrative clinical experiences, the American Epilepsy Society fosters impactful interaction and communication among pediatric epilepsy specialists worldwide. This session has impacted the way we help children with difficult-to-treat epilepsy.

This SIG will be of interest to neurology residents, epilepsy fellows, and epilepsy faculty interested in pursuing careers as clinician-educators. TARGET AUDIENCE

Clinicians

NIH and Non-Profit Research Resources/Junior Investigator Workshop | Pearls on Writing a Successful Research Proposal

TARGET AUDIENCE

Clinicians, scientists, nurses, behavioral health providers, technicians, fellows, trainees

Convention Center, Room 102 B, Street Level Coordinators: Vicky Whittemore, Ph.D., Catherine Chu, M.D.

Psychogenic Non-epileptic Seizures (PNES) | Novel Approaches in the Psychotherapeutic Treatment of PNES

Speakers: Elizabeth Webber, Ph.D., Devin Binder, M.D., Ph.D., George Richerson, M.D., Ph.D., Chris Dulla, Ph.D., Catherine Christian, Ph.D., Peter Patrylo, Ph.D., Jeffrey Loeb, M.D., Ph.D., Helen Scharfman, Ph.D., Manisha Patel, Ph.D., Suzanne Bausch, Ph.D., Greg Bergey, M.D., Michelle Jacobs, Ph.D., John Swann, Ph.D.

Convention Center, Salon C, Street Level Coordinators: Lorna Myers, Ph.D., Julia Doss, Psy.D.

OVERVIEW

When neurologists diagnose PNES, one of the biggest challenges they encounter is providing the patient with a proper treatment referral, as only a small number of geographically-restricted specialists understand and treat this condition. Progress in evidence-based cognitive behavioral treatment (CBT) has widened

Speakers: Gaston Baslet, M.D., Laurie Zandberg, Psy.D., Rochelle Caplan, M.D. OVERVIEW

This session will begin with an NIH/NINDS mock study section reviewing one K and one F. Reviewers include members of prior and current NINDS study sections and grant recipients. Following the mock study sections, reviewers will provide pearls and insights into successful

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

referral options. This SIG aims to present other treatment modalities for PNES that are currently being studied and have had initial positive results.

of theseâ&#x20AC;&#x201D;starting with childhood sleep epilepsy syndromes and continuing with adult epilepsy syndromes.

The following psychotherapeutic approaches will be highlighted:

PROGRAM

Introduction Milena K. Pavlova, M.D.

1) Mindfulness-based therapy for conversion disorders (mindfulness is a state in which one becomes more aware of one's physical, mental, and emotional condition in the present moment without judging any of these. Patients learn to pay attention to a variety of experiences, such as bodily sensations, cognitions, and feelings; this eventually results in more self-control)

Childhood Epilepsy Syndromes Sanjeev Kothare, M.D. Sleep Epilepsy Syndromes in Adulthood Milena Pavlova, M.D. TARGET AUDIENCE

Clinicians, nurses, behavioral health providers, technicians, fellows, trainees

2) Prolonged exposure therapy (PE) for dually diagnosed PNES/PTSD (PTSD is one of the most common psychiatric comorbidities in PNES. PE has been widely tested and has strong empirical support in the treatment of PTSD. Studies underway to test the effectiveness of PE in patients with PNES and PTSD have shown preliminary results are positive)

6:00 PM - 8:00 PM

Satellite Symposium Convention Center, Room 147, Street Level

TARGET AUDIENCE

Looking Beyond the Seizure: Harnessing Recent Advances to Expedite Diagnosis and Optimize Treatment of Late Infantile Neuronal Ceroid Lipofuscinosisâ&#x20AC;&#x201D;New Science and Encouraging Stories

Clinicians, nurses, behavioral health providers, technicians, fellows, trainees

For further details, please visit www.peerviewpress.com/CLN2

Sleep and Epilepsy | Updates On Sleep Related Epilepsy Syndromes Across the Ages

Pre-registration was requested. On-site registration may be available, space permitting. Dinner is provided.

3) Child-specific PNES treatment (including parental and school interventions as well as direct treatment of the child)

Convention Center, Room 146 B/C, Street Level Coordinators: Milena Pavlova, M.D., Erik St Louis, M.D.

This live activity is supported by an independent educational grant from BioMarin Pharmaceutical Inc.

Speakers: Sanjeev Kothare, M.D., Milena Pavlova, M.D.

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

OVERVIEW

There have been multiple advances regarding optimizing the diagnosis and treatment of sleep-related epilepsy syndromes. These include genetic testing and new treatment options. This session will examine each

AES ANNUAL MEETING | meeting.aesnet.org

To claim credit for this symposium, please contact live@peerview.com or call 877.833.6141. Reference the December 1 meeting at AES.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

FRIDAY, DECEMBER 1

SATURDAY, DECEMBER 2

Global Health | Global Health Update: Challenges and Future Directions

7:00 AM - 8:30 AM

Special Interest Groups

Convention Center, Room 101, Street Level Coordinators: Sheryl Haut, M.D., Mary Spiciarich, M.D.

These programs are not accredited for continuing education credits.

Speakers: Gretchen Birbeck, M.D., Jorge Vidaurre, M.D., Lionel Carmant, M.D.

SATURDAY, DECEMBER 2

Epidemiology | Epidemiologic Estimates and Outcomes: Are We Doing Better?

OVERVIEW

Successful global health outreach projects in epilepsy are occurring all over the world, but we face many challenges in optimizing their design to achieve longevity and high impact. Our speakers will report on their respective projects which fuse research and service in under-served areas of the world, including Zambia, Haiti, and others. We will discuss challenges in designing projects that are sustainable and meaningful, and the role of neurologists in delivering this important care. Additionally, we will discuss future directions for global health work within the field of epilepsy and neurology.

Convention Center, Room 102 B, Street Level Coordinators: Christine M. Baca, M.D., MSHS, Zachary Grinspan, M.D., M.S. Speakers: Zachary Grinspan, M.D., M.S., Jeffrey Buchhalter, M.D., Ph.D., RenĂŠe Shellhaas, M.D., M.S., Anne Berg, Ph.D., Hyunmi Choi, M.D., Edward Chang, M.D., Christine M. Baca, M.D., MSHS OVERVIEW

The past half-century has witnessed a steady expansion of epilepsy epidemiology and outcomes research, which has dramatically improved our understanding of epilepsy and its consequences. But have we made a difference? Did any of our work improve lives for people with epilepsy? In this session, we examine recent advances in epilepsy epidemiology and outcomes. Each speaker will very briefly present his or her work (and/or review of literature), and argue whether the knowledge gained has made lives better for people with epilepsy.

TARGET AUDIENCE

Clinicians, nurses, behavioral health providers, fellows, trainees

MEG / MSI | Clinical Magnetoencephalography in Infants Convention Center, Salon C, Street Level Coordinators: Michael Funke, M.D., Ph.D., Gretchen Von Allmen, M.D.

PROGRAM

Speakers: Stephanie Garcia-Tarodo, M.D., Richard Burgess, M.D., Ph.D., Yoshio Okada, Ph.D.

1) Introduction 2) Everything is Horrible 3) Nothing Has Changed 4) New Findings in Neonatal Seizures 5) New Findings in Early Life Epilepsy 6) New Findings in Geriatric Epilepsy 7) More and More Anti-seizure Medications 8) The Changing Landscape of Epilepsy Surgery 9) We Are Doing Better 10) Discussion

OVERVIEW

Despite growing literature on the validity of the MEG in the pre-surgical work-up of epilepsy patients, an important component to consider is whether these standards can be extrapolated to any age group, and namely children under the age of 2 years. MEG in the clinical setting, as a noninvasive procedure, seems wellsuited for pediatric cases. However, there are no reports of MEG experiences on a large infant group and namely, its clinical application in infants with epilepsy. The program aims to showcase the most recent advances in this fast-evolving field of pediatric MEG by presentations and a vivid discussion by international experts.

Talks will be brief (less than eight minutes) and are intended to stimulate discussion and debate amongst members of the panel and the audience. Speakers will be encouraged to take a stance as to whether or not we are doing better. We will encourage audience members to join the debate in the second portion of the program. We anticipate a lively and collegial discussion.

TARGET AUDIENCE

Clinicians, scientists, technicians

TARGET AUDIENCE

Clinicians, scientists, behavioral health providers

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SATURDAY, DECEMBER 2

Practice Management | 2017 AES Practice Management

Tuberous Sclerosis | Biomarkers and Risk Factors for Epilepsy in TSC: Diagnosis, Prediction and Prevention

Convention Center, Room 204 A/B, Level 2 Coordinator: Gregory L. Barkley, M.D.

Convention Center, Room 147 A/B, Street Level Coordinators: Michael Wong, M.D., Ph.D., Darcy Krueger, M.D., Ph.D.

Speakers: To be announced OVERVIEW

Speakers: Anna Jeong, M.D., Jurriaan Peters, M.D., Ph.D., Joyce Wu, M.D. OVERVIEW

Epilepsy is a common neurological manifestation of tuberous sclerosis complex (TSC) and is often resistant to available treatments. As patients are often diagnosed with TSC in infancy prior to the onset of epilepsy, opportunities for early intervention, potentially with preventative or disease-modifying therapies for epilepsy, are feasible and are starting to be investigated in TSC. The identification of clinical risk factors or biomarkers for epilepsy in TSC would aid in selecting those TSC patients at highest risk to target with potential preventative treatment or in predicting or following response to treatment. In this SIG, we will review recent progress in identifying such risk factors and biomarkers for epilepsy in TSC. Anna Jeong from Northwestern will discuss clinical risk factors for drug-resistant epilepsy in TSC. Joyce Wu from UCLA will present the latest data on utilizing EEG in presymptomatic TSC infants to predict epilepsy. Jurriaan Peters from Harvard will discuss potential MRI biomarkers of epilepsy in TSC. Ample time will be reserved for discussion of other potential biomarkers, such as biochemical markers of mTOR pathway activation.

TARGET AUDIENCE

Clinicians, nurses, technicians

SUDEP | Deadly Bedfellows: SUDEP and Sleep Convention Center, Room 146 B/C, Street Level Coordinators: Gordon Buchanan, M.D., Ph.D. Lisa Bateman, M.D., Daniel Friedman, M.D. Speakers: Benton Purnell, M.D., Ph.D., Kristina Simeone, Ph.D., Roland Thijs, M.D., Ph.D. OVERVIEW

The majority of SUDEP cases occur during the night and most often the victim is found dead in bed in the morning by family members. Nocturnal seizures are also a clinical risk factor for SUDEP. In this SIG, we will discuss the role that that sleep may play in facilitating seizure-related sudden death. Speakers will examine how seizures during sleep impact autonomic and respiratory function in patients with epilepsy and animal models of seizures and SUDEP. Speakers will also discuss the neurobiology of sleep and arousal and how seizures affect these mechanisms, and under the right circumstances, may lead to death. Finally, speakers will address potential interventions targeting sleep and arousal that could reduce SUDEP risk.

TARGET AUDIENCE

Clinicians, scientists, fellows, trainees COMMERCIAL SUPPORT ACKNOWLEDGEMENT

This educational activity is supported in part by an educational grant from Greenwich Biosciences, Inc. 7:00 AM - 8:30 AM

Junior Investigators Roundtable Discussions Convention Center, Salon B, Street Level

TARGET AUDIENCE

OVERVIEW

Clinicians, scientists, nurses, behavioral health providers, technicians, fellows, trainees

This session will provide an opportunity for junior investigators to connect with each other, senior investigators, and other experts in an informal setting to share ideas, strategies, and challenges. Expert facilitators will lead small group discussions on a range of topics such as diversity in the workforce, publishing and funding research, starting and managing a lab,

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SATURDAY, DECEMBER 2

This meeting, held annually, discusses changes in billing and coding policies for the upcoming year. This is based upon the changes in the ICD-10 CM codes that started on 10/1/2017 and the CMS Final Rule that was issued in November of this year. There is an additional degree of uncertainty for 2018 as there is considerable talk about repealing and replacing the ACA (Obamacare). Any changes to the ACA may affect the MACRA implementation as well. How these changes will play out and affect care for patients with epilepsy will be discussed.

SATURDAY, DECEMBER 2

balancing clinical and research duties, managing industry relationships, navigating the job market across clinical, clinical educator, academic, and other industries. Participants may rotate among topics of interests. Space will be available for general networking as well.

8:30 AM - 11:45 AM

Presidential Symposium | Epilepsy in Context: Complex Issues Beyond Seizure Management Convention Center, Ballroom A/B, Level 3

TARGET AUDIENCE

Award Presentations: AES William G. Lennox Award; AES Research Recognition Awards in Basic and Clinical Science

SATURDAY, DECEMBER 2

Fellows, junior investigators, and others at an early career stage or considering a transition. PROGRAM

OVERVIEW

Table Topics and Expert Facilitators Moderator: Susan Herman, M.D.

The diagnosis and management of epilepsy is complicated by the changing clinical setting in which the disorder occurs. Both epilepsy and its co-existing clinical conditions are dynamic. Often times, issues related to epilepsy and seizure control are emphasized, with less focus on the clinical setting itself. This session addresses the issues of diagnosis and management of epilepsy when other conditions intervene.

Publishing Your Research: Epilepsy-Specific Journals Aristea Galanopoulou, M.D., Ph.D., and Andres M. Kanner, M.D., FANA, FAAN Publishing Your Research: Neuroscience And Neurology Journals Gregory Cascino, M.D., and Christophe Bernard, Ph.D. Funding Your Research: Government Sources Adam Hartman, M.D., and Vicky Whittemore, Ph.D.

LEARNING OBJECTIVES

Following participation in this activity, learners should be able to:

Funding Your Research: Non-Profit Sources Penny Dacks, Ph.D., Laura Lubbers, Ph.D., and Tracy Dixon-Salazar, Ph.D.

• Delineate and discuss the principles of transitioning the care of children with epilepsy to adult clinical care settings

Navigating The Job Market: Clinical O’Neill D’Cruz, M.D., M.B.A., and Robert Flamini, M.D.

• Recognize the potential of decline in memory, cognition and behavior following epilepsy surgery, which may be independent of the degree of postsurgical seizure control

Navigating The Job Market: Industry/Government/Non-Profit Brandy Fureman, Ph.D., Carlos Peña, Ph.D., M.S., and Rachel Lane, Ph.D.

• Develop management plans for women with epilepsy considering pregnancy, during pregnancy and labor, and post-partum

Navigating The Job Market: Academia Karen Wilcox, Ph.D., Patrick Forcelli, Ph.D., and Alica M. Goldman, M.D., Ph.D., M.S.

• Identify diagnostic and therapeutic strategies to recognize and mitigate mood disorders of depression and suicide risk in those with epilepsy

Balancing Research And Clinical Dutie Mark Quigg M.D., and Catherine Schevon, M.D., Ph.D.

• Review and discuss emerging behavioral and pharmacologic options for mood disorder exacerbation and the interaction of mood disorders with cognition

Starting And Managing A Lab Steve Danzer, Ph.D., and Catherine Chu, M.D. Diversity In The Workforce Michelle D. Jones-London, Ph.D., and Joaquin Lugo, Ph.D.

• Consider translational scientific evidence of overlapping pathophysiologic mechanism of epilepsy and Alzheimer’s disease and potential novel interventions

Becoming A Clinician Educator Phillip Pearl, M.D., Susan Koh, M.D., and Nina Garga, M.D. Managing Industry Relationships Brian Litt, M.D., and Jeremy D. Slater, M.D.

TARGET AUDIENCE

Neurologists, epileptologists, pediatric neurologists, nurses, psychologists/neuropsychologists, nurse practitioners/physician assistants, pharmacists

This program is not accredited for continuing education credits.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SATURDAY, DECEMBER 2

PROGRAM

12:00 PM – 6:00 PM

Chair: Eli M. Mizrahi, M.D.

Poster Session 1

Introduction Eli M. Mizrahi, M.D.

Convention Center, Hall B, Lower Level

Transition of Care in Epilepsy: Next Steps Rebecca J. Schultz, Ph.D., RN, CPNP (Fritz E. Dreifuss Award Winner)

Numbers shown indicate the poster hall board assignment. Refer to www.aesnet.org/abstracts for details. POSTER SESSION 1

Management of Epilepsy During Pregnancy Page B. Pennell, M.D.

Translational Research................................................1.001 – 1.072 Interprofessional Care/Professionals in Epilepsy ........................................................................1.073 – 1.077

Mood Disorders and Self-management in Epilepsy Barbara Jobst, M.D., Ph.D., FAAN

Neurophysiology ............................................................1.078 – 1.153

Epilepsy and Neurodegenerative Disorders: Overlapping Mechanisms and Therapeutic Opportunities Lennart Mucke, M.D.

Clinical Epilepsy................................................................1.154 – 1.221 Neuroimaging ................................................................1.222 – 1.254 Comorbidities (Somatic and Psychiatric)........1.255 – 1.266

Conclusion and Panel Discussion Eli M. Mizrahi, M.D.

Antiepileptic Drugs ......................................................1.267 – 1.319

EDUCATION CREDIT

Behavior/Neuropsychology/Language............1.349 – 1.368

3.0 CME credits

Genetics ............................................................................1.369 – 1.380

Nurses may claim up to 3.0 contact hours for this session.

Health Services................................................................1.381 – 1.392

Surgery ..............................................................................1.320 – 1.348

Neuropathology of Epilepsy ..................................1.393 – 1.398 Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 3.0 contact hours (0.3 CEUs). UAN 0077-9999-17-043L01-P. Initial Release Date: 12/2/17.

Epidemiology ................................................................1.399 – 1.407 Public Health ..................................................................1.408 – 1.414 Case Studies ....................................................................1.415 – 1.425

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

Late Breaking..................................................................1.426 - 1.436

This educational activity is supported in part by educational grants from Eisai Inc., Lundbeck, Sunovion Pharmaceuticals Inc., and UCB Inc.

This program is not accredited for continuing education credits. 12:00 PM – 2:00 PM

12:00 PM – 6:00 PM

Poster Session 1 | Authors Present

Exhibit Hall

Convention Center, Hall B, Lower Level

Refer to aesnet.org/abstracts for details.

Grand Opening at Noon

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SATURDAY, DECEMBER 2

Epilepsy Surgery and Cognitive Decline J. Helen Cross, M.D., ChB, Ph.D.

SATURDAY, DECEMBER 2

LEARNING OBJECTIVES

12:15 PM – 1:45 PM

Following participation in this activity, learners should be able to:

SATURDAY, DECEMBER 2

Poster Walking Tours Convention Center, Hall B, Lower Level

• Discuss the sex differences in the neurobiology, etiology, and treatment of epilepsy

Tour Leaders: Jean Gotman, Ph.D., Ilo Leppik, M.D., Andres M. Kanner, M.D., FANA, FAAN, and Elaine Wirrell, M.D.

• Recognize sex-related differences in epilepsy presentation and response to therapy

Join leading experts as they spotlight interesting posters and facilitate discussion with authors, gaining new and different perspectives on the data presented.

• Describe the impact of hormonal influences in the epilepsy expression, temporal fluctuation, and severity and discuss the therapeutic application of neuroactive steroid/hormonal therapy in the treatment of epilepsy

To join a walking tour, gather at the poster information table near booth #1305 and poster board #001. A schedule of topics and tour leaders will be available.

TARGET AUDIENCE

Neurologists, epileptologists, pediatric neurologists, basic scientists, neuroscientists

2:00 PM - 6:00 PM

PROGRAM

AES Partner Event | Epilepsy Foundation— Community of Practice

Chair: Lori Isom, M.D., Ph.D. Introduction Lori Isom, M.D., Ph.D.

More information available in the mobile app.

Neuroactive Steroids in Gender-specific Models of Epilepsy Samba Reddy, Ph.D.

This invitation-only meeting brings together the Epilepsy Foundation’s National Epilepsy Education and Awareness Collaborative (NEEAC) Community of Practice (COP) members and partners. During this meeting, the participants will assess and discuss progress made towards the COP goals and objectives, plan strategies to implement COP activities over the next year, and explore opportunities to expand the COP activities in regional and local settings.

Sex Differences in the Neurobiology of Epilepsy Helen Scharfman, Ph.D. Adverse Impacts on the Hypothalamic Control of Reproduction in a Mouse Model of Temporal Lobe Epilepsy Catherine Christian, Ph.D.

This program is not accredited for continuing education credits.

Hormonal Therapy and Outcome in National Infantile Spasm Cohort Kelly Knupp, M.D.

2:15 PM - 4:45 PM

Sex in the Neurobiology and Treatment of Pediatric Epilepsies Aristea Galanopoulou, M.D., Ph.D.

Scientific Symposium | Sex and the Seizure

Neuroactive Steroids in the Management of Human Epilepsy Andrew Herzog, M.D.

Convention Center, Ballroom A/B, Level 3 OVERVIEW

This symposium will present information on the translational perspectives on the current state of knowledge related to sex differences in the neurobiology of epilepsy in experimental research and clinical practice. Emerging information on the therapeutic applications of hormonal therapy in the treatment of epilepsy will be presented as will strategies for facilitating collaboration with experts in reproductive medicine. The evidence for neuroactive steroids/hormonal interventions in the management of patients’ epilepsy will be discussed.

AES ANNUAL MEETING | meeting.aesnet.org

EDUCATION CREDIT

2.5 CME credits Nurses may claim up to 2.5 contact hours for this session. Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-17-044L01-P. Initial Release Date: 12/2/17.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SATURDAY, DECEMBER 2

to clinical practice. The session will conclude with a discussion and recommendations by the entire expert panel, who will field questions as time permits.

2:30 PM - 4:00 PM

Investigators Workshop Investigators Workshop Committee

LEARNING OBJECTIVES

Chair, Basic Science: Viji Santhakumar, Ph.D.

Following participation in this activity, learners should be able to:

Chair, Clinical: Edward J. Novotny Jr., M.D.

TARGET AUDIENCE

Neurologists, neuroscientists, pharmacologists, neuropsychologists, neurosurgeons, and other scientists, professionals, and trainees who are performing research in epilepsy.

• Use the method of focused ultrasound, considering the types and sizes of surgical targets that can be treated with this method, and the common sideeffects of treatment

This program is not accredited for continuing education credits.

• Select patients who are most likely to realize the potential benefits and avoid the pitfalls of CBD treatment

Divergent and Overlapping Mechanisms Contribute to Epilepsy and its Comorbidities

• Use the information gained by electrical source imaging when planning epilepsy surgery, and be aware of the limitations of this method

Convention Center, Room 207 A/B, Level 2 Moderators: Julia Kahn, Ph.D., Christophe Bernard, Ph.D.

TARGET AUDIENCE

Speakers: Tallie Z. Baram, M.D., Ph.D., Christophe Bernard, Ph.D., Pierre-Pascal Lenck-Santini, Ph.D.

Neurologists, epileptologists, pediatric neurologists, nurses, psychologists/neuropsychologists, nurse practitioners/physician assistants

OVERVIEW

Epilepsy is defined by spontaneous seizures. Whereas the seizures have been the central focus of epilepsy research, they are commonly accompanied by cognitive and emotional problems that contribute to poor quality of life including memory issues, decision-making deficits, and depression. These co-morbidities are observed in many types of epilepsy and cognitive and emotional problems are especially prominent in temporal lobe epilepsy, involving the hippocampallimbic circuit. The mechanisms underlying the impairments remain unclear and recent work has begun to uncover mechanisms that uniquely contribute to cognitive/ emotional problems after a genetic or acquired ‘insult’. Concurrently, recent and emerging studies are identifying common molecular, cellular, and circuit processes that may promote both the epileptic seizures and the cognitive and emotional impairments.

PROGRAM

Introduction Fred Lado, M.D., Ph.D. Use of Ketamine for Refractory Status Epilepticus Nicholas Gaspard, M.D. Use of MRI-guided Focused Ultrasound for Epilepsy Surgery Nathan Fountain, M.D. CBD Case Presentation Jules Beal, M.D. Debate: Should CBD be Used for the Treatment of Medically Refractory Epilepsy? Elizabeth Thiele, M.D., Ph.D., and Shlomo Shinnar, M.D., Ph.D.

5:30 PM - 8:00 PM

Use of Electrical Source Imaging to Identify the Epileptogenic Zone Serge Vulliemoz, M.D.

Hot Topics Symposium | New Tools for Diagnosis and Treatment

Panel Discussion and Conclusion All faculty

Convention Center, Ballroom A/B, Level 3 OVERVIEW

A panel of experts will present the latest information on current topics of interest, then debate, describe, discuss, and illustrate the implications of each topic with respect

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SATURDAY, DECEMBER 2

• Evaluate the mechanism of action of ketamine, major side effects, and assess the clinical scenarios where ketamine may be beneficial

Vice-Chair, Clinical: Tobias Loddenkemper, M.D.

SATURDAY, DECEMBER 2

EDUCATION CREDIT

• Delineate the interprofessional contribution of psychologists/ neuropsychologists as part of the comprehensive epilepsy team in assessing and tracking quality of life and making recommendations for indicated psychosocial care (Physicians, Nurses, NPs, PAs, Pharmacists, Psychologists/ Neuropsychologists)

2.5 CME credits Nurses may claim up to 2.5 contact hours for this session.

SATURDAY, DECEMBER 2

Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-17-050L01-P. Initial Release Date: 12/2/17.

TARGET AUDIENCE

Neurologists, epileptologists, pediatric neurologists, nurses, psychologists/neuropsychologists, nurse practitioners/physician assistants, pharmacists

5:30 PM - 8:00 PM

Interprofessional Care Symposium | Quality of Life: Measurement and Clinical Use Across the Lifespan of Epilepsy

PROGRAM

Co-chairs: Janelle Wagner, Ph.D. and Madona Pleuger, APRN, ACNS-BC

Convention Center, Ballroom C, Level 3 Introduction: Overview of QoL in Persons with Epilepsy Janelle Wagner, Ph.D.

OVERVIEW

Despite evidence that epilepsy significantly impacts quality of life, no comprehensive epilepsy care guidelines exist as of this printing regarding the evaluation and use of quality of life measures in clinical practice. This symposium will focus on the impact that quality of life has on people with epilepsy and their caregivers. The focus will be on the assessment of quality of life for people with epilepsy and will provide strategies for developing and executing an interprofessional approach to this important issue.

The Who, What and Why of Quality of Life in People with Epilepsy Christine M. Baca, M.D., MSHS Validation of the PedsQL Epilepsy Modules and How to Use Them in Practice Avani Modi, Ph.D. Using QoL as an Outcome in a Self-Management Intervention Trial for Adults with Epilepsy Samantha Schmidt, B.S.

LEARNING OBJECTIVES

QoL and Adherence to Anti-Epileptic Drugs: How to Integrate QoL Assessment into Practice James McAuley, RPh, Ph.D., FAPhA

Following participation in this activity, learners should be able to: • Recognize and implement strategies to assess and track quality of life into practice, to include: networking with other health care providers regarding comprehensive patient care needs, including the primary care provider, other epilepsy specialists, and community organizations (Physicians)

Introduction of Speaker Panel for Q&A/Conclusion Madona Pleuger, APRN, ACNS-BC EDUCATION CREDIT

2.5 CME credits Nurses may claim up to 2.5 contact hours for this session.

• Assess quality of life as part of the comprehensive epilepsy team including providing quality of life education, resources, and tracking over time to persons with epilepsy and their families (Nurses, NPs, PAs)

Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-17-045L01-P. Initial Release Date: 12/2/17.

• Delineate the role and responsibilities of pharmacists as part of the comprehensive epilepsy team assessing the patient's quality of life as it pertains to medication therapy adherence and treatment needs (Physicians, Nurses, NPs, PAs, Pharmacists, Psychologists/Neuropsychologists)

AES ANNUAL MEETING | meeting.aesnet.org

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

This educational activity is supported in part by an educational grant from UCB Inc.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

The course will conclude with a look into the future, where topics such as precision medicine and innovative imaging will be front and center. These innovations will be placed in the context of bringing appropriate epilepsy care to underserved communities by highlighting the barriers to care in global health. To wrap up, Dr. Mizrahi, President of the American Epilepsy Society, will provide a futuristic vision of the most needed future innovations in epilepsy.

8:00 AM – 8:30 AM

American Epilepsy Society Annual Business Meeting Marriott Marquis, Independence Ballroom, Salon B, M4 Level President, Eli M. Mizrahi, M.D. Open to all AES members

LEARNING OBJECTIVES

8:00 AM – 5:00 PM

Convention Center, Street Level These exhibits provide meeting attendees an opportunity to stay current on the latest epilepsy research. Authors will be present throughout entire the exhibit window. See page 30 for details. 8:45 AM – 12:00 PM, 2:00 PM – 5:15 PM

Annual Course | Epilepsy Across the Lifespan Convention Center, Ballroom A/B, Level 3 OVERVIEW

The first quarter of the course will tackle diagnostic challenges across the lifespan. Imaging diagnostic challenges will be addressed by age group. Diagnostic distinctions between epilepsy and normal aging will be discussed, along with the diagnostic role of amplitudeintegrated EEG in neonates. A debate will discuss pertinent issues in genetic testing in adults. The second quarter of the course will tackle medical management of epilepsy and its comorbidities across the lifespan. The role of ketogenic diet in infancy will be reviewed, as well as the under-recognized sleep disorders in children. Psychiatric comorbidities will be discussed by age group and unique therapeutic considerations when using anti-seizure drugs in the elderly will be reviewed. The third quarter of the course will elaborate on issues pertaining to surgical therapy in different age groups. Expanding indications in pediatrics and specific considerations in the elderly will be discussed. Tailoring therapy choices among the multiple available neuromodulatory options will be discussed. Finally, a debate will highlight specific risk/benefit considerations while considering the extent of resection in pediatric versus adult populations with epilepsy.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

Following participation in this activity, learners should be able to: • Delineate the appropriate role of genetic testing and advanced neuroimaging in children, adults, and the elderly • Recognize when genetic testing is appropriate in the work-up of epilepsy at all ages • Recognize when specific advanced neuroimaging tests are indicated in the work-up of epilepsy at all ages • Delineate the indications for amplitude integrated EEG in neonates • Distinguish clinical signs that should raise the suspicion of epilepsy in the elderly population • Delineate the most critical psychiatric co-morbidities to consider across the lifespan • Be knowledgeable in the various considerations necessary prior to prescribing seizure medications in the elderly (metabolism, effectiveness profiles, interactions with other medications, among others) • Recognize the warning signs of specific comorbidities, mainly sleep disorders, in children with epilepsy • Recognize and treat psychiatric co-morbidities across the lifespan in patients with epilepsy. • Appropriately select candidates for epilepsy surgery in infancy • Recognize indications and risks of epilepsy surgery in the elderly • Delineate the distinctions among different neuromodulatory treatments (VNS, DBS, RNS) • Discuss innovative minimally invasive surgical techniques such as laser and thermal ablation • Conceptualize methods to incorporate innovative technology into daily practice

Scientific Exhibits

SUNDAY, DECEMBER 3

• Review and discuss the cutting-edge knowledge regarding diagnosis and treatment of people with epilepsy • Identify barriers to care implementation and discuss strategies for overcoming said barriers

LUNCH BREAK: 12:00 PM – 2:00 PM

Lunch available in the Exhibit Hall. SURGICAL TREATMENT OF EPILEPSY ACROSS THE LIFESPAN: 2:00 PM – 3:25 PM

Case: 36-year-old with Presumed Dominant Hemisphere Drug-resistant Epilepsy and Normal MRI Who Had Surgery Jeremy Moeller, M.D.

TARGET AUDIENCE

Neurologists, epileptologists, pediatric neurologists, nurses, psychologists/neuropsychologists, nurse practitioners/physician assistants, pharmacists

Lecture: Epilepsy Surgery for Infants? Pushing the Boundaries Ajay Gupta, M.D.

PROGRAM

Introduction Lara Jehi, M.D.

Lecture: VNS, RNS, DBS: Approved for Adults but What’s the Science for How to Choose One Over the Other? Robert Fisher M.D., Ph.D.

DIAGNOSTIC CHALLENGES ACROSS THE LIFESPAN: 8:55 AM – 10:20 AM

SUNDAY, DECEMBER 3

Case: Neonate with Failure to Thrive and Myoclonic Jerks Akila Venkataraman, M.B.B.S.

Lecture: Epilepsy Surgery in the Elderly: Seizure Outcomes and Complications. Jerome Engel, Jr., M.D., Ph.D.

Lecture: Top Four Imaging Diagnoses You Can’t Miss in Each Age Group Graeme Jackson, M.D.

Debate: Surgical Perspectives PRO: “Minimally invasive” Epilepsy Surgery Options Are the Future: An Adult Epilepsy Surgeon’s Perspective

Lecture: Just How Valuable is Amplitude Integrated EEG in Neonatal Seizure Detection? Renée Shellhaas, M.D.

Guy McKhann, M.D.

Lecture: Epilepsy or Just Getting Old? Diagnostic Challenges in Elderly Colin Josephson, M.D.

William Bingaman, M.D.

CON: The Bigger the Hole, the Better the Outcome: A Pediatric Epilepsy Surgeon’s Perspective

LOOKING TO THE FUTURE: 3:40 PM – 5:00 PM

Debate: Value of Genetic Testing in Adults with Epilepsy Heather Mefford, M.D., Ph.D., and Ingo Helbig, M.D.

Case: 10-year-old Boy with Refractory Epilepsy in Rural Africa Satya Gedela, M.D.

MEDICAL MANAGEMENT AND CO-MORBIDITIES ACROSS THE LIFESPAN: 10:35 AM – 12:00 PM

Lecture: Precision Medicine: How Close Are We to Personalized Care? Daniel Lowenstein, M.D.

Case: Elderly Patient with Temporal Lobe Epilepsy and Multiple Medical Co-Morbidities Kim Pargeon, M.D.

Lecture: What Should an Ideal “Epilepsy Protocol MRI” Look Like in the Future for Adults and for Children? Neda Bernasconi, M.D., Ph.D.

Lecture: Unique Therapeutic Considerations When Using Anti-Seizure Drugs in the Elderly Ilo Leppik, M.D.

Lecture: Barriers to Advanced Epilepsy Care: Closing the Gap in Global Health Gretchen Birbeck, M.D., M.P.H.

Lecture: Sleep Disorders and Epilepsy in Children Sejal Jain, M.D.

Lecture: My Top 3 Innovations Needed for Children, Adults, and Elderly with Epilepsy in the Next Decade Eli M. Mizrahi, M.D.

Lecture: Under-Recognized Psychiatric Co-Morbidities Per Age Group Tatiana Falcone, M.D.

Course Wrap-up Lara Jehi, M.D.

Lecture: Ketogenic Diet in Infancy? How Low Can We Go? Stéphane Auvin, M.D. 12:00 PM – 2:00 PM Break, Boxed Lunch available

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

EDUCATION CREDIT

OVERVIEW

6.0 CME credits

The KCC2 chloride co-transporter is the chief Clextruder in CNS neurons. KCC2 is known to co-localize with GABAA receptors but is also expressed at excitatory synapses. KCC2 plays significant roles in dendritic spine morphogenesis and glutamatergic synaptic function. KCC2 activity is both positively and negatively regulated by many pathways including phosphorylation of different sites on its protein structure. KCC2 hypofunction has now been shown to play a critical role in the emergence of seizures by multiple independent research groups. More interestingly, enhancing or preserving KCC2 function during seizures can positively impact seizure outcomes and therefore highlight the need to develop true enhancers of KCC2 as a novel therapeutic strategy.

Nurses may claim up to 6.0 contact hours for this session. Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 6.0 contact hours (0.6 CEUs). UAN 0077-9999-17-046L01-P. Initial Release Date: 12/3/17. COMMERCIAL SUPPORT ACKNOWLEDGEMENT

This educational activity is supported in part by educational grants from Eisai Inc., Lundbeck, UCB Inc., and Sunovion Pharmaceuticals Inc. 8:45 AM - 4:45 PM

Investigators Workshops Program

2. Inflammation and Epilepsy: Where Do We Stand and Where Do We Go From Here?

Convention Center, see room assignments below Investigators Workshop Committee

Convention Center, Room 202 A, Level 2 Moderator: William H. Theodore, M.D.

Chair, Clinical: Edward J. Novotny Jr., M.D.

Speakers: Luca Bartolini, M.D., Annamaria Vezzani, Ph.D., Jacqueline A. French, M.D.

Vice-Chair, Clinical: Tobias Loddenkemper, M.D. OVERVIEW TARGET AUDIENCE

This session will focus on discussing the crucial role of inflammation in epileptogenesis. This mechanism is not targeted by conventional antiepileptic drugs and may contribute to the high number of refractory epilepsy cases. We will present the results of a cross-sectional study analyzing the potential role of HHV-6 and EBV infection and the immune response in children with various forms of seizures. We will discuss evidence for inflammation in the pathophysiology of epilepsy, including immunological aspects of epileptogenesis and role of biomarkers, and will exchange views on approaches to novel therapeutic trials of viral and immunomodulatory treatments aimed to decrease the disease burden.

Neurologists, neuroscientists, pharmacologists, neuropsychologists, neurosurgeons, and other scientists, professionals, and trainees who are performing research in epilepsy. This program is not accredited for continuing education credits. OVERVIEW

These workshops highlight exciting developments in basic, translational, and clinical epilepsy research and are designed to encourage interactive discussions about challenges and opportunities for future advances. Speakers include established and junior epilepsy investigators, as well as researchers from other fields with expertise that may be applied to epilepsy. In addition, one workshop will feature presentations by junior investigators in cutting-edge areas of research. A poster session will accompany the workshops on Sunday, with posters selected from among highlyranked Annual Meeting abstracts.

3. NMDA Receptors in Epilepsy: Mutations, Inhibitory Circuits, and Personalized Medicine Convention Center, Room 202 B, Level 2 Moderator: Heather Mefford, M.D., Ph.D. Speakers: Chris Dulla, Ph.D., Stephen Traynelis, Ph.D., Gemma Carvill, Ph.D.

MORNING SESSION I: 8:45 AM â&#x20AC;&#x201C; 10:15 AM

OVERVIEW

1. KCC2 Hypofunction in Epilepsy: Developing Novel Therapeutic Strategies to Modulate K+/ClCo-Transporter 2 (KCC2) Function

NMDA receptors are critical for synaptic plasticity and memory, but also contribute to multiple aspects of abnormal excitation in the epileptic brain. First, human mutations in NMDA receptors have been linked to epilepsy-aphasia syndromes, infantile spasms, and other early onset epileptic encephalopathies. Second, abnormal NMDA receptor expression and function

Convention Center, Room 201, Level 2 Moderator: Stephen Moss, Ph.D. Speakers: Shilpa Kadam, Ph.D., Tarek Deeb, Ph.D., Matthew Kelley, B.S., Ph.D. candidate AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

Chair, Basic Science: Viji Santhakumar, Ph.D.

SUNDAY, DECEMBER 3

contributes to circuit reorganization associated with epileptogenesis, the transition to the ictal state, and seizure generalization. Last, disrupted glutamate signaling acting through NMDA receptors can induce excitotoxicity, interfere with important spontaneous network activity in the developing brain, and disturb cellular and circuit maturation.

MORNING SESSION II: 10:30 AM - 12:00 PM 4. Psychogenic Non-epileptic Seizures: New Developments and Future Directions Convention Center, Room 201, Level 2 Moderator: Ali A. Asadi-Pooya M.D. Speakers: Ali A. Asadi-Pooya, M.D., W. Curt LaFrance Jr., M.D., M.P.H., Markus Reuber M.D., Ph.D., F.R.C.P.

Targeting NMDA receptors therapeutically, however, has been a significant challenge due to adverse side effects. Recent studies suggest, however, that pharmacological interventions in specific developmental windows, or that affect specific sub-types of NMDA receptors, may allow manipulation of NMDA receptor symptoms with reduced adverse effects.

OVERVIEW

Psychogenic non-epileptic seizures (PNES) are relatively common cases seen in epilepsy centers. However, PNES is a unique condition in that it is largely defined in terms of what it is not rather than what it is. During this workshop, we will discuss why PNES are important, review the recent advances with respect to etiology and management, and talk about directions for future research in the field.

In this Investigators Workshop, we will focus on:

SUNDAY, DECEMBER 3

1) Novel mutations in NMDA receptors associated with epilepsy 2) Opportunities and challenges associated with evaluating pharmacological strategies to utilize personalized medicine to treat epilepsy associated with NMDA receptor mutations

5. From Inflammation to Phagocytosis: How Microglia Shape Vulnerable Neuronal Networks in Epilepsy

3) Studies showing that transient disruption of specific NMDA receptor subtypes during cortical development can lead to long term circuit hyperexcitability

Moderator: Joaquin Lugo, Ph.D.

Convention Center, Room 202 A, Level 2 Speakers: Amy Brewster, Ph.D., Sookyong Koh, M.D., Ph.D., Amanda Sierra, Ph.D. OVERVIEW

The session will be moderated by Dr. Mefford a human geneticist and epileptologist.

Microglia are the brainâ&#x20AC;&#x2122;s innate immune cells and contribute to the neuropathology and pathophysiology of epilepsy. When their microenvironment is challenged with events such as seizures, microglia cells can develop an inflammatory or phagocytic response. It is widely known that microglia-mediated neuroinflammatory mechanisms play a role in neuronal hyperexcitability; however, the contribution of their phagocytic response to seizures and epilepsy is less known. Emerging evidence suggests that microglial phagocytic signaling cascades contribute to the activity-dependent modification of neuronal networks under physiological and pathological conditions.

Presentations include: Expanding Genotypes and Phenoypes in the GRIN Gene Family Gemma Carvill, Ph.D. Challenges in Designing Strategies to Exploit Personalized Medicine in Patients with GRIN Mutations Stephen Traynelis, Ph.D. Disruption of NR2C/D Activity During Reocortical Development Causes Inhibitory Hypofunction and Network Hyperexcitability Chris Dulla, Ph.D.

This workshop will begin by reviewing the contributions of the microglia-mediated neuroinflammatory alterations to the hippocampal network (Sookyong Koh).

Participants in this workshop will leaving with an understanding of: 1) How NMDA receptors dysfunction can contribute to epilepsy

The second speaker will present evidence for the role for the classical complement pathway in the regulation of the hippocampal synaptodendritic profile in experimental and human epilepsy (Amy Brewster).

2) How sub-type specific disruption of NMDA receptor activity during development can lead to network hyperexcitability

The third speaker will present research on the pathological role of a recently identified microglial phagocytic impairment in the hippocampus of both genetic and acquired models of epilepsy (Amanda Sierra).

3) The promise and difficulties in developing novel NMDA-based pharmacological tools for personalized pharmacological treatment for epilepsy

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

1.011 SCN8A Epileptic Encephalopathy Mutations Produce Hyperexcitability by Differentially Modulating Persistent and Resurgent Sodium Current in Human iPSC-derived Excitatory Cortical Neurons | Luis LopezSantiago

6. Are Animal Models of Post-Traumatic Epilepsy Translational? Convention Center, Room 202 B, Level 2 Moderator: Bret Smith, Ph.D. Speakers: Bret Smith, Ph.D., Asla Pitkanen, M.D., Robert Hunt, Ph.D.

1.012 Transcriptional Profiling of Adult Parvalbumin Interneurons in a Conditional Knock-out Model of Arx | Markus von Deimling

OVERVIEW

Traumatic brain injury (TBI) greatly increases the risk of medically intractable epilepsy. Several models of TBI have been developed to investigate the relationship between TBI and the development of posttraumatic epilepsy (PTE). Because the incident that precipitates development of epilepsy is known, studying mechanisms of posttraumatic epileptogenesis, identifying biomarkers to predict PTE, and developing treatments to prevent epilepsy after TBI are attainable goals. Understanding posttraumatic epileptogenesis may also inform investigations of other acquired epilepsy syndromes. Speakers will discuss the current state of animal models of PTE, the cellular similarities (and differences) between PTE and other types of acquired epilepsy, potential biomarkers specific to PTE develppment in the context of those associated with injury alone, and treatments that modify injury recovery and posttraumatic epileptogenesis. Understanding the processes underlying epileptogenesis after a temporally and spatially well-defined, precipitating event will provide insight into the causes of other types of acquired epilepsy.

1.013 BRAF Somatic Mutation in Developing Neurons Underlies the Intrinsic REST Mediated Epileptogenicity in Long-term Epilepsy-associated Tumors (LEATs) | Hyun Yong Koh 1.014 In Vivo Two-photon Calcium Imaging Shows Cell Type-specific Activity During Seizure Propagation in an Experimental Model of Dravet Syndrome | Conny Tran 1.045 Circadian Differences in Postictal Breathing and Mortality in Mice | Benton Purnell 1.046 Models and Mechanisms of DEPDC5-related Focal Epilepsies | Tuo Ji

1.056 Breathing and the Amygdala: Potential Implications for SUDEP | William Nobis 1.139 Role of Respiratory Control in Dravet Syndrome | Fu-Shan Kuo 1.140 Bumetanide Delays SUDEP in the SCN1B Mouse Model of Dravet Syndrome | Heather O'Malley 1.141 Developmental Trajectory of Tonic GABA Currents Contribute to Maturation of Membrane Properties in Dentate Semilunar Granule Cells | Akshay Gupta

12:00 PM - 1:30 PM

Investigators Workshop - Poster Session and Lunch

1.142 Optogenetic Activation of the Anterior Striatum Suppresses Seizures in Two Rat Models of Epilepsy | Safwan Hyder

Convention Center, Room 207, Level 2

1.143 Abnormal Dentate Granule Cells Support Dentate Hyperexcitability in a PTEN Knockout Model of Temporal Lobe Epilepsy | Candi LaSarge

Note: Number below refers to poster hall assignment. 1.006 Spontaneous Low-voltage Fast Limbic Seizures in Humans Exhibit a Specific Excitatory-inhibitory Imbalance at Seizure Onset | Bahareh Elahian

1.247 Resting State Functional Connectivity Patterns are Associated with Pharmacological Response in Temporal Lobe Epilepsy | Christina Pressl

1.007 Significance of M-type Potassium Channels in the Dentate Fyrus in Contribution to Neuronal Excitability and Seizure | Chase Carver

1.254 The Epilepsy Connectome Project | Jeffrey Binder 3.015 Seizure Effects on Cholinergic Arousal: Mechanistic Insights Through Whole-cell Recording in Vivo | John Andrews

1.008 Chronic T Cell Infiltration is Associated with Inflammation and Blood-brain Barrier Impairment During Post-traumatic Epileptogenesis | Xavier Ekolle Ndode-Ekane

3.016 A Data-driven Characterization of High Frequency Oscillations Based on Time Series Anomaly Detection | Krit Charupanit

1.010 Functional Properties of GRIN Mutations in the M2 Channel Pore-Forming Domain Associated with Epileptic Encephalopathy | Hongjie Yuan

AES ANNUAL MEETING | meeting.aesnet.org

3.017 Detection of Rhythmic High Frequency Oscillations on Surface EEG in Patients with Refractory Epilepsy | Amir Al-Bakri

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

1.047 Characterization of a Novel Mouse Model of KCNB1-associated Encephalopathy | Nicole Hawkins

SUNDAY, DECEMBER 3

3.023 Disruption of Seizures In Vitro Using Targeted Optical Stimulation at Cellular Resolution | Kyle Lillis

3.205 Evidence for Brainstem Network Disruption in Focal Epilepsy and Sudden Unexplained Death in Epilepsy: A First Validation Study | Susanne Mueller

3.024 Death-associated Protein Kinase Expression in Human Drug-resistant Epileptic Brain: A potential Molecular Target for Therapeutic Intervention | Mohammed Hossain

3.236 Thalamic Dysfunction in TLE Patients with Secondarily Generalised Tonic-clonic Seizures: A Verbal Fluency fMRI Study | Lorenzo Caciagli

3.025 HDAC1,3 as a Novel Target for Antiseizure Drug Discovery | Deborah Kurrasch

AFTERNOON SESSION I: 1:30 PM - 3:00 PM 7. Seizures Among Critically Ill Children: Optimizing Treatment Strategies to Improve Outcomes

3.026 The Role of Excitatory GABAergic Signaling on Benzodiazepine Efficacy During Prolonged Seizure Activity | Richard Burman

Convention Center, Room 201, Level 2

3.027 Potent Disease-Modifying Effects of Systemicallydelivered MicroRNA Inhibitor in Experimental Epilepsy | Cristina Reschke

Moderator: Cecil Hahn, M.D. Speakers: Eric Payne, M.D., M.P.H., F.R.C.P.C., Tobias Loddenkemper, M.D., Nicholas Abend, M.D., M.S.C.E.

3.028 Evaluation of Anti-Inflammatory Compounds in the Theiler’s Murine Encephalomyelitis Virus Model of Epilepsy | Karen Wilcox

OVERVIEW

The growing use of continuous EEG monitoring in the pediatric ICU setting has led to growing awareness of the high prevalence of seizures among certain groups of critically ill children. Although higher seizure burdens have been associated with worse short- and long-term outcomes, it remains unclear whether more aggressive seizure management can improve outcomes. This investigators workshop will provide a forum for discussion of the relationship seizures among critically ill children and outcome, and their optimal treatment. The presenters will highlight gaps in knowledge that require further study, and propose strategies for optimal study design. Discussion will be focused on setting research priorities and designing future collaborative studies.

SUNDAY, DECEMBER 3

3.031 Altered Cortical-striatal CIrcuits in a New Genetically Modified Mouse Model of Infantile Spasms and Seizures | Antonella Pirone 3.032 Propagation and Development of Ictal Discharges Generated in an Acute Experimental Epileptic Focus | Lin Li 3.033 A Universal Automated Tool for Reliable Detection of Seizures in Rodent Models of Acquired and Genetic Epilepsy | Armen Sargsyan 3.034 Tsc1-GFAP-CKO Mice: A Robust and Reproducible Model for Evaluating Potential New Anti-epileptic Therapies for Tuberous Sclerosis Complex | Steven Roberds

8. Incorporating Sex and Gender into Epilepsy Research

3.053 Disrupted Rest-active Rhythms Precedes Sudden Death in Epilepsy Kv1.1 Knockout Mouse Model | Shruthi Iyer

Convention Center, 202 A, Level 2 Moderators: Page B. Pennell, M.D., Jacqueline A. French, M.D.

3.116 High Frequency Oscillations: Separating Normal from Pathological | Laura Ewell

Speakers: Alison Pack, M.D., M.P.H., Lia Ernst, M.D., Jaideep Kapur, M.D., Ph.D.

3.117 A Continuous Hippocampal Stimulation Model of Status Epilepticus and Temporal Lobe Epilepsy in Mice | Suchitra Joshi

OVERVIEW

3.118 Uncovering Limbic Seizure Networks in Vivo: An Optogenetic and Neuroanatomical Tracing Approach | Lim-Anna Sieu

This symposium will address both the underlying theory as well as the practical aspects of incorporating sex/gender into your research in a meaningful way.

3.119 Development of a Rodent Epilepsy Monitoring Unit for Continuous Months-long Electrographic and Behavioral Studies in Rats | Senan Ebrahim

2. Lessons learned from recent clinical studies in women with epilepsy: gathering the best data

3.187 Developing a Predictive Model for Pediatric Sudden Unexplained Death in Epilepsy | Kishore Vedala

AES ANNUAL MEETING | meeting.aesnet.org

Incorporating sex and gender issues in preclinical epilepsy research

3. Learning about gender-based issues from “big data”promise and pitfalls

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

9. Hot Topics From Young Investigators in the Epilepsy Community

11. Data-driven Computational Modeling of Epileptic Network Structure

Convention Center, Room 202 B, Level 2

Convention Center, Room 202 A, Level 2

Moderators: Viji Santhakumar, Ph.D., Sydney Cash, M.D., Ph.D.

Moderator: Sarah Muldoon, Ph.D. Speakers: Viktor Jirsa, Ph.D., Marcus Kaiser, M.D., Ph.D., Ankit Khambhati, Ph.D.

OVERVIEW

This session will highlight presentations from young investigators conducting basic, translational, or clinical epilepsy research.

OVERVIEW

Many recent efforts in computational modeling of largescale brain dynamics have begun to take a more data-driven approach, incorporating structural and/or functional brain networks derived from patient data into the model. In this workshop, we will focus on approaches that use either structurally or functionally derived network connectivity as a base of brain network structure in virtual models of epileptic brains. This workshop will include presentations by some of the leaders in this new direction of computational research (Viktor Jirsa, Marcus Kaiser, and Ankit Khambhati), and promote discussion on how virtual experiments (lesions, resections) can guide experimental epilepsy research.

Topics that will be presented include: Potent Disease-modifying Effects of Systemicallydelivered MicroRNA Inhibitor in Experimental Epilepsy Cristina Reschke, B.Sc., PharmD., M.Sc., Ph.D. STXBP1 Haploinsufficient Mice Recapitulate Many Features of STXBP1 Encephalopathy Wu Chen, Ph.D.

12. MicroRNA-induced Silencing in Epilepsy â&#x20AC;&#x201C; Potential Treatment Target and Biomarker

In Vivo Two-photon Calcium Imaging Shows Cell Typespecific Activity During Seizure Propagation in an Experimental Model of Dravet Syndrome Conny Tran, B.S., Ph.D. candidate

Convention Center, Room 202 B, Level 2 Moderator: Christina Gross, Ph.D.

AFTERNOON SESSIONS II: 3:15 PM - 4:45 PM

Speakers: David Henshall, Ph.D., Eleonara Aronica, M.D., Ph.D., Karl Martin Klein, M.D., Ph.D.

10. Structural and Functional Connectivity of the Insula: Toward a Deeper Understanding of Insular Epilepsy

OVERVIEW

MicroRNAs control the expression of many target proteins and therefore can influence cellular function by regulating entire protein networks. In recent years, microRNA expression and function have been shown to be altered following seizures and in epilepsy. Manipulation of single microRNAs in rodent models of status epilepticus and epilepsy alters seizure susceptibility and severity, and can reduce neurodegeneration and neuroinflammation. This suggests microRNA-induced silencing as a novel therapeutic target in epilepsy that is mechanistically very different from currently available antiepileptic drugs. The goal of this workshop is to provide insight into the current state of the field regarding the role of microRNAs in epilepsy and an assessment of what is needed to move microRNA-based therapeutics into clinical application.

Convention Center, Room 201, Level 2 Moderator: Dang Nguyen, M.D. Speakers: Jimmy Ghaziri, Ph.D., Elie Bou Assi, Ph.D. candidate, Phillipe Ryvlin, M.D. OVERVIEW

A better understanding of insular connectivity observed at different spatial scales can improve our understanding of the clinical manifestations of insular epilepsy and increase its recognition. The first theme of this workshop will address the structural connectivity of the insula and the alterations of that connectivity as a consequence of the epileptic condition. The second will look at the aberrant functional connectivity of the insula during both spontaneous and electrically-induced epileptiform activity. The panel will also explore links between alterations in structural/functional connectivity and clinical manifestations of insular epilepsy

AES ANNUAL MEETING | meeting.aesnet.org

This workshop will discuss recent advances in understanding the mechanisms of microRNA-induced silencing in epilepsy and their implications for the development of novel therapies and biomarkers. We will cover the role of microRNAs for epileptogenesis and

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

Spontaneous Low-voltage Fast Limbic Seizures in Humans Exhibit a Specific Excitatory-Inhibitory Imbalance at Seizure Onset Bahareh Elahian, Ph.D. candidate

SUNDAY, DECEMBER 3

acquired epilepsy, as well as in genetic forms of epilepsy, and describe new technologies to quickly identify microRNAs that could be targeted to prevent hyperexcitability in the brain. Dr. Henshall will talk about neuroprotective effects of inhibiting select microRNAs in the brain in status epilepticus and epileptogenesis. Dr. Aronica will discuss how altered microRNA expression in Tuberous Sclerosis may influence neuroinflammation and epilepsy development. Dr. Klein will present recent advances in identifying genetic variation in microRNAs associated with epilepsy.

12:15 PM – 1:45 PM

Poster Walking Tours Convention Center, Hall B, Lower Level Tour Leaders: Peter Crino, M.D., Jacqueline A. French, M.D., Bruce Hermann, Ph.D., and Paul Van Ness, M.D. Join leading experts as they spotlight interesting posters and facilitate discussion with authors, gaining new and different perspectives on the data presented. To join a Walking Tour, gather at the poster information table near booth #1305 and poster board #001. A schedule of topics and tour leaders will be available.

10:00 AM – 4:00 PM

Exhibit Hall Convention Center, Hall B, Lower Level

12:00 PM – 1:30 PM

Investigators Workshop Poster Session 10:00 AM – 4:00 PM Convention Center, Room 207, Level 2

Poster Session 2

Refer to page 63 for details.

SUNDAY, DECEMBER 3

Convention Center, Hall B, Lower Level Numbers shown indicate the poster hall board assignment. Refer to aesnet.org/abstracts for details.

6:00 PM - 7:30 PM

Special Interest Groups

POSTER SESSION 2

These programs are not accredited for continuing education credits.

Translational Research..............................................2.001 – 2.073 Neurophysiology..........................................................2.074 – 2.150

Cognitive and Behavioral Treatment | Evidencebased Psychobehavioral Treatment Recommendations For Adults and Children with Epilepsy

Clinical Epilepsy ..............................................................2.151 – 2.212 Neuroimaging ................................................................2.213 – 2.245 Comorbidities (Somatic and Psychiatric)......2.246 – 2.257 Antiepileptic Drugs ....................................................2.258 – 2.321 Surgery ............................................................................2.326 – 2.354

Convention Center, Room 201, Level 2 Coordinators: Janelle Wagner, Ph.D., W Curt LaFrance, M.D., M.P.H.

Behavior/Neuropsychology/Language ..........2.355 – 2.374

Speakers: Chelsea Weyland, PsyD, Rosa Michaelis, M.D.

Non-AED/Non-Surgical Treatments ................2.322 – 2.325

Genetics ..........................................................................2.375 – 2.386

OVERVIEW

Health Services ............................................................2.387 – 2.398

Given the comorbidities associated with epilepsy and the substantial impact epilepsy and its treatments have on health-related quality of life (HRQOL), psychological and behavioral health interventions aimed at enhancing psychological well-being and self-management are essential for persons with epilepsy (PWE). Psychological/behavioral health interventions include a broad range of interventions that use psychological or behavioral techniques designed to improve HRQOL, seizure frequency and severity, and psychiatric/psychological comorbidities. A recent Cochrane review was conducted and subsequent treatment recommendations manuscript developed by the ILAE Psychobehavioral Treatment Task Force. ILAE Committee members will present therapeutic

Epidemiology ..............................................................2.399 – 2.406 Public Health..................................................................2.407 – 2.413 Case Studies ..................................................................2.414 – 2.425 Late Breaking................................................................2.426 - 2.436 This program is not accredited for continuing education credits. 12:00 PM – 2:00 PM

Poster Session 2 | Authors Present Convention Center, Hall B, Lower Level Refer to aesnet.org/abstracts for details.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

PROGRAM

recommendations with discussion of specific evidencebased treatment components based on the findings of the Cochrane review. Both adult and pediatric interventions will be covered. The SIG format will involve brief presentations and case examples with significant time for discussion of and questions regarding findings and future directions.

State-of-the-Art EEG Seizure Detection Algorithms Chris Sackallares, M.D. Accelerometer-based Seizure Detection Robert Fisher, M.D., Ph.D.

TARGET AUDIENCE

Cardiac and Respiratory Monitoring for Seizure Detection Samden Lhatoo, M.D.

Clinicians, nurses, behavioral health providers, fellows, trainees

Multimodality Non-EEG Monitoring To be announced

EEG | Multimodality Physiologic Recording for Seizure Detection in the Epilepsy Monitoring Unit

TARGET AUDIENCE

Clinicians, technicians, fellows, trainees

Convention Center, Room 146 A, Street Level Coordinators: Susan Herman, M.D., John Stern, M.D.

Epilepsy and Aging | Hyperexcitability in Alzheimer's Disease

Speakers: J. Chris Sackallares, M.D., Robert Fisher, M.D., Ph.D., Samden Lhatoo, M.D.

Convention Center, Room 202 A, Level 2 Coordinators: Helen Scharfman, Ph.D., Bruce Hermann, Ph.D., Kimford Meador, M.D.

OVERVIEW

Speakers: Lennart Mucke, M.D., Andrew Cole, M.D., Jeannie Chin, Ph.D. OVERVIEW

Three experts will discuss issues related to hyperexcitability in Alzheimer's disease from basic science and clinical perspectives. First, Dr. Lennart Mucke will describe the detection of nonconvulsive epileptiform activity in patients with Alzheimer's disease and related animal models, present data on molecular and cellular mechanisms Alzheimer's disease may have in common with epileptic encephalopathies, and discuss the development of investigational therapeutic strategies that could be of benefit in both conditions. Next, Dr. Andrew Cole will discuss innovative recordings from patients using the foramen ovale as a site for minimally invasive electrode insertion. His data suggest that there are ictal and interictal epileptiform events in patients with Alzheimer's disease that scalp EEG methods are unable to detect. The implications are very important because they suggest there is much more seizure activity in aging and Alzheimer's disease than many people would have thought. Finally, Dr. Jeannie Chin will discuss her work examining the molecular mechanisms by which seizures induce persistent cognitive deficits in animal models of epilepsy and animal models of Alzheimer's disease, which reveal molecular parallels that are novel and unanticipated.

This session will: 1) Review the technical aspects, sensitivity, and false positive rates for various monitoring techniques 2) Discuss which methods should be routinely employed during video-EEG monitoring 3) Introduce systems for large-scale analyses of multimodality physiologic data

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUNDAY, DECEMBER 3

Video-EEG monitoring is the gold standard for noninvasive diagnosis and localization of epileptic seizures. A variety of techniques are typically utilized for real-time identification of seizures in the epilepsy monitoring unit (EMU), including patient and family event markers, video review by trained observers, and automated seizure detection algorithms, but all detect seizures imperfectly. Over the past several years, multiple new techniques have been introduced to supplement EEG-based methods. These include inertial or accelerometer-based systems, automated video analysis of patient movements, electrodermal activity, quantitative electromyography, respiratory monitoring, oxygen saturation, and electrocardiogram. Combinations of these monitoring techniques may improve seizure detection in the EMU, enhancing patient safety during diagnostic evaluations. In addition, multimodality monitoring may detect physiologic abnormalities which place patients at increased risk of adverse cardiac or respiratory events during out-ofhospital seizures.

SUNDAY, DECEMBER 3

TARGET AUDIENCE

6:00 PM - 8:00 PM

SUNDAY, DECEMBER 3

Clinicians, scientists, nurses, behavioral health providers

Satellite Symposium

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

Convention Center, Salon C, Street Level

This educational activity is supported in part by an educational grant from Greenwich Biosciences, Inc.

Dravet Syndrome: Emerging Insights, New Treatment Approaches

Epilepsy Surgery | Minimally Invasive Approaches to Epilepsy Surgery

For further details, please visit https://courses.elseviercme.com/aes2017

Convention Center, Room 146 B/C, Street Level Coordinators: Gerald Grant, M.D., Nitin Tandon, M.D. Speakers: To be announced

Pre-registration was requested. On-site registration may be available, space permitting. Dinner is provided.

OVERVIEW

This live activity is supported by an independent educational grant from Zogenix, Inc.

This session will feature debates regarding the possible (traditional vs. minimally invasive) approaches to cases with pharmaco-resistant epilepsy. Participants may submit epilepsy surgery cases to the SIG coordinators in advance of the meeting to highlight the role of minimally vs. maximally invasive localization and treatment modalities in managing these cases. We will assess how minimally invasive surgical techniques such as SEEG, laser ablation, neuromodulation, and innovative microsurgical approaches may be applied to individual cases and will evaluate the long term outcomes. All cases will be required to have one year post-operative follow-up to assess intermediate range durability of these therapies.

This CME activity is jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. To claim credit for this symposium, please contact maria.delcegno@millermeded.com. 6:00 PM - 8:00 PM

Satellite Symposium Convention Center, Room 147, Street Level

Patient and Caregiver Perspectives in Pediatric Epilepsy: Established Strategies and Emerging Approaches for Focal Seizures

Clinicians, technicians, fellows, trainees

For further details, please visit www.medscape.org/sites/townhall/public/pediatricseizures.

Tumor-Related Epilepsy | Advances in NeuroImaging

Pre-registration was requested. On-site registration may be available, space permitting. Dinner is provided.

Convention Center, Room 202 B, Level 2 Coordinators: Jeffrey Politsky, M.D., M.Sc., Sandeep Mittal, M.D.

This live activity is supported by an independent educational grant from Sunovion Pharmaceuticals Inc.

TARGET AUDIENCE

This CME activity is provided by Medscape.

Speakers: To be announced

To claim credit for this symposium, please contact the accredited provider at CME@medscape.net.

OVERVIEW

This year's SIG focuses on the latest advances in neuroimaging relative to the diagnosis, treatment, and follow-up of patients with tumor-related epilepsy.

9:30 PM – 10:30 PM

AES Attendee Reception TARGET AUDIENCE

Marriott Marquis, Independence Ballroom Salon B, M4 Level

Clinicians, scientists, fellows, trainees

Wind down after a jam-packed weekend! Come one, come all to mingle and indulge in sweet desserts, plus your choice of wine, beer, or coffee. Dance it off to the sounds of “Ear Candy”, featuring DJ Floss and the Rockin’ MDMC. All Annual Meeting registrants are welcome, with or without dancing shoes.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

members of the audience will be invited to describe and analyze seizure semiology and to form hypotheses of seizure onset and spread. The faculty will then comment on the material with brief discussion of particular clinical features. The presenter will give the final explanation based upon neuroimaging, intracranial EEG, and the surgical outcome. Brief didactic material is delivered to end each case.

7:00 AM - 8:30 AM

Special Interest Groups These programs are not accredited for continuing education credits.

Basic Mechanisms and Neuroscience | Wnt/Betacatenin Signaling Dysfunction and Epilepsy Convention Center, Salon C, Street Level Coordinators: Joaquin Lugo, Ph.D., Katty (Jing-Qiong) Kang, M.D., Ph.D.

TARGET AUDIENCE

Clinicians, technicians, fellows, trainees

Neonatal Seizures | Neonatal Seizures â&#x20AC;&#x201C; Enhancing Detection

Speakers: Chris Dulla, Ph.D., Michele Jacob, Ph.D., Joaquin Lugo, Ph.D.

Convention Center, Room 202 A, Level 2 Coordinators: Timothy Benke, M.D., Ph.D., Shavonne Massey, M.D.

OVERVIEW

The speakers will present evidence from animal models supporting a role for the dysfunction of Wnt/betacatenin signaling in the pathogenesis of epilepsy. Chris Dulla will discuss how a mouse model of infantile spams has elevated neuronal beta-catenin levels and seizures. Michele Jacobs will discuss how disruption of the pathway may contribute to the autistic and learning impairment comorbidities in epilepsy. Joaquin Lugo will discuss how seizures can lead to a disruption of neuronal Wnt signaling and how Wnt and mTOR pathways can converge.

Speakers: Tammy Tsuchida, M.D., Ph.D., Cecil Hahn, M.D., Jan Claassen, M.D. OVERVIEW

This session is intended to illustrate the role of EEG in the neonatal intensive care unit and the impact that EEG use has in acute and chronic outcomes in neonates with cerebral injury. In addition to a review of the epidemiology of neonatal seizures, current neuromonitoring recommendations and guidelines, and current treatment best practices, more controversial topics will also be introduced, including the role of the EEG background in prognostication and clinical decision-making, innovative methods of seizure burden quantification, and the ever-evolving role of alternative neuromonitoring tools in the neonatal intensive care unit.

TARGET AUDIENCE

Scientists

Ictal Semiology | Case Studies in Seizure Semiology

TARGET AUDIENCE

Scientists, fellows, trainees

Speakers: Andrew Bleasel, M.B.B.S., Hajo Hamer, M.D., Hans LĂźders, M.D., Philippe Kahane, M.D.

Psychosocial Comorbidities | The Impact of Pharmacological Interventions on Behavior, Cognition, and Seizure Control

OVERVIEW

Clinical cases are presented to illustrate how seizure semiology can be used in the localization of seizure onset and routes of ictal propagation. The panel and the audience are challenged in the detailed examination of seizure semiology with 4-6 cases of typical or unusual seizures. The format of the session is interactive with the main aim to show the audience how to use subjective and observable clinical elements to localize the seizure onset and reconstruct the propagation pattern of the ictal discharge.

Convention Center, Room 146 A, Street Level Coordinators: Gaston Baslet, M.D., Jana Jones, Ph.D. Speakers: Tatiana Falcone, M.D., Daniel Weisholtz, M.D. OVERVIEW

A thorough evaluation of epilepsy patients includes an examination of the impact of anti-epileptic drugs on behavior and cognition. On the other end, selection of a psychotropic agent to treat psychosocial comorbidities needs to be informed by potential impact on seizure control. In this SIG, experts will review the current evidence on behavioral and cognitive effects of antiepileptic drugs, and the risk of seizure occurrence with

Format: 1 short slide of presentation, 1 video (two-tothree minutes), discussion (five-to-eight minutes), 1 slide showing the explanation (two minutes), for a maximum of 15 minutes per case. After showing each video,

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

Convention Center, Room 146 B/C, Street Level Coordinators: Andrew Bleasel, M.B.B.S., Ph.D., Hajo Hamer, M.D.

MONDAY, DECEMBER 4

different classes of psychotropic agents and will discuss specific considerations across different age groups. Illustrations with clinical cases will be included and participation from the audience encouraged.

than in other procedures. Does existing data warrant its use? And what types of outcomes should we expect? How do seizure freedom rates, surgical risks, and neuropsychological consequences compare with what occurs after more aggressive approaches? Are we targeting appropriately to adequately disrupt the epileptogenic network or should targeting be altered? What is an acceptable trade-off between seizure freedom and neuroposychological deficits?

TARGET AUDIENCE

Clinicians, nurses, behavioral health providers, fellows, trainees

Seizures and Cerebrovascular Disease | Seizures in Posterior Reversible Encephalopathy Syndrome (PRES)

TARGET AUDIENCE

Clinicians, scientists, nurses, behavioral health providers, technicians, fellows, trainees

Convention Center, Room 202 B, Level 2 Coordinators: Naim Haddad, M.D., David Chuang, M.D.

8:00 AM – 2:00 PM

Speakers: Kinshuk Sahaya, M.D., Sudhakar Tummala, M.D., Zhiyi Sha M.D., Ph.D.

Poster Session 3

OVERVIEW

Convention Center, Hall B, Lower Level

Seizures are a common manifestation of posterior reversible encephalopathy syndrome (PRES). In rare instances, they may progress to epilepsy. There has been new interest in PRES-related seizures reflected by a slew of new papers on this topic. Speakers who recently published on the topic will discuss risk factors of seizures in PRES, EEG findings in PRES, and clinical outcomes of PRES-related seizures. Presentations will include didactic sessions as well as engaging brief casebased discussions.

Use alternate entrance to poster session, near Rotunda B, between 8:00 AM - 10:00 AM. Continental breakfast available. Numbers shown indicate the poster hall board assignment. Refer to www.aesnet.org/abstracts for details. POSTER SESSION 3

Translational Research ............................................3.001 – 3.060 Neurophysiology ..........................................................3.061 – 3.135 Clinical Epilepsy............................................................3.136 – 3.203 Neuroimaging ..............................................................3.204 – 3.236 Comorbidities (Somatic and Psychiatric)......3.237 – 3.248 Antiepileptic Drugs....................................................3.249 – 3.297 Surgery ............................................................................3.298 – 3.328 Dietary..............................................................................3.329 – 3.342 Behavior/Neuropsychology/Language..........3.343 – 3.362 Genetics ..........................................................................3.363 – 3.374 Health Services ............................................................3.375 – 3.386 Neuropathology of Epilepsy ................................3.387 – 3.392 Practice Resources....................................................3.393 – 3.396 Epidemiology ..............................................................3.397 – 3.405 Public Health ................................................................3.406 – 3.413 Case Studies ..................................................................3.414 – 3.424 Non-AED/Non-Surgical Treatments ................3.425 – 3.425

PRESENTATIONS

Predictors of Acute Seizures in Patients with PRES: Kinshuk Sahaya, M.D.

MONDAY, DECEMBER 4

Electrographic Patterns in Patients with PRES and Seizures: Sudhakar Tummala, M.D. Longterm Risk of Epilepsy in Patients with PRES: Zhiyi Sha M.D., Ph.D. TARGET AUDIENCE

Clinicians, fellows, trainees

Temporal Lobe Club | Thermal Ablation for Mesial Temporal Lobe Epilepsy Convention Center, Room 147 A/B, Street Level Coordinators: Michael Sperling, M.D., Jerome Engel, Jr., M.D., Ph.D. Speakers: Ivan Soltesz, Ph.D., Robert Gross, M.D., Ph.D., Susan Bookheimer, Ph.D., Chengyuan Wu, M.D., Michael Sperling, M.D.

Late Breaking ..............................................................3.426 - 3.436

OVERVIEW

This program is not accredited for continuing education credits.

Thermal ablation (TA) is rapidly gaining popularity as a minimally invasive treatment for mesial temporal lobe epilepsy. The volume of tissue ablated with TA is far less

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

d. Multicenter trials to expedite the progress of preclinical research projects and to demonstrate reproducibility of the findings

8:00 AM – 11:00 AM

Scientific Exhibits Convention Center, Street Level

• Discuss the relative benefits of translational research that begins by establishing mechanism of action as contrasted to research that begins with screening or empiric observation

These exhibits provide meeting attendees an opportunity to get updates on the latest research. Authors will be present throughout the exhibit time.

• Identify funding opportunities for each approach and critically assess research utilizing either approach

See page 30 for details.

• Discuss current and soon-to-come therapies for epilepsy and comorbid conditions and be prepared for changes in practice that will occur as devices become a standard approach to epilepsy therapy

9:00 AM - 11:30 AM

Translational Research Symposium | Getting to Yes

• Identify what is required to move a promising therapy from preclinical and early clinical work to late stage commercial development and consider these elements when developing a long-term translational plan

Convention Center, Ballroom A/B, Level 3 OVERVIEW

Translational research encompasses a range of activities needed to develop and implement a new therapy for the clinic. This symposium will review new resources and diverse perspectives central to efficient and effective translational research. Specifically, the ILAE/AES Joint Translational Task Force will present updates from their efforts to accelerate preclinical translational research with preclinical common data elements, harmonization of EEG and other methods, choice of preclinical endpoints for translation to human studies, and multicenter preclinical trials. In addition, the pros and cons of drug discovery programs based on empiric observation versus known mechanism-of-action will be debated. The utility of preclinical translational research in humans will be discussed, with focus on neurotechnology and device-based therapeutics. Lastly, the expectations and requirements for successful translational programs will be reviewed from the perspective of both regulators and commercial developers.

• Delineate the basic components of regulatory requirements for efficient translation of preclinical and clinical development • Delineate the mechanisms by which FDA guidance can be obtained • Identify NIH and FDA-harmonized clinical trial templates • Restate the requirements for advancing a promising therapy from preclinical and early clinical work to late stage commercial development; incorporate these elements when developing a long-term translational plan TARGET AUDIENCE

LEARNING OBJECTIVES

PROGRAM

Following participation in this activity, should be able to:

Introduction: Translation Defined Andrew J. Cole, M.D.

• Define translation and describe its constituent elements, sometimes referred to as T0-T6 • Review the work of the ILAE/AES joint task force, which addresses limitations in the traditional preclinical approaches that have impeded translation into human therapies

Preclinical Epilepsy Research: Report of the ILAE/AES Translational Task Force 1) Overview and Goals of the ILAE/AES Translational Task Force Terence O’Brien, M.B.B.S., M.D.

• Describe the areas identified by the ILAE/AES task force that should be addressed, including:

2) Development of Common Data Elements Vicky Whittemore, Ph.D.

a. Preclinical common data elements

3) Harmonization Of EEG Methods and Interpretation in Animal Models Solomon Moshe, M.D., Ph.D.

b. Harmonization of EEG and other methods c. Identifying preclinical endpoints that will be translatable to clinical endpoints in human studies AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

Neurologists, epileptologists, pediatric neurologists, researchers, nurses, psychologists/neuropsychologists, nurse practitioners/physician assistants, pharmacists

MONDAY, DECEMBER 4

4) Endpoints for Translational Pre-Clinical Studies Michele Simonato, M.D., Ph.D.

Multiscale Rhythms of Interictal Epileptiform Activity Help Determine Seizure Risk Maxime Baud, M.D., Ph.D., and Vikram Rao, M.D., Ph.D.

5) Multi-Center Pre-Clinical Trials Terence Oâ&#x20AC;&#x2122;Brien, M.B.B.S., M.D.

Crowd-Sourcing and an Open Data Ecosystem for Seizure prediction Levin Kuhlmann, Ph.D.

6) Panel Discussion Karen Wilcox, Ph.D.

Long-term Rhythms, Clusters, and Seizure Forecasting in Epilepsy Dean Freestone, Ph.D.

Debate: Mechanism of Action (MOA)-based vs. Empiric or Screening-based Discovery of Epilepsy Therapies Dennis Dlugos, M.D. and Raman Sankar, M.D., Ph.D.

TARGET AUDIENCE

Scientists, fellows, trainees

Neurotechnology: Pre-Clinical Translational Research in Humans Sydney Cash, M.D., Ph.D.

Global Pregnancy Registry Outcomes | Emerging Data from The International Pregnancy Registries

Reverse Translation Henrik Klitgaard, Ph.D.

Convention Center, Room 204 A/B, Level 2 Coordinators: Naymee J. Velez Ruiz, M.D., Esther Bui, M.D.

Moving from Bench to Bedside: What Does it Take to Make a Go/No Decision on Commercial Development Roy Twyman, M.D., Ph.D.

Speakers: TorbjĂśrn Tomson, M.D., Ph.D., John Craig, M.D., Piero Perucca, M.D., Lewis Holmes, M.D., Kimford Meador, M.D., Page B. Pennell, M.D.

Conclusion Martha Morrell, M.D.

OVERVIEW

This program is not accredited for continuing education credits.

Includes the presentation of the Kimford J. Meador Research in Women with Epilepsy Award (supported by My Epilepsy Story), Michael O. Kinney, BSc, MB, BCh, BAO, MRCP (Poster 3.203).

9:00 AM - 10:30 AM

Special Interest Groups

The management of epilepsy during pregnancy is one of the most rapidly evolving fields within neurology and one that generates a great deal of anxiety among providers. The international pregnancy registries have been essential to pushing forward our understanding of how to treat and counsel this extremely vulnerable group of patients (and their children). The pregnancies registry SIG provides the opportunity for AES attendees to review the constantly evolving data being generated by these powerful registries at one time. Attendees receive critical emerging data that may dramatically influence their care of all women of child-bearing age with epilepsy. We also try to apply this data and the opinions of our expert speakers to clinically relevant cases handled by all attendees. Speakers from key principal registries will present their most recent prepublication data and discuss some of the related controversies. This is an interactive session with case review by the expert panel and the audience. SIG participants may submit cases for discussion via the AES Connect forum in advance of the meeting.

These programs are not accredited for continuing education credits.

MONDAY, DECEMBER 4

Engineering and Neurostimulation | What Are the Next Steps for Closed Loop Control of Seizures? Convention Center, Room 146 B/C, Street Level Coordinators: William Stacey, M.D., Ph.D., Richard Staba, Ph.D. Speakers: Dean Freestone, Ph.D., Vikram Rao, M.D., Ph.D., Maxime Baud, M.D., Ph.D., David Mogul, Ph.D., Levin Kuhlmann, Ph.D. OVERVIEW

The approval of a closed loop control device for epilepsy has opened a new era of potential epilepsy treatments. However, there is great room for improvement as technology and our understanding of seizures expands. This session will address recent advancements in potential biomarkers and optimized stimulation protocols that might lead to the next generation of closed loop control.

TARGET AUDIENCE

Clinicians, nurses, fellows, trainees

PROGRAM

Tailoring Deep Brain Stimulation Protocols to Reflect Seizure Dynamics Improves its Therapeutic Efficacy David Mogul, Ph.D. AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

Neuropharmacology | Nonconventional Treatment of Seizures and Epilepsy

Scientific Publishing | Meet the Editors: Looking Towards the Future of Scientific Publishing

Convention Center, Salon C, Street Level Coordinators: Archana Shrestha, M.D., Mikiko YamadaTakeda, Pharm.D., M.S., Ph.C.

Convention Center, Room 202 B, Level 2 Coordinators: Markus Reuber, M.D., Ph.D., Andres M. Kanner, M.D., FANA, FAAN

Speakers: Lauren Frey M.D., Mesha Gay-Brown M.D.

Speakers: Astrid Nehlig, Ph.D., Michael Sperling, M.D., Andres M. Kanner, M.D., FANA, FAAN, Markus Reuber, M.D., Ph.D.

OVERVIEW

Assessing other potential treatment options for epilepsy aside from the standard anticonvulsant medications including SSRI, neurofeedback, and adult diet therapy.

OVERVIEW

The effective publication of scientific discoveries is of great importance for the advancement of medicine but also as a metric for institutions and individuals. Four editors of international epilepsy journals will address questions about current publication practices, the use and abuse of citation metrics, and the changes to scientific publishing likely to result from developments in communication methods, professional organization, and funding models.

TARGET AUDIENCE

Clinicians, scientists, fellows, trainees

Neuropsychology | Cognition, Mood, and Social Behavior in Frontal Lobe Epilepsy Convention Center, Room 147 A/B, Street Level Coordinators: Gail L. Risse, Ph.D., Robyn Busch, Ph.D.

TARGET AUDIENCE

Speakers: Robyn Busch, Ph.D., Mary Lou Smith, Ph.D., Anna Rita Giovagnoli, Ph.D., Jennifer Haut, Ph.D.

Clinicians, scientists, nurses, behavioral health providers, technicians, fellows, trainees

OVERVIEW

This session will review the complex behavioral and cognitive functions and dysfunction associated with frontal lobe epilepsy in adults and children. Consideration of specific patterns of impairment unique to frontal lobe networks, post-surgical outcome data, and the contribution of frontal lobe epilepsy to social cognition, meed, and behavior will be explored.

10:00 AM – 2:00 PM

Exhibit Hall Convention Center, Hall B, Lower Level 12:00 PM – 2:00 PM

Poster Session 3 | Authors Present

TARGET AUDIENCE

Convention Center, Hall B, Lower Level

Clinicians, nurses, behavioral health providers, fellows, trainees

Refer to www.aesnet.org/abstracts for details. 12:15 PM – 1:45 PM

Poster Walking Tours

Convention Center, Room 204 C, Level 2 Coordinators: Kathleen Boreale, APN-C, M.S., Erin McCrone, APN-C

Convention Center, Hall B, Lower Level Tour Leaders: Anne Anderson, M.D., Greg Bergey, M.D., Eric Kossoff, M.D., Kimford Meador, M.D., and Dennis Spencer, M.D.

Speakers: Alyson Bolton, RN, CPN, Melissa A. Burnside, Elizabeth Kleber, Ph.D., RN

Join leading experts as they spotlight interesting posters and facilitate discussion with authors, gaining new and different perspectives on the data presented.

OVERVIEW

A panel discussion to address the issues that arise with transitions from inpatient to outpatient settings as well as meeting outpatient needs to improve healthcare and quality of life. Case studies will assist in identifying ways to seamlessly provide safe transitions and discuss helpful tools and resources to best support patients and their families.

To join a walking tour, gather at the poster information table near booth #1305 and poster board #001. A schedule of topics and tour leaders will be available.

TARGET AUDIENCE

Nurses

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

Nursing | Nursing's Role in Patient Transitions: Assisting with Seamless Safe Transitions to Meet Patient Needs

MONDAY, DECEMBER 4

1.176 Infantile Epilepsy with Polonged Focal Myoclonic Seizures: A Distinctive Syndrome Associated with TBC1D24 Mutation | Deepa Sirsi

2:15 PM - 3:00 PM

Lennox and Lombroso Lecture Convention Center, Ballroom A/B, Level 3

1.236 Brain MRI Abnormalities in Patients with Infantile Spasms and Down Syndrome | Sara Trowbridge

OVERVIEW

The dentate gyrus has been the subject of many studies about temporal lobe epilepsy, both in basic and clinical research. As technical advances have occurred over the last 10-20 years, some long-standing ideas have been supported whereas others have been called into question. Questions that were previously impossible to ask have been investigated. In some cases, surprising findings have required major conceptual shifts. A synthesis of old and new will be presented and the most pressing current questions for the future will be discussed.

1.302 High Vigabatrin Dosage is Associated with Lower Risk of Infantile Spasms Relapse Among Children with Tuberous Sclerosis Complex | Ernst Schmid

TARGET AUDIENCE

2.366 Neurodevelopment in Infantile Onset Epilepsy Characterization of the First Fifty Patients in the EPIPEG Study | Katharina Vezyroglou

1.303 Comparative Effectiveness of ACTH Versus Other Therapies for Infantile Spasms: Counterfactual Calculations and Potential Effect of Practice Change | Renee Shellhaas 2.291 Superior Effectiveness of Levetiracetam Over Phenobarbital for Infantile Nonsyndromic Epilepsy: A Prospective Multi-Center Observational Study | Zachary Grinspan

Clinicians, scientists, nurses, behavioral health providers, technicians, fellows, trainees

2.368 Memory Function Following Febrile Status Epilepticus: Results of the Febstat Study | Erica Weiss

PROGRAM

The Dentate Gyrus, Seizures and Temporal Lobe Epilepsy in 2017 Lecturer: Helen Scharfman, Ph.D.

2.375 A Recurrent Missense Variant in the Transcription Factor and Upper Layer Neuronal Marker, CUX2, Causes Developmental and Epileptic Encephalopathy | Gemma Carvill

This program is not accredited for continuing education credits.

3:15 PM - 5:30 PM

Pediatric Epilepsy Highlights Session

3:15 PM - 5:15 PM

The 2012 Institute of Medicine/National Academies of Science and Medicine (IOM/NASEM): Report on Epilepsy Five Years Out

Convention Center, Room 147 A/B, Street Level MONDAY, DECEMBER 4

OVERVIEW

This session will showcase selected scientific abstracts focused on topics in clinical care and research in pediatric epilepsy. Authors will present a six-minute overview of their work. Presentations are chosen from all submitted abstracts. Participants will be able to view posters and meet the authors at the end of the program. Numbers shown indicate the poster hall assignment.

Convention Center, Ballroom C, Level 3 OVERVIEW

Institute of Medicine published its first Report on Epilepsy, entitled: â&#x20AC;&#x153;Epilepsy Across the Spectrum: The Public Health Dimensions of the Epilepsiesâ&#x20AC;? in 2012. The emphasis was on the challenges faced by patients, care givers, and health care organizations in helping people with epilepsy achieve optimal care and quality of life. This remarkable body of work was due to the cooperation of numerous public and private entities, ranging from the NIH and the CDC, to professional societies including AES and numerous patient organizations such as CURE and EF, among many others. We learned new population data regarding epilepsy incidence and burden, demographic disparities, and prevalence of its cognitive comorbidities. The IOM

This program is not accredited for continuing education credits. PROGRAM

1.016 Onset of Interictal Ripples in Intracranial Electroencephalography Predicts Seizure Outcome In Children Undergoing Epilepsy Surgery | Eleonora Tamilia 1.093 Interrater Variability of EEG Interpretation after Pediatric Cardiac Arrest Utilizing Standardized Critical Care EEG Terminology | Nicholas Abend

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

report resulted in the formalization of new collaborations between the initial contributing entities which has continued to enlighten the field and build new support structures around the care of epilepsy, which is an evolving process. This session will highlight the initial charges put forth from the original report as well as the exceptional progress made in the past five years by numerous collaborative groups.

3:15 PM - 4:45 PM

Investigators Workshop: In-vivo Imaging of Network Dynamics in Epilepsy Convention Center, Room 202 A, Level 2 Moderator: Peyman Golshani, M.D., Ph.D. Speakers: Stelios Smirnakis, M.D., Ph.D., Matthew Shrtahman, M.D., Ph.D., Istvan Mody, Ph.D.

TARGET AUDIENCE OVERVIEW

Clinicians, nurses, behavioral health providers, technicians, fellows, trainees

New tools now enable high-speed simultaneous imaging of activity in hundreds of neurons in behaving animals. We will highlight three speakers that show how calcium and voltage imaging of large ensembles can be used to to follow the activity patterns of large populations of precisely identified neurons in models of temporal lobe and generalized epilepsy. These approaches can be used to discover dysfunction in key cell types that may be driving initiation of seizures or network dysfunction during cognition in epilepsy.

PROGRAM

Introductory Remarks Frances E. Jensen, M.D., FAAN (2012 AES President) IOM/NAM: Setting the Agenda in Health and Medicine Victor J. Dzau, M.D., President, National Academy of Medicine The Path to the IOM Report Susan Axelrod, MBA, Founding Chair, CURE (Citizens United for Research in Epilepsy)

3:15 PM - 4:45 PM

Investigators Workshop: Somatic Mutation: The ‘Hidden Genetics’ of Brain Malformations

The IOM/NASEM Report on Epilepsy Howard Koh, M.D., M.PH., Harvey V. Fineberg Professor of the Practice of Public Health Leadership at the Harvard T.H. Chan School of Public Health and the Harvard Kennedy School. Former Assistant Secretary for Health for the U.S. Department of Health and Human Services

Convention Center, Room 202 B, Level 2

Update on Epilepsy Public Health Impact: Monitoring Prevalence, Incidence, and Burden Dale Hesdorffer, Ph.D., Professor, Epidemiology (in the Sergievsky Center) at the Columbia University Medical Center

OVERVIEW

Moderators: Michael Hildebrand, Ph.D., Heather Mefford, M.D., Ph.D. Speakers: Annapurna Poduri, M.D., Naomichi Matsumoto, M.D., Ph.D.

Extinguishing the Stigma and Social Burden of Epilepsy Joan Austin, Ph.D., RN, FAAN, Distinguished Professor Emerita, Indiana University School of Nursing The Complementary Role of the IOM/NASEM Report and Ongoing NIH Research Initiatives Focused on Epilepsy Walter Koroshetz, M.D., Director NINDS

In this workshop, we intend to push the boundaries by discussing three major challenges of this exciting field. Dr. Poduri will discuss advances in clinical evaluations including MRI that permit improved diagnostic yield even for subtle brain malformations. Dr. Hildebrand will address the need for alternative tissue sources including CSF and nasal epithelium to interrogate genetically. Dr. Matsumoto will introduce the latest molecular approaches to detect ultra-low-level somatic mosaicism. These strategies are applicable to epilepsies and other brain disorders to maximize gene discovery, clinical diagnosis, and, eventually, to facilitate translation of precision therapies to the clinic.

Panel Discussion - The Path Forward Moderated by Eli M. Mizrahi, M.D., 2017 AES President This program is not accredited for continuing education credits. 3:15 PM - 5:30 PM

Concurrent Platform Sessions See page 76

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

Somatic mutation is a genetic mechanism increasingly being recognized in neurological disorders. It has recently been posited that there may be a sizeable ‘hidden genetics’ component of epilepsy due to somatic mutation. This occurs post-zygotically, is largely confined to the brain, and is difficult or impossible to detect in blood. At present, the route to discovery in brain is via the privileged situation of brain tissue from surgical or autopsy specimens and many somatic mutations are mosaic at very low level in brain tissue.

MONDAY, DECEMBER 4

3:15 PM - 5:30 PM Concurrent Platform Sessions There will be three concurrent sessions consisting of selected key scientific abstracts. Authors will present a 12-minute overview of their work followed by a two-minute Q&A session.

MONDAY, DECEMBER 4

This program is not accredited for continuing education credits Platform A: Genetics

Platform B: Neurophysiology

Platform C: Neuroimaging

Convention Center, Room 146 A, Street Level Moderators: Heather Mefford, M.D., Ph.D. and Miriam Meisler, Ph.D.

Convention Center, Room 146 B, Street Level Moderators: Kevin Chapman, M.D. and Ivan Soltesz, Ph.D.

Convention Center, Room 146 C, Street Level Moderators: Graeme Jackson, M.D. and Sara Inati, M.D.

3:15 PM

A.01 Peripheral Epigenetic Biomarkers for Idiopathic Epilepsies: The Testament of Twins | Lata Vadlamudi

B.01 Electrophysiological and Clinical Biomarkers of ACTH (Acthar Gel) Treatment | Ahmet Tanritanir

C.01 Hub Analysis Using Resting State fMRI in Patients with Focal Epilepsy and Surgical Outcomes | Satoshi Maesawa

3:28 PM

A.02 Identification of Somatic Mutations in Three Subtypes of Malformations of Cortical Development | Nicole Griffin

B.02 Mouse Model of Myoclonus Epilepsy and Ataxia Due to Potassium Channel Mutation | Nikola Jancovski

C.02 MRI Connectivity May Predict Surgical Outcome in Mesial Temporal Lobe Epilepsy | Victoria Morgan

3:41 PM

A.03 Experiences of Whole Exome Sequencing in a Broad Adult and Pediatric Epilepsy Cohort | Michelle Ernst

B.03 Bumetanide Delays SUDEP in the Scn1b Mouse Model of Dravet Syndrome | Heather O'Malley

C.03 NMDA-receptor Activation Measured with [18F]GE-179 PET Lateralizes and Localizes the Epileptic Focus | Marian Galovic

3:54 PM

A.04 Diagnostic Testing Using Capturebased Next Generation Sequencing Reveals a High Rate of Mosaicism in Genes Associated with Epilepsy-related Neurodevelopmental Disorders | Dianalee McKnight

B.04 Relative Value of Spot vs Prolonged EEG (pEEG) | Jaysingh Singh

C.04 Development of Automated, Patient-Specific Algorithm to Visualize Epilepsy Network in 3D | Elliot Neal

4:07 PM

A.05 De Movo and Inherited Variants in MAP1B in Periventricular Nodular Heterotopia | Erin Heinzen

B.05 Axonal and Somatic Sodium Current Defects in a Cell Type Specific and Development Independent Model of SCN1B-linked Dravet Syndrome | Jacob Hull

C.05 Patient-specific Brain Abnormalities in Refractory Focal Epilepsy: Adjusted Local Connectivity (ALC) | Mangor Pedersen

4:20 PM

A.06 The Genetic Landscape of the Epilepsy-aphasia Spectrum Disorders | Candace Myers

B.06 Region-specific Normative Values of High-frequency Oscillations: Development of a Multicenter Atlas for Intracranial Physiological Activity | Birgit Frauscher

4:33 PM

A.07 Scottish Whole Population Based Prospective Genetic and Autoimmune Testing in New Onset Epilepsy and Complex Febrile Seizures in Children <3 years: Diagnostic and Clinical Utility | Joseph Symonds

B.07 Using Electrocorticogram Baseline Seizure Frequency to Assess Responsive Neurostimulation Efficacy | Michael Young

C.07 fMRI and Direct Cortical Stimulation: Prediction of Post-operative Language Deficits | Alison Austermuehle

4:46 PM

A.08 Shedding Light Into Voltage-gated Sodium Channel Associated Neurodevelopmental Disorders | Dennis Lal

B.08 Cortical Maturation Metrics Obtained by Neuronavigated Transcranial Magnetic Stimulation (nTMS) in Patients with Intractable Focal Epilepsy | Harper Kaye

C.08 Local Resting Connectivity is Decreased in Regions of Metabolic Dysfunction | Jing Huei Lee

5:00 PM

A.09 Rare Coding Variants in GABAA Receptor Subunit Genes in Genetic Generalized Epilepsies | Roland Krause

B.09 Effect of Intraoperative Highdensity-ECoG on Surgical Outcome After Awake Craniotomies | Karim ReFaey

C.09 Open Source Interactive 3D Webbased Visualization for Intracranial Electroencephalography | Joel Stein

A.10 Ultra-Sensitive Quantitative Detection of Somatic Mosaic Mutation in â&#x20AC;&#x153;Double Cortexâ&#x20AC;? Syndrome | Michael Hildebrand

B.10 Uncovering LImbic Seizure Networks in Vivo: An Optogenetic and Neuroanatomical Tracing Approach | Lim-Anna Sieu

C.10 Thalamic Dysfunction in TLE Patients with Secondarily Generalised Tonic-clonic Seizures: A Verbal Fluency fMRI Study | Lorenzo Caciagli

5:13 PM

5:25 PM

C.06 Resting State Connectivity Network Abnormalities in Newly Diagnosed Focal Epilepsy | Heath Pardoe

B.11 The 'Epileptic Personality' Revisited: Is The Broader Autism Phenoype More Frequent in People with Seizures? | Annie Richard Selected for the Rebecca Goldberg Kauffman Honor*

*The Rebecca Goldberg Kaufman Honor is awarded to the highest-ranking abstract in the comorbidities topic category and is scheduled as Platform B.11. The abstract honored is selected from more than 1,300 submitted abstracts by the Scientific Program Committee.

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

TARGET AUDIENCE

5:45 PM - 8:15 PM Epilepsy Therapies Symposium | Innovations in Epilepsy Treatment: Are We on the Cusp of a Paradigm Shift?

Neurologists, epileptologists, nurse practitioners, physician assistants, nurses, pharmacists PROGRAM

Co-chairs: Cynthia Harden, M.D. and Jerry Shih, M.D. Convention Center, Ballroom A/B, Level 3

Introduction Cynthia Harden, M.D.

Award Presentation: J. Kiffin Penry Award for Excellence in Epilepsy Care

Debate: Should Staged Epilepsy Surgery Start with Minimally Invasive Approaches? Saadi Ghatan, M.D. and Jeffrey P. Blount, M.D.

OVERVIEW

This symposium focuses on challenges and innovations in epilepsy treatment. While epilepsy surgery for refractory epilepsy continues to be underutilized, minimally invasive techniques for localizing and treating focal epilepsy are making epilepsy surgery more attractive to patients due to their relative safety and tolerability in terms of discomfort and length of hospital stay. Genetic testing in adults with seizures can aid in the diagnosis and treatment of focal epilepsy. The specific sequence and duration of treatment for immune-related epilepsy is rarely discussed in detail, particularly in association with the causative antibody. Although there is abundant literature on this topic, healthcare providers are still seeking more detailed guidance on the treatment approaches of this difficult clinical entity. Finally, the initial and second choice of AEDs remains complex.

Testing and Treating for Focal Genetic Epilepsies Piero Perucca, M.D. The What, When, How, and How Much When Treating Immune-related Epilepsy? Sarah E. Schmitt, M.D. Debate: Should the Latest Generation of AEDs be Used the Earliest? Madeline Fields, M.D. and Korwyn Williams, M.D., Ph.D. Conclusion Jerry Shih, M.D. EDUCATION CREDIT

LEARNING OBJECTIVES

Following participation in this activity, learners should be able to: • Discuss all technical approaches, inclusive of minimally invasive tools (stereo-EEG, standard depth electrodes, subdural grids and strips, mapping for eloquent cortex with each technique, cortical resection, stereo-EEG thermos-ablation, laser ablation and responsive neurostimulator placement), and delineate the limitations and advantages of each

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

• Formulate a possible epilepsy surgical plan that incorporates all technical approaches including the aforementioned minimally invasive tools • Appropriately select focal epilepsy patients for genetic testing; describe how to prioritize and select the genetic test(s) and develop treatment strategies implicated by the genetic results • Formulate a treatment sequence for immune-related epilepsies, depending on response, with incorporation of the duration of each treatment course, according to the best available information • Identify the AEDs to be used earlier in the course of treatment based on effectiveness, side effect profile, and cost

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

MONDAY, DECEMBER 4

This educational activity is supported in part by educational grants from Eisai Inc. and UCB Inc.

TUESDAY, DECEMBER 5

Dietary Therapies | Are There Beneficial/Detrimental Effects of Dietary Therapies on Co-morbidities Associated with Epilepsy? Evidence from Clinical and Basic Research

7:00 AM - 8:30 AM

Special Interest Groups These programs are not accredited for continuing education credits.

Convention Center, Room 101, Street Level Coordinators: Timothy A. Simeone, Ph.D., Amy Kao, M.D.

Children's Hour | What if Rare Became Common? The Evolving Landscape of Rare Epilepsiesâ&#x20AC;&#x201D; Charm and Challenge for the Clinician

Speakers: To be announced OVERVIEW

Convention Center, Salon C, Street Level Coordinators: Rima Nabbout, M.D., Ph.D., Charuta Joshi, M.B.B.S.

Dietary therapies such as the ketogenic diet, medium chain triglyceride diet, modified Atkins diet, and lowglycemic index diet are useful in treating patients with refractory epilepsy. Often these are patients with the most severe types of epilepsy that are fraught with comorbidities such as autism, cognitive dysfunction/decline, sleep disorders, and higher risk of SUDEP. This raises the question of whether dietary therapies have effects on these co-morbidities. In this SIG, we will highlight the most recent clinical and basic research into these areas and discuss the implications for epilepsy treatments.

Speakers: Rima Nabbout, M.D., Ph.D., Annapurna Poduri, M.D., Edward Cooper, M.D., Ph.D., Ronald Thibert, D.O., Ms.P.H. OVERVIEW

This session will follow four tracks beginning with an overview of the orphan and rare epilepsies We shall discuss the importance of grouping patients in large multicenter databases/studies by genotype to define common phenotypes and then how this will segue into orphan drug development. We shall then have a slightly more focused discussion on the role of genetics in these rare epilepsies and how subgrouping of patients has led to better phenotypes thus actually leading to a better understanding of treatment options and monitoring options. The third speaker will give insights into treatment options in K channelopathies. The fourth speaker will discuss how we can improve the quality of life of these patients by using medications that take into consideration the suspected pathophysiology of the disease and attempt treatments that do not necessarily target seizures but other symptoms.

TARGET AUDIENCE

Clinicians, scientists, nurses

Frontal Lobe Epilepsy | Focal Cortical Dysplasia: Genotyping, Pathogenic Signaling and MRI Phenotyping Convention Center, Room 102 B, Street Level Coordinator: Andrea Bernasconi, M.D. Speakers: Peter Crino, M.D., Ph.D., Renzo Guerrini, M.D., Suk Jun Hong, Ph.D. OVERVIEW

TARGET AUDIENCE

Focal cortical dysplasia is a frequent cause of drugresistant frontal lobe epilepsy. This SIG will cover new research related to genotyping, pathogenic mTOR signaling, and phenotyping using advanced MRI processing.

Clinicians, scientists, fellows, trainees

TARGET AUDIENCE

TUESDAY, DECEMBER 5

Clinicians, scientists, fellows, trainees

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

TUESDAY, DECEMBER 5

Neuroendocrinology | Neuroendocrine Regulation of GABA-A Receptors in Epilepsy

Neuroimaging | Connectome Models: From Disease Description to Intervention

Convention Center, Room 204 A/B, Level 2 Coordinators: D. Samba Reddy, Ph.D., RPh, FAES

Convention Center, Room 147 A/B, Street Level Coordinators: Neda Bernasconi, M.D., Ph.D., Boris Bernhardt, Ph.D.

Speakers: Jaideep Kapur, M.D., Ph.D., Istvan Mody, Ph.D., Samba D. Reddy, Ph.D.

Speakers: Leonardo Bonilha, M.D., Ph.D., Graeme Jackson, M.D., John Duncan, D.M.

OVERVIEW

This session will discuss the emerging concepts in neuroendocrine regulation of GABA-A receptors in epilepsy. GABA-A receptors play a pivotal role in neuronal excitability and epilepsy. These membrane receptors are the most common targets for clinicallyused benzodiazepines and barbiturates. GABA-A receptors are the prime targets for endogenous steroids such as the neurosteroid allopregnanolone and THDOC synthesized within the nervous system. Since the 1940s, it was known that the steroid hormones progesterone and deoxycorticosterone could exert anesthetic and anticonvulsant actions. A major advance occurred in the early 1980s demonstrating that these hormones, after they are converted to neurosteroids, enhance GABA-A receptor function and regulate neuronal network excitability, seizures, and behavior. However, GABA-A receptors are not static, but undergo rapid changes in their number or subunit composition, as evident from receptor plasticity, internalization or desensitization in response to certain drugs and neuroendocrine conditions. There is emerging evidence that steroid hormones control the plasticity and function of synaptic and extra-synaptic GABA-A receptors with significant clinical implications in women with epilepsy and men with stress-sensitive conditions. The neuroendocrine regulation of GABA-A receptors is providing unique new therapeutic approaches for epilepsy, status epilepticus, and certain sex-specific seizure disorders.

OVERVIEW

TARGET AUDIENCE

Following participation in this activity, learners should be able to:

This session will cover the most recent research in structural and functional connectomics and how these methods are used to describe the disease and study outcomes. TARGET AUDIENCE

Clinicians, scientists, technicians, fellows, trainees 8:45 AM - 10:45 AM

Merritt-Putnam Symposium | Epilepsy and Comorbidities Convention Center, Ballroom C, Level 3 OVERVIEW

This symposium focuses on mood disorders, neurobehavioral issues, and memory and cognitive deficits in people with epilepsy. These conditions are either not diagnosed, or there is a delay in diagnosis and referral. The recognition and treatment of depression and cognitive problems is important for treating people with epilepsy as they negatively affect the quality and functionality of their lives. This session will provide the learner with strategies for recognizing these comorbidities and for integrating said strategies into their daily clinical practice. LEARNING OBJECTIVES

Clinicians, scientists

• Recognize and diagnose depression and cognitive deficits • Recognize the signs and symptoms of depression as a common comorbidity • Discuss the mechanisms of depression, the role of epilepsy, medications, and psychological impact on people with epilepsy

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

TUESDAY, DECEMBER 5

• Appropriately treat and refer patients with mood disorders

TUESDAY, DECEMBER 5

TARGET AUDIENCE

8:45 AM - 10:45 AM

Neurologists, epileptologists, nurse practitioners, nurses, physician assistants, pharmacists

Pediatric State of the Art Symposium | Infantile Spasms: Making Progress

PROGRAM

Co-Chairs: Gregory Worrell, M.D. and Catherine Schevon, M.D., Ph.D.

Convention Center, Room 146, Street Level

Introduction Gregory Worrell, M.D.

Infantile spasms represent an age-related epileptic encephalopathy. Outcomes depend on several modifiable risk factors such as early recognition of the syndrome, appropriate treatment, and appropriate follow-up. Since infantile spasms are rare, clinical advances require multicenter collaborative research. Although much progress has been made, multiple areas of controversy remain. This symposium will provide an update on recent clinical research for infantile spasms. We will review key topics, such as diagnosis and etiologies, EEG findings, evidence for treatment and what to do when standard treatments fail.

OVERVIEW

Update on Institute of Medicine Report: Epilepsy Across the Spectrum Frances Jensen, M.D. Depression in Epilepsy Andres M. Kanner, M.D., FANA, FAAN Neurobehavioral Comorbidities in Pediatric Epilepsy Amy Brooks-Kayal, M.D. Cognition and Memory in Epilepsy Gregory Holmes, M.D.

LEARNING OBJECTIVES

Restoring Active Memory: Therapeutic Stimulation Michael Kahana, Ph.D.

Following participation in this activity, learners should be able to:

Conclusion Catherine Schevon, M.D., Ph.D.

• Identify the criteria for West syndrome • Recognize other syndromes that may be confused with West syndrome

EDUCATION CREDIT

2.0 CME credits Nurses may claim up to 2.0 contact hours for this session.

• Restate etiologies associated with West syndrome

Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.0 contact hours (0.2 CEUs). UAN 0077-9999-17-048L01-P. Initial Release Date: 12/5/17.

• Identify tools to improve inter-rater reliability of hypsarrythmia

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

• Identify factors that may influence treatment outcomes, such as EEG findings and etiology

• Identify common features of hypsarrhthmia

• Identify patients who should be referred to an epilepsy center for surgical evaluation

This educational activity is supported in part by an educational grant from Eisai Inc.

• Locate evidence undergirding treatment recommendations • Recognize response rates to non-standard medications • Identify additional treatment options available for infantile spasms when medications fail TARGET AUDIENCE

TUESDAY, DECEMBER 5

Neurologists, epileptologists, pediatric neurologists, nurses, psychologists/neuropsychologists, nurse practitioners/physician assistants, pharmacists

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

TUESDAY, DECEMBER 5

PROGRAM

11:00 AM - 12:30 PM

Co-chairs: Kelly Knupp, M.D. and Renée Shellhaas, M.D., M.S.

Skills Workshops | Session 1

Introduction Kelly Knupp, M.D.

Advance registration and tickets are required for these concurrent sessions. Visit the registration area for information about fees and availability; space is limited.

What is West Syndrome? Katherine Nickels, M.D.

These programs are not accredited for continuing education credits.

“The H word” Hypsarhythmia—What Is It? Courtney Wustoff, M.D.

Basic EEG in Epilepsy: Fundamentals and Interpretation

Debate: Which is Better, Early or Late Surgery for Infantile Spasms? Sarah Kelly, M.D., and Erin Fedak Romanowski, D.O.

Convention Center, Room 202 B, Level 2 Moderator: William Tatum, D.O.

Mythbusters Scott Demarest, M.D.

OVERVIEW

What is the Evidence for Treatment? Finbar O’Callaghan, M.D., Ph.D.

The routine EEG recording remains essential in the care and management of individuals with seizures and suspected epilepsy. The EEG is used for diagnosis, classification of seizure type, and identification of a specific epileptic syndrome. EEG findings may be of prognostic importance and be used to assess the efficacy of treatment. Use of appropriate EEG methodology and recognition of artifact and benign variant patterns are essential for satisfactory clinical studies.

Debate: How to Manage the Complicated Patient— Standard vs Non-standard Treatment Lionel Carmant, M.D., and Zachary Grinspan, M.D. When Treatment Fails Christina Bergqvist, M.D. Conclusion Renée Shellhaas, M.D., M.S.

Pharmacists: AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.0 contact hours (0.2 CEUs). UAN 0077-9999-17-049L01-P. Initial Release Date: 12/5/17.

This workshop will review basic methodologies of EEG for the evaluation and treatment of pediatric and adult patients with seizure disorders. This will include use of appropriate EEG techniques and fundamentals of EEG recordings. Recognition of benign variant alterations and ictal interictal epileptogenic discharges will be addressed. The presentations will also discuss the importance of EEG to identify characteristics of specific epilepsies and epileptic syndromes.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

TARGET AUDIENCE

This educational activity is supported in part by educational grants from Lundbeck and Mallinckrodt Pharmaceuticals.

Clinicians, technicians, fellows, trainees

EDUCATION CREDIT

2.0 CME credits Nurses may claim up to 2.0 contact hours for this session.

Basics of Neuroimaging Acquisition and Processing: What the Clinician Needs to Know Convention Center, Room 207 B, Level 2 11:00 AM – 12:30 PM Please note this workshop occurs only once. Moderator: R. Edward Hogan, M.D. OVERVIEW

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

TUESDAY, DECEMBER 5

Basic principles of image acquisition and post-imageacquisition-processing have important implications for correlation with clinical history and EEG findings in the diagnosis and treatment of epilepsy. The workshop will focus on pertinent basic principles of acquisition and processing of MRI, PET, and SPECT. The program will review the basic steps of structural MR image

TUESDAY, DECEMBER 5

acquisition and processing using a simple algorithm (â&#x20AC;&#x153;processing pipelineâ&#x20AC;? figures), and discussion of common pitfalls (movement, inhomogeneity, causes for miss-segmentation, manual corrections). For PET, we will concentrate primarily on imaging glucose metabolism with FDG emphasizing best practice of data acquisition and analysis. There will be a cursory mention of the current state-of-play of clinical use of novel PET ligands. Discussion of SPECT will include important issues of administration of radiopharmaceutical in the epilepsy monitoring unit, as well as basics of image acquisition, co-registration, and normalization for subtraction SPECT studies.

Intracranial Electrode Studies: How Do You Choose a Technique for Optimum Localization Convention Center, Room 202 A, Level 2 Moderator: Dennis Spencer, M.D. OVERVIEW

Over the past 30 years, resection for medically intractable epilepsy has become a standard treatment option. However, in many instances, successful surgery is not possible without defining the potential respective volume by intracranial electrophysiology. Imaging and stereotactic navigation have made great strides and epilepsy centers have many choices regarding types of electrodes, number of contacts needed, and how they are delivered. This is an interactive workshop where two-to-three cases are presented illustrating different problems to be solved in defining a region of epileptogenesis. The participants work in groups to provide a consensus intracranial study. An experienced epileptologist will provide his or her institution's approach to the case, and we will then describe what was done as well as the outcome. There will be an attempt to discuss as many alternative approaches as possible, balancing the invasiveness of the various procedures and risk versus benefit.

TARGET AUDIENCE

Clinicians, fellows, trainees

Genetics Testing in Epilepsy Patients Convention Center, Room 201, Level 2 Moderators: Alica M. Goldman, M.D., Ph.D., M.S., and Annapurna Poduri, M.D. OVERVIEW

Novel detection platforms have accelerated scientific discoveries of genes relevant to patients with epilepsy of all ages. These research findings are being used by institutions and commercial laboratories. Selection of patients that would most benefit from the genetic investigations, identification of the appropriate tests, and reporting of results are increasingly complex. This skills workshop will review available testing platforms and outline case scenarios driven by testing algorithms. The aim is to provide practical clinical guide in selecting patients, testing methods, and the workflow involved in ordering, submitting, and reporting genetic tests. The workshop is designed to be an interactive, case driven discussion and a practical guide for clinical care. Participants are encouraged to submit questions and cases to Drs. Goldman and Poduri. The goal is to address pressing questions and discuss real-life cases within the context of genetic testing driven diagnostics and care.

TARGET AUDIENCE

Clinicians, fellows, trainees

Neurostimulation / VNS Convention Center, Room 207 A, Level 2 Moderators: Mohamad Koubeissi, M.D., and Vikram R. Rao, M.D., Ph.D. OVERVIEW

Neurostimulation is now an accepted treatment option for patients with refractory epilepsy. Two devices are approved by the FDA for patients with epilepsy: the vagus nerve stimulator (VNS) and the responsive neurostimulator (RNS). This workshop will discuss the trials and post-marketing experience that established the tolerability and efficacy of these devices, and instruct on how to use them effectively. Hands-on experience for interrogating and programming the devices will be arranged. After the workshop, participants should be able to identify appropriate patients, understand how implantation is carried out, and be able to program the devices. The session will also discuss possible side effects of these treatments and how to practically manage them.

TARGET AUDIENCE

TUESDAY, DECEMBER 5

Clinicians, nurses, fellows, trainees

TARGET AUDIENCE

Clinicians, fellows, trainees

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

TUESDAY, DECEMBER 5

Optimal Use of Neuroimaging in Diagnosing and Treating Epilepsy

Treating Patients with Psychogenic Nonepileptic Seizures

Convention Center, Room 206, Level 2 Moderators: John Stern, M.D., David Millett, M.D., Ph.D., and Noriko Salamon, M.D., Ph.D.

Convention Center, Room 207 B, Level 2 Please note this workshop occurs only once Moderators: W. Curt LaFrance Jr., M.D., and Karen Parko, M.D.

OVERVIEW OVERVIEW

Neuroimaging is an essential tool in the diagnosis and treatment of epilepsy. It has opened a window on the pathological substrate underlying epilepsy, ranging from subtle gliotic lesions and cortical malformations to larger, more extensive structural disturbances. This workshop will review the techniques used to diagnose epilepsy, emphasizing both basic MRI customized for epilepsy and advanced neuroimaging techniques. We will review a rational approach to the use of neuroimaging, highlight specific techniques that enhance diagnostic ability along with newer fMRI and other functional imaging methods. Interpretation of scans and various findings will be reviewed in this practical session.

Psychogenic nonepileptic seizures (PNES) are prevalent, disabling, and are often identified in seizure monitoring units. Neurologists readily diagnose PNES, but the majority of providers do not feel equipped to treat patients with PNES. Psychogenic NES present in adults and children with neurologic signs, psychological stressors, and comorbid psychiatric disorders. For years, neurologists, psychiatrists, and psychologists have accumulated data about NES phenomenology, epidemiology, risks, comorbidities, and prognosis. The role of the neurologist and mental health providers in the diagnosis and management of these patients will be discussed, and common obstacles that preclude proper treatment will be reviewed. ILAE Task Force recommendations and randomized clinical trial data will be presented, including pharmacologic and nonpharmacologic interventions. Participants will observe treatment of patients with PNES using a validated intervention shown to reduce seizures and improve comorbidities and quality of life. Session participants will view video vignettes from in-session interactions between clinicians (including epileptologists and mental health workers) providing PNES treatment. During this workshop, participants will learn the elements of the 12session intervention, using the seizure treatment workbook.

TARGET AUDIENCE

Clinicians, fellows, trainees 12:45 PM - 2:15 PM

Skills Workshops | Session 2 Basic EEG in Epilepsy: Fundamentals and Interpretation Refer to description on page 81.

Genetics Testing in Epilepsy Patients Refer to description on page 82.

TARGET AUDIENCE

Intracranial Electrode Studies: How Do You Choose a Technique for Optimum Localization

Clinicians, nurses, behavioral health providers, fellows, trainees

Refer to description on page 82.

Neurostimulation / VNS Refer to description on page 82.

Optimal Use of Neuroimaging in Diagnosing and Treating Epilepsy Refer to description on page 83.

TUESDAY, DECEMBER 5

AES ANNUAL MEETING | meeting.aesnet.org

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

Mark Your Calendar For Upcoming AES Meetings

AES ANNUAL MEETING 2018

NEW ORLEANS NOV 30 - DEC 4

SAVE THESE FUTURE MEETING DATES AES ANNUAL MEETING 2019 Baltimore | December 6 - 10

AES ANNUAL MEETING 2021 Chicago | December 3 - 7

AES ANNUAL MEETING 2020 Seattle | December 4 - 8

AES ANNUAL MEETING 2022 Nashville | December 2 - 6

aesn et .org/a nn u a l_m ee t i ng

EXHIBITOR LOCATIONS

EXHIBITING AS

BOOTH/TABLE

ABRET Neurodiagnostic Credentialing & Accreditation ..........1127 Ad-Tech Medical Instrument Corp. ..1005 Alpha MED Scientific Inc.........................633 Ambry Genetics ..........................................723 American Board of Clinical Neurophysiology ....................................1129 American Board of Psychiatry and Neurology ..................................................1122 American Clinical Magnetoencephalography Society (ACMEGS) ................................1232 American Clinical Neurophysiology Society (ACNS) ......................................1230 American Epilepsy Society ....................1119 The Anita Kaufmann Foundation ......1224 ANT North America ..................................533 ASET - The Neurodiagnostic Society ..........................................................1131 Batten Disease Support and Research Assoc. ....................................1330 BioMarin Pharmaceutical Inc. ....409, 415 Blueprint Genetics ........................................311 BPNA ..............................................................1432 The Brain Recovery Project: Childhood Epilepsy Surgery Foundation ..............................................1424 Brain Sentinel ..............................................308 Brain Vision LLC ..........................................222 Bridge the Gap - SYNGAP Education and Research Foundation................................................1325 Cadwell Laboratories, Inc. ......................821 CAPTUREPROOF........................................1114 Cascade Survey Research, LLC ..........205 The Charlie Foundation..........................1329 Child Neurology Foundation................1227 Children's Healthcare of Atlanta ........1031 Citizens United for Research in Epilepsy (CURE) ......................................215 Cleveland Clinic ..........................................200 Cohen's Children's Medical Center, Northwell Health......................................207 Compumedics/Neuroscan ......................513 Cook Children's Healthcare System ........................................................1033 CortiCore ........................................................1112 CREmedical Corp.......................................209 Demos Medical Publishing ..................1023 DigiTrace Care Services ..........................322 Dravet Syndrome Foundation..............1125 Eisai Inc. ..........................................................301 EGI ......................................................................1011 ELEKTA ..........................................................1207 Elsevier ..........................................................1027 emka TECHNOLOGIES Inc. ....................319

AES ANNUAL MEETING | meeting.aesnet.org

EXHIBITING AS

BOOTH/TABLE

Empatica ........................................................627 EpiFinder Inc. ................................................213 Epilepsy Foundation......................532, 1327 Epilog ..............................................................208 EpiNet Study Group................................1430 Epitel, Inc ......................................................1032 Evogen Precision Medicine ....................631 The FamilieSCN2a Foundation ..........1332 FHC, Inc. ........................................................1309 Fulgent Genetics..........................................412 GeneDx ............................................................321 Glut1 Deficiency Foundation................1225 Greenwich Biosciences, Inc. ..................419 Guger Technologies OG ..........................1315 HOLBERG EEG ............................................315 Integra Lifesciences ..................................630 International Foundation for CDKL5 Research ....................................1229 International League Against Epilepsy ........................................................214 IntraDiagnostics ..........................................1213 Invitae................................................................314 Jack Pribaz Foundation ........................1428 John Libbey EUROTEXT ........................822 LGS Foundation ........................................1328 Lifelines Neurodiagnostic Systems, Inc. ..............................................418 LivaNova ..........................................................616 Lundbeck ......................................................505 Mallinckrodt Pharmaceuticals......1130, 1312 Managing Epilepsy Well Network ....1233 Mayo Medical Laboratories ....................212 Medtronic ........................................................1113 Micromed LLC ............................................304 MNG Laboratories ......................................531 Moberg ICU Solutions................................618 Monteris Medical ........................................626 MRI Interventions Inc. ..............................1313 Multi Channel Systems ............................1314 MVAP Medical Supplies Inc...................204 National Association of Epilepsy Centers ........................................................622 NINDS - National Institute of Neurological Disorders & Stroke ......527 Natus Neuro ..................................................727 Neuralynx, Inc ................................................911 NEUROELECTRICS ....................................931 Neurology Reviews....................................1215 NeuroNexus ................................................1030 NeuroOne Medical Technologies Corp ................................................................217 NeuroPace, Inc. ............................................1101 Neurotech, LLC............................................1316 Neurovirtual USA, Inc. ..............................733 Nihon Kohden America, Inc. ..................919

EXHIBITING AS

BOOTH/TABLE

NINDS CDE Project....................................529 The North American AED Pregnancy Registry................................933 Nutricia ............................................................220 Ochsner Health System............................414 OWP Pharmaceuticals ............................632 Oxford University Press............................1116 Pairnomix, LLC ............................................228 PatientPop ......................................................218 PCDH19 Alliance..........................................1331 Penn State Health ......................................232 Persyst Development Corp. ..................730 Pinnacle Technology, Inc. ......................1323 PMT Corporation ........................................726 Practical Neurology ..................................206 Prasco..............................................................408 PsychoGenics Inc. ......................................309 Purple Day Japan......................................1226 Renishaw Healthcare Inc ......................1026 Reserve ..........................................................1329 Rhythmlink International, LLC ..............832 Ricoh USA, Inc. ............................................903 Ripple..............................................................1029 RosmanSearch, Inc. ..................................230 ROW Foundation ......................................1333 RSC Diagnostic Services ........................226 SeizureTracker.com ..................................1326 SK Life Science ............................................815 Smart Monitor Corp. ................................1217 STX Disorders ..............................................1231 Sunovion Pharmaceuticals Inc. ....705, 715 Supernus Pharmaceuticals, Inc. ..........327 Sutter Health Sacramento Sierra Region ..............................................216 TESS Research Foundation ................1426 Texas Children's Hospital ........................223 Tuberous Sclerosis Alliance..................1324 UCB, Inc. ........................................................603 UCSF Medical Center ................................1311 University of Florida Health ................1228 University of Maryland Medical Center ............................................................313 Upsher-Smith Laboratories, Inc ..........1126 VA Epilepsy Centers of Excellence ..................................................1133 Validus Pharmaceuticals ........................1104 Wiley ................................................................1017 Wolters Kluwer Health ..............................316 York Instruments ........................................927 Zeto ....................................................................312 Zimmer Biomet ..........................................1107

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AES ANNUAL MEETING | meeting.aesnet.org

86 321 418

327

419

200

Hall B Entrance down from Concourse B, registration area

ENTRANCE

301

505

603

705 903

911

1005 1104

1110

1011 1112

1114

1017 1116

1023 1122

1101

1107

1113

1119

AES

1201 1300

1207

1313

1305

1307

1309

1311

1315 1213 1312

1323

1215 1314

1217 1316

1221

DISCOVERY CENTER

205 304

207

409

815

919

204

206

209 308

408

513

715

821

309

311

313 412

415

616

723 822

1029 1027 1126

208

213 312

215 314

315 414

618

622

927 1026

212

217 316

319

523

827

F&B

1033 1031 1130

EXHIBITOR OFFICES

214

216

218

223 322

727

931 1030

933 1032

1336

F&B

EPILEPSY RESOURCE AREA See detailRESOURCE on next page. EPILEPSY AREA

PAVILION F

220

726

733 832

PAVILION E

222

627

730

PAVILION D

527

626

631

633

PAVILION C

226

529

531

228

632 630

533

227

PAVILION B

230

F&B

PAVILION A

EXHIBITOR SERVICES

POSTER BOARDS

232

CYBER CAFE 236

AES in the Exhibit Hall SHOW OFFICE

HALL B

EXHIBIT HALL MAP

Walter E. Washington Convention Center

Hall B, Lower Level

AES Booth and Selfie Station Booth #1119

Discovery Center Booth #1221

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

EXHIBIT HALL Convention Center, Hall B, Lower Level

1432 1428 1426 1424

1430

1333 1329 1327 1325

1331

1332 1330 1328 1326 1324

1233 1231 1227 1225

1228 1226 1224

1229

1232 1230

1131 1129 1127

Many exhibitors will be offering mini-workshops and presentations in the new Discovery Center (Booth # 1221—across from the AES Membership Booth). A daily schedule will be posted.

1125

A special feature of the AES Exhibit Hall is the Epilepsy Resource Area. Network with non-profit organizations doing important work in advocacy, patient outreach, patient services, and research funding.

1133

Visit the Epilepsy Resource Area

Innovation Pavilions Visit the Innovation Pavilions to experience in-depth education and training from exhibitors—featuring some of the latest research and technology related to the treatment and prevention of epilepsy. Saturday, December 2

Sunday, December 3

Monday, December 4

12:00 PM – 6:00 PM

10:00 AM – 4:00 PM

10:00 AM – 2:00 PM

Pavilion A - LivaNova

Pavilion B - Lundbeck

Pavilion C - NeuroPace

Pavilion D - Tuberous Sclerosis Alliance

Pavilion D - Greenwich Biosciences, Inc.

Pavilion D – Eisai Inc.

Pavilion E – Sunovion Pharmaceuticals Inc. Pavilion F - UCB Inc.

AES ANNUAL MEETING | meeting.aesnet.org

Pavilion E - Sunovion Pharmaceuticals Inc.

Pavilion E - Sunovion Pharmaceuticals Inc. Pavilion F - UCB Inc.

Pavilion F - UCB Inc.

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

EXHIBITORS BY CATEGORY BOOTH/TABLE

Accreditation/Credentialing ABRET Neurodiagnostic Credentialing & Accreditation ........................................1127 American Board of Clinical Neurophysiology ....................................1129 American Board of Psychiatry and Neurology....................................................1122 National Association of Epilepsy Centers ......................................622

Brain Mapping Ad-Tech Medical Instrument Corp. ............................................................1005 ANT North America ....................................533 CREmedical Corp.........................................209 ELEKTA ............................................................1207 Epilog ................................................................208 Integra Lifesciences ....................................630 Monteris Medical ..........................................626 NeuroOne Medical Technologies Corp ................................................................217 Neurovirtual USA, Inc. ................................733 Nihon Kohden America, Inc. ....................919 PMT Corporation ..........................................726 Ripple................................................................1029 York Instruments ..........................................927

Clinical Tools Brain Sentinel ................................................308 EGI ........................................................................1011 EpiFinder Inc. ..................................................213 FHC, Inc. ..........................................................1309 Invitae..................................................................314 Moberg ICU Solutions..................................618 MVAP Medical Supplies Inc.....................204 Neuralynx, Inc ..................................................911 NINDS CDE Project......................................529 Persyst Development Corp. ....................730 SeizureTracker.com ....................................1326 Smart Monitor Corp. ..................................1217

Diagnostics Ambry Genetics ............................................723 Brain Sentinel ................................................308 DigiTrace Care Services ............................322 ELEKTA ............................................................1207 EpiFinder Inc. ..................................................213 Epilog ................................................................208 Evogen Precision Medicine ......................631 Invitae..................................................................314 MNG Laboratories ........................................531 MVAP Medical Supplies Inc.....................204 Natus Neuro ....................................................727 NEUROELECTRICS ......................................931 NINDS - National Institute of Neurological Disorders & Stroke ......527 Rhythmlink International, LLC ................832 York Instruments ..........................................927

Education American Clinical Neurophysiology Society (ACNS) ......................................1230 ASET - The Neurodiagnostic Society ..........................................................1131 AES ANNUAL MEETING | meeting.aesnet.org

BOOTH/TABLE

BPNA ................................................................1432 Bridge the Gap - SYNGAP Education and Research Foundation..................1325 Child Neurology Foundation..................1227 Cohen's Children's Medical Center, Northwell Health ......................................207 Elsevier ............................................................1027 EpiFinder Inc. ..................................................213 Epilepsy Foundation ........................1327, 523 International League Against Epilepsy ........................................................214 NINDS - National Institute of Neurological Disorders & Stroke ......527 Nutricia ..............................................................220 PCDH19 Alliance............................................1331 TESS Research Foundation ..................1426 The Anita Kaufmann Foundation ........1224 The FamilieSCN2a Foundation ............1332 The North American AED Pregnancy Registry ................................933 University of Florida Health ..................1228 VA Epilepsy Centers of Excellence......1133 Wiley ..................................................................1017

NeuroNexus ..................................................1030 Neurovirtual USA, Inc. ................................733 PMT Corporation ..........................................726 Rhythmlink International, LLC ................832 Ripple................................................................1029 Zeto ......................................................................312

EEG Systems ANT North America ....................................533 Cadwell Laboratories, Inc. ........................821 CortiCare............................................................1112 CREmedical Corp.........................................209 DigiTrace Care Services ............................322 EGI ........................................................................1011 Epitel, Inc ........................................................1032 HOLBERG EEG ..............................................315 Lifelines Neurodiagnostic Systems, Inc.................................................418 Micromed LLC ..............................................304 Moberg ICU Solutions..................................618 MVAP Medical Supplies Inc.....................204 Natus Neuro ....................................................727 Neuralynx, Inc ..................................................911 NEUROELECTRICS ......................................931 Neurovirtual USA, Inc. ................................733 Nihon Kohden America, Inc. ....................919 Pinnacle Technology, Inc. ........................1323 Rhythmlink International, LLC ................832 Ripple................................................................1029 York Instruments ..........................................927 Zeto ......................................................................312

Electrodes Ad-Tech Medical Instrument Corp. ....1005 Alpha MED Scientific Inc...........................633 ANT North America ....................................533 Cadwell Laboratories, Inc. ........................821 CREmedical Corp.........................................209 Epitel, Inc ........................................................1032 Micromed LLC ..............................................304 Multi Channel Systems ..............................1314 MVAP Medical Supplies Inc.....................204 Natus Neuro ....................................................727 Neuralynx, Inc ..................................................911 NEUROELECTRICS ......................................931

104

Genetic Services Blueprint Genetics ..........................................311 Evogen Precision Medicine ......................631 Invitae..................................................................314 MNG Laboratories ........................................531 Pairnomix, LLC ..............................................228 The North American AED Pregnancy Registry ................................933

Hospital/Medical Center Children's Healthcare of Atlanta ..........1031 Cohen's Children's Medical Center, Northwell Health ......................................207 NINDS - National Institute of Neurological Disorders & Stroke ......527 Persyst Development Corp. ....................730 Sutter Health Sacramento Sierra Region ..............................................216 Texas Children's Hospital ..........................223 UCSF Medical Center ..................................1311 University of Florida Health ..................1228 University of Maryland Medical Center. ............................................................313

Imaging ANT North America ....................................533 EGI ........................................................................1011 ELEKTA ............................................................1207 Epilog ................................................................208 Medtronic ..........................................................1113 Ricoh USA, Inc. ..............................................903 York Instruments ..........................................927

Medical Device Ad-Tech Medical Instrument Corp. ....1005 Brain Sentinel ................................................308 ELEKTA ...........................................................1207 Empatica ..........................................................627 Epilog ................................................................208 Epitel, Inc ........................................................1032 Evogen Precision Medicine ......................631 FHC, Inc. ..........................................................1309 Integra Lifesciences ....................................630 Micromed LLC ..............................................304 Moberg ICU Solutions..................................618 Monteris Medical ..........................................626 MRI Interventions Inc. ................................1313 MVAP Medical Supplies Inc.....................204 Neuralynx, Inc ..................................................911 NEUROELECTRICS ......................................931 NeuroPace, Inc. ..............................................1101 Neurovirtual USA, Inc. ................................733 Nihon Kohden America, Inc. ....................919 PMT Corporation ..........................................726 Renishaw Healthcare Inc ........................1026 Rhythmlink International, LLC ................832 Ripple................................................................1029 DECEMBER 1-5, 2017 | WASHINGTON, D.C.

EXHIBITORS BY CATEGORY BOOTH/TABLE

BOOTH/TABLE

Smart Monitor Corp. ..................................1217 York Instruments ..........................................927 Zeto ......................................................................312 Zimmer Biomet ............................................1107

Glut1 Deficiency Foundation..................1225 LGS Foundation ..........................................1328 PCDH19 Alliance............................................1331 Purple Day Japan .......................................1226 SeizureTracker.com ....................................1326 STX Disorders ................................................1231 TESS Research Foundation ..................1426 The Anita Kaufmann Foundation ........1224 The Brain Recovery Project: Childhood Epilepsy Surgery Foundation ..........1424 The FamilieSCN2a Foundation ............1332 The North American AED Pregnancy Registry ................................933 Tuberous Sclerosis Alliance....................1324

Medical Equipment Brain Sentinel ................................................308 Cadwell Laboratories, Inc. ........................821 ELEKTA ............................................................1207 Empatica ..........................................................627 Renishaw Healthcare Inc ........................1026 Ricoh Company ............................................903

Mobile App CAPTUREPROOF..........................................1114 EpiFinder Inc. ..................................................213 Persyst Development Corp. ....................730 SeizureTracker.com ....................................1326 Smart Monitor Corp. ..................................1217

Monitoring Systems Brain Sentinel ................................................308 Cadwell Laboratories, Inc. ........................821 CAPTUREPROOF..........................................1114 DigiTrace Care Services ............................322 Empatica ..........................................................627 Epitel, Inc ........................................................1032 Evogen Precision Medicine ......................631 Integra Lifesciences ....................................630 Micromed LLC ..............................................304 Moberg ICU Solutions..................................618 Natus Neurology Incorporated ..............727 Neuralynx, Inc ..................................................911 Neurovirtual USA, Inc. ................................733 Nihon Kohden America, Inc. ....................919 Smart Monitor Corp. ..................................1217 Zeto ......................................................................312

Other Alpha MED Scientific Inc...........................633 Citizens United for Research in Epilepsy (CURE) ..........................................................215 Epilepsy Foundation ........................1327, 523 FHC, Inc. ..........................................................1309 Integra Lifesciences ....................................630 International League Against Epilepsy214 Managing Epilepsy Well Network ......1233 Monteris Medical ..........................................626 Multi Channel Systems ..............................1314 Nutricia ..............................................................220 PsychoGenics Inc. ........................................309 ROW Foundation ........................................1333 VA Epilepsy Centers of Excellence......1133 Wolters Kluwer Health ................................316

AES ANNUAL MEETING | meeting.aesnet.org

Research Aids Bridge the Gap - SYNGAP Education and Research Foundation..................1325 DigiTrace Care Services ............................322 emka TECHNOLOGIES Inc. ......................319 Multi Channel Systems ..............................1314 Pairnomix, LLC ..............................................228 Pinnacle Technology, Inc. ........................1323 The North American AED Pregnancy Registry ........................................................933 Wiley ..................................................................1017

Seizure Detection

Practice Services

Cadwell Laboratories, Inc. ........................821 CREmedical Corp.........................................209 EGI ........................................................................1011 Empatica ..........................................................627 Epitel, Inc ........................................................1032 Evogen Precision Medicine ......................631 Micromed LLC ..............................................304 Natus Neuro ....................................................727 NeuroPace, Inc. ..............................................1101 Nihon Kohden America, Inc. ....................919 NINDS - National Institute of Neurological Disorders & Stroke ......527 Persyst Development Corp. ....................730 Pinnacle Technology, Inc. ........................1323 PMT Corporation ..........................................726 SeizureTracker.com ....................................1326 Smart Monitor Corp. ..................................1217

Pairnomix, LLC ..............................................228 PatientPop ........................................................218

Software

Pharmaceutical BioMarin Pharmaceutical Inc. ....1201, 1305 Eisai Inc. ............................................................301 Greenwich Biosciences, Inc. ....................419 Lundbeck ........................................................505 Mallinckrodt Pharmaceuticals ....1130, 1312 OWP Pharmaceuticals ..............................632 SK Life Science ..............................................815 Sunovion Pharmaceuticals Inc...............705 Supernus Pharmaceuticals, Inc. ............327 UCB Inc. ............................................................603 Upsher-Smith Laboratories, Inc ............1126 Validus Pharmaceuticals ..........................1104

Professional Society American Clinical Neurophysiology Society (ACNS) ......................................1230 ASET - The Neurodiagnostic Society..1131 National Association of Epilepsy Centers ......................................622

Publications American Clinical Magnetoencephalography Society (ACMEGS) ................................1232 American Clinical Neurophysiology Society (ACNS) ......................................1230 ASET - The Neurodiagnostic Society..1131 Elsevier ............................................................1027 Epilepsy Foundation ........................1327, 523 John Libbey EUROTEXT ..........................822 Neurology Reviews......................................1215 NINDS - National Institute of Neurological Disorders & Stroke ......527 Oxford University Press..............................1116 Practical Neurology ....................................206 Wolters Kluwer Health ................................316

Patient Advocacy Group Batten Disease Support and Research Assoc. ....................................1330 Bridge the Gap - SYNGAP Education and Research Foundation..................1325 The Charlie Foundation............................1329 Child Neurology Foundation..................1227 Dravet Syndrome Foundation................1125

BOOTH/TABLE

Recruiter Cohen's Children's Medical Center, Northwell Health ......................................207 Ochsner Health System..............................414 Penn State Health ........................................232 University of Florida Health ..................1228

105

ANT North America ....................................533 EGI ........................................................................1011 EpiFinder Inc. ..................................................213 Epilog ................................................................208 FHC, Inc. ..........................................................1309 Moberg ICU Solutions..................................618 Multi Channel Systems ..............................1314 NEUROELECTRICS ......................................931 NeuroNexus ..................................................1030 Persyst Development Corp. ....................730 SeizureTracker.com ....................................1326 Zeto ......................................................................312

Surgical Tools FHC, Inc. ..........................................................1309 Medtronic ..........................................................1113 PMT Corporation ..........................................726 Renishaw Healthcare Inc ........................1026

Testing Ambry Genetics ............................................723 American Board of Clinical Neurophysiology ....................................1129 MNG Laboratories ........................................531 NeuroNexus ..................................................1030 PsychoGenics Inc. ........................................309

Video Tools CAPTUREPROOF..........................................1114 Child Neurology Foundation..................1227 DigiTrace Care Services ............................322 Pinnacle Technology, Inc. ........................1323 DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Benefactor Level Special thanks to

Sunovion Pharmaceuticals Inc. • Exhibit Booths

• Coat Check Sponsorship

• Innovation Pavilion

• Exclusive Door Drop (Friday)

• Office on Exhibit Floor

• Shared Door Drops (Saturday)

• Scientific Exhibit

• Passport to Prizes

• Mobile app

• Cyber Café Sponsorship

• Footprints to Booth

• Exhibit Hall Opening Sponsorship

• Program Book Advertising

• Epilepsy Leadership Council Support

• Park Benches

• AES Industry Leadership Roundtable

• Media Wall Advertising

• Satellite Symposium Support

• Poster Breakfast (Monday)

• At-A-Glance Meeting Guide

• Digital signage at Convention Center

• AES Fellows Program Support

• Digital signage in Marriott Connector

• CME Grant: Annual Course

• Coffee Breaks in Exhibit Hall (Saturday and Sunday)

• CME Grant: Presidential Symposium

AES ANNUAL MEETING | meeting.aesnet.org

106

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Benefactor Level Special thanks to

Eisai Inc. • Exhibit Booth

• Epilepsy Currents Advertising

• Innovation Pavilion

• Epilepsy Quiz Game Sponsorship

• Office on Exhibit Floor

• Speed Networking Sponsorship

• Scientific Exhibit

• CME Grant: Presidential Symposium

• Premier Sponsorship of Passport to Prizes

• CME Grant: Epilepsy Therapies Symposium

• Program Book Advertising

• CME Grant: Merritt-Putnam Symposium

• Program Book Belly Band

• CME Grant: Annual Course

• Media Wall Advertising

• AES Fellows Program Support

• Footprints to Booth

• AES Industry Leadership Roundtable

• Door Drops (Saturday)

AES ANNUAL MEETING | meeting.aesnet.org

107

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Leader Level Special thanks to

UCB Inc. • Exhibit Booth

• Park Bench

• Innovation Pavilion

• Buffet Lunches (Saturday, Sunday, Monday)

• Office on Exhibit Floor

• CME Grant: Annual Course

• Scientific Exhibit

• CME Grant: Presidential Symposium

• Passport to Prizes

• CME Grant: Epilepsy Therapies Symposium

• Program Book Advertising • Media Wall Advertising • Advertising Cling

• CME Grant: Interprofessional Symposium

• Exclusive Door Drop (Sunday)

• Epilepsy Currents Advertising

• Shared Door Drops (Saturday)

• AES Industry Leadership Roundtable

AES ANNUAL MEETING | meeting.aesnet.org

108

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Leader Level Special thanks to

Lundbeck • Exhibit Booth

• Epilepsy Currents Advertising

• Innovation Pavilion

• CME Grant: Presidential Symposium

• Scientific Exhibit

• CME Grant: Pediatric State of the Art Symposium

• Passport to Prizes

• CME Grant: Annual Course

• Program Book Advertising

• AES Fellows Program Support

• Media Wall Advertising

• AES Industry Leadership Roundtable

• Door Drops (Saturday) • Hotel Key Card Sponsorship • Expert Talks in Discovery Center

AES ANNUAL MEETING | meeting.aesnet.org

109

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Partner Level Special thanks to

LivaNova • Exhibit Booth

• Wine Event Sponsorship

• Innovation Pavilion

• Epilepsy Currents Advertising

• Media Wall Advertising

• Named Fellows Grant

• Passport to Prizes

• AES Industry Leadership Roundtable

• Cell Phone Charging Stations

AES ANNUAL MEETING | meeting.aesnet.org

110

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Partner Level Special thanks to

Upsher-Smith Laboratories, Inc. • Exhibit Booth

• Seed Grant Funding

• Passport to Prizes

• AES Fellows Program Support

• Program Book Advertising

• Charitable Grant: Pellock Pediatric Fellows

• Hoyer Lecture Sponsorship

• AES Industry Leadership Roundtable

• Epilepsy Currents Advertising

AES ANNUAL MEETING | meeting.aesnet.org

111

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Partner Level Special thanks to

Greenwich Biosciences, Inc. • Exhibit Booth

• CME Grant: Annual Fundamentals Symposium

• Innovation Pavilion

• Epilepsy & Aging Special Interest Group Sponsorship

• Office on Exhibit Floor • Scientific Exhibit • AES Abstract Search Sponsorship

• Tuberous Sclerosis Special Interest Group Sponsorship

• Hoyer Lecture Webcast Sponsorship

• AES Fellows Program Support

• CME Grant: Annual Course

• AES Industry Leadership Roundtable

AES ANNUAL MEETING | meeting.aesnet.org

112

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Partner Level Special thanks to

Supernus Pharmaceuticals, Inc. • Exhibit Booth

• Water Cooler Sponsorships

• Passport to Prizes

• Coffee Break Sponsorship (Sunday)

• Program Book Advertising

• AES Fellows Support

• Door Drop (Saturday)

• AES Industry Leadership Roundtable

AES ANNUAL MEETING | meeting.aesnet.org

113

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Supporter Level Special thanks to

AbbVie • Epilepsy Currents Advertising

Special thanks to

SK Life Science • Exhibit Booth

• Selfie Station Sponsorship

• Passport to Prizes

• Epilepsy Currents Advertising

• Media Wall Advertising

• Program Book Advertising

AES ANNUAL MEETING | meeting.aesnet.org

114

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Supporter Level Special thanks to

Nihon Kohden America, Inc. • Exhibit Booth

• Donation of Proceeds from Equipment Sale

• Passport to Prizes • Media Wall Advertising

Special thanks to

BioMarin Pharmaceutical Inc. • Exhibit Booths

• Epilepsy Currents Advertising

• Door Drop

• Satellite Symposium Support

AES ANNUAL MEETING | meeting.aesnet.org

115

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Supporter Level Special thanks to

Zogenix, Inc. • Scientific Exhibit

• Satellite Symposium Support

• Door Drop

AES ANNUAL MEETING | meeting.aesnet.org

116

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Contributor Level Special thanks to

Special thanks to

Mallinckrodt Pharmaceuticals

Ricoh USA, Inc.

• Exhibit Booths

• Exhibit Booth

• CME Grant: Pediatric State of the Art Symposium

• Passport to Prizes

Special thanks to

NeuroPace

Medtronic

• Exhibit Booth

• Innovation Pavilion

• Young Investigator Awards • CME Grant: Epilepsy Specialist Symposium

AES ANNUAL MEETING | meeting.aesnet.org

117

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Advocate Level Special thanks to

Special thanks to

Sage Therapeutics

Rhythmlink International, LLC

• General Support

• AES Fellows Program Support

• Exhibit Booth

• Epilepsy Currents Advertising

Special thanks to

Persyst Development Corporation

Neuralynx, Inc.

• Exhibit Booth

• Epilepsy Currents Advertising

Special thanks to

Texas Children’s Hospital

Natus Neuro

• Exhibit Booth • Media Wall Advertising

• Leadership Breakfast Sponsorship

• Exhibit Booth

Special thanks to

Validus Pharmaceuticals LLC

Cadwell Industries, Inc.

• Exhibit Booth • Passport to Prizes

• Exhibit Booth

• Epilepsy Currents Advertising

AES ANNUAL MEETING | meeting.aesnet.org

118

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Advocate Level Special thanks to

Special thanks to

Compumedics Neuroscan Inc.

Elekta • Exhibit Booth

• Exhibit Booth

Special thanks to

Zimmer Biomet

Sun Neurosciences

• Exhibit Booth

• General Support

Special thanks to

Lifelines Neurodiagnostics Systems, Inc

Prasco

• Exhibit Booth

• Epilepsy Currents Advertising

AES ANNUAL MEETING | meeting.aesnet.org

• Exhibit Booth

119

• Passport to Prizes

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

SUPPORTER RECOGNITION

Patron Level Child Neurology Foundation Electrical Geodesics, Inc. University of Maryland Medical Center Tuberous Sclerosis Alliance Cleveland Clinic Empatica Micromed LLC Renishaw Healthcare Inc York Instruments Ad-Tech Medical Instrument Corporation GeneDx Monteris Medical Moberg ICU Solutions PMT Corporation Mayo Medical Laboratories Brain Sentinel, Inc. MNG Laboratories

AES ANNUAL MEETING | meeting.aesnet.org

120

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

AES RESEARCH FUNDING PARTNERS

The American Epilepsy Society is proud to partner with several non-profit organizations to fund early career researchers and leverage resources to make dollars go further. We deeply appreciate these partners for their support and their commitment to the next generation.

AES ANNUAL MEETING | meeting.aesnet.org

121

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

APPENDIX: MEETING REFERENCE

Faculty Ready Room

SAE Zone

Convention Center, Room 208 A, Level 2

Convention Center, Room 306, Level 3

All faculty PowerPoint presentations have already been uploaded through the AES Faculty Management System. All faculty must confirm their presentation with an audiovisual technician in the faculty ready room.

Need to catch up on your MOC points? AES offers selfassessment activities on-demand anytime. New this year—the Self Assessment in Epilepsy Zone is a quiet room where you can bring your laptop and complete an activity while in Washington D.C.

Thursday, November 30..........................4:00 PM – 8:00 PM Friday, December 1 ..................................8:00 AM – 6:00 PM Saturday, December 2 ............................8:00 AM – 6:00 PM

Member and nonmember fees will apply, but, enjoy a 50% discount if you register and complete any AES self-assessment activity during the meeting.

Sunday, December 3 ................................8:00 AM – 6:00 PM

Friday, December 1 ..................................7:00 AM – 5:00 PM Saturday, December 2..............................7:00 AM – 5:00 PM Sunday, December 3 ................................7:00 AM – 5:00 PM Monday, December 4 ..............................7:00 AM – 5:00 PM Tuesday, December 5 ................................7:00 AM – 2:15 PM

Monday, December 4 ..............................8:00 AM – 6:00 PM Tuesday, December 5 ..............................8:00 AM – 11:00 AM

Press Room Convention Center, Room 301, Level 3 AES hosts a press room to assist journalists to find resources and identify experts at the Annual Meeting. Exhibitors may leave press releases on designated tables in the press room.

Lost and Found – Registration Desk Convention Center, Concourse B, Concourse Level Please visit the registration desk to look for items lost or to turn in items found. The American Epilepsy Society is not responsible for missing items. Please do not leave unattended packages (i.e. briefcases, meeting totes, laptops, purses, etc.) in any area of the convention center or hotel. Rooms are cleaned between sessions and any items left behind will be discarded.

Friday, December 1. ....................................7:30 AM - 5:00 PM Saturday, December 2 ..............................7:30 AM - 5:00 PM Sunday, December 3. ................................7:30 AM - 5:00 PM Monday, December 4 ................................7:30 AM - 5:00 PM Tuesday, December 5 ............................7:30 AM – 12:00 PM For more information about press at the Annual Meeting, please visit the AES website at aesnet.org/annual_meeting/press

Business Centers Two full-service business centers are conveniently located for attendees. Both offer a variety of services that include shipping, mailing, faxing and photocopying. Please contact the office directly for details.

First Aid Convention Center, Room 205, Level 2

Capital Business Center 801 Mount Vernon Place, NW Washington, D.C. 20001

Mother's Room Convention Center, Room 205, Level 2 Nursing mothers may utilize this private room at the convention center available during session times. Please note that parents or guardians are responsible to provide infant care supplies.

Located in the Walter E. Washington Convention Center in the L Street Lobby South, Street Level, under the escalators.

Quiet Room

Phone: 202.289.5233 Fax: 202.289.0299 Email: info@capitalbusinesscenter.com

Convention Center, Salon E, Street Level The room is intended to provide a quiet, calm space where attendees can spend time away from noise, lights and other stimuli. The quiet room is not available for conversations or meetings.

FedEx Office – Marriott Marquis Washington DC 901 Massachusetts Avenue, NW Washington, D.C. 20001

Coat and Luggage Check (Complimentary)

Phone: 202.783.8412 Email: usa5656@fedex.com Website:http://www.fedex.com/us/office/HotelsConventions/marriott-marquis-DC.html

Located on the Mezzanine Level

Convention Center, East Salon, Street Level Attendees may check coats and luggage at the coat check, supported by Sunovion Pharmaceuticals Inc.

AES ANNUAL MEETING | meeting.aesnet.org

122

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

APPENDIX: MEETING REFERENCE

• Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.) in any area of the convention center or hotel

Guidelines and Policies Photography Release AES uses photographs of meeting events in its promotional materials. Unless the permission is revoked in writing to AES, by virtue of their attendance, all meeting visitors agree to use of their likeness in such materials.

• Please report any suspicious activity to security staff or to the AES registration desk staff

No Smoking Policy For the comfort and health of all attendees, smoking is not permitted at any AES function. This includes educational sessions, meetings and all food functions. The Walter E. Washington Convention Center and all the official meeting hotels are smoke-free facilities. Please note: smoking is also not permitted in public buildings, restaurants or bars.

Insurance/Liabilities AES cannot be held responsible for any personal injury, loss, damage, accident to private property, or additional expenses incurred as a result of delays or changes in air, rail, sea, road or other services, strikes, sickness, weather, acts of terrorism, and any other cause. All participants are encouraged to make their own arrangements for health and travel insurance.

Meeting Attire Dress for the Annual Meeting is business casual. Consider bringing a light jacket or sweater with you since meeting room temperatures and personal comfort levels vary.

Safety and Security Information The following security measures have been designed to further enhance your personal and professional safety.

Session Room Capacity Pick up any convention center house phone in the facility and dial the Security Command Station at extension 4111. Or call 202-249-4111 from a cell phone

Due to safety and fire regulations, doors will be closed to all session rooms that fill to capacity.

Scooter/Wheelchair Rental

• Uniformed convention center employees have radios and are ready to assist you. Advise the dispatcher of the exact location within the convention center. We respectfully request that you do NOT call 911 directly

Contact one of the following companies to arrange rental and delivery of a scooter or wheelchair:

• An EMT will be on duty in the convention center throughout the meeting in Room 205, Level 2

Orthopaedic Mobility Rentals 15th & Constitution NW Washington, DC 20001

• A government-issued photo identification is required to receive a badge and to replace a lost badge

Phone: (571) 340-8961 Website: http://kneescootersrental.com

• Convention center security may randomly check packages and bags at the convention center entrances, meeting rooms and in the Exhibit Hall

Contact: Jorge Manzano Email: contact@kneescootersrental.com Scootaround Wheelchair and Scooter Rentals A-6 1414 Ritchie Marlboro RD Capitol Heights, MD 20790

• You will be asked to always clearly display your name badge and to use only approved convention center entrances and exits

Phone: (888) 982-0657 Website: http://scootaround.com

• Appropriate badges will be required to enter all educational sessions, poster sessions, exhibit hall and meetings. Due to safety and fire regulations, doors will be closed to session rooms that fill to capacity

Contact: Adrian Guglielmo Email: info@scootaround.com

• Throughout the meeting, you will notice security staff presence to monitor the safety of all participants

AES ANNUAL MEETING | meeting.aesnet.org

123

DECEMBER 1-5, 2017 | WASHINGTON, D.C.

PATIENT AND CAREGIVER PERSPECTIVES IN PEDIATRIC EPILEPSY: ESTABLISHED STRATEGIES AND EMERGING APPROACHES FOR FOCAL SEIZURES SUNDAY, DECEMBER 3, 2017

FACULTY Tracy A. Glauser, MD Professor, Department of Pediatrics Associate Director Cincinnati Children's Research Foundation Director, Comprehensive Epilepsy Center University of Cinncinnati Cincinnati, Ohio

Dennis J. Dlugos, MD, MSCE Professor of Neurology and Pediatrics Catherine D. Brown Endowed Chair in Pediatric Epilepsy Children’s Hospital of Philadelphia and the University of Pennsylvania School of Medicine Philadelphia, Pennsylvania

Anup Patel, MD Section Chief of Neurology Associate Professor Neurology and Pediatrics Nationwide Children’s Hospital and The Ohio State University College of Medicine Columbus, Ohio

REGISTRATION AND DINNER: 6:00 PM – 6:30 PM SYMPOSIUM: 6:30 PM – 8:00 PM VENUE: WALTER E. WASHINGTON CONFERENCE CENTER ROOM: 147 - STREET LEVEL

www.medscape.org/sites/townhall/public/pediatric-seizures Activity Overview In this engaging, live interactive program, a panel of expert faculty will discuss diagnosis, prognosis, and treatment of focal seizures in childhood to assist clinicians in better understanding issues related to caring for children and patients entering adolescence.This symposium will integrate patient and caregiver videos to enhance the discussion.

Accreditation Statement

Target Audience This activity is intended for epileptologists, neurologists, pediatricians, and primary care physicians.

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Learning Objectives Upon completion of this activity, participants will: • Have increased knowledge regarding the – Appropriate initial AED therapy for the management of focal epilepsy in pediatric patients – Emerging therapies for the treatment of focal epilepsy in pediatric patients • Have greater competence related to

For Physicians Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Disclaimer: Opinions presented during the Medscape Industry-Supported Satellite CME Symposium are those of the speakers and the ACCME-accredited provider (Medscape) and are not a reflection of American Epilepsy Society opinions, nor are they supported, sponsored or endorsed by the American Epilepsy Society.

– Use of clinical tools to diagnose focal epilepsy in pediatric patients – Selection of an appropriate therapeutic approach in the management of refractory focal seizures Supported by an independent educational grant from Sunovion Pharmaceuticals Inc.

AES 2017 Ad_8.5x11_BW rev 3.qxp_Layout 1 10/24/17 4:29 PM Page 1

Join us for a CME Dinner Symposium being held during the American Epilepsy Society (AES) 71st Annual Meeting 2017

DRAVET SYNDROME Emerging Insights, New Treatment Approaches

SUNDAY, DECEMBER 3, 2017 6:00 PM – 6:30 PM On-site Check-in and Dinner 6:30 PM – 8:00 PM CME Symposium Walter E. Washington Convention Center • salon C, street level

PROGRAM CHAIR

PROGRAM OVERVIEW

linda C. laux, Md

dravet syndrome (ds), a rare form of epilepsy, occurs in approximately 1 in 20,000 live births and is associated with a significant humanistic and economic burden on caregivers, families, and patients. while many medications are used in treating the seizures associated with ds, there are currently no Fda-approved treatments, and nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime. several investigational therapies are in late-stage development with the potential to provide new treatment options to address the serious medical needs for patients with ds.

Medical Director Comprehensive Epilepsy Center Assistant Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois

targEt audiEnCE This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with Dravet syndrome.

CME CrEdit (PhysiCian) This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

EduCational objECtivEs Upon completion of this activity, participants will be better able to do the following: • Summarize the epidemiology of DS • Identify the burden of illness of DS, including SUDEP • Cite mechanisms of action and key clinical trial data for therapies for DS in late-stage development • Review emerging preclinical models for SUDEP prevention

The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. aMEriCans with disabilitiEs aCt Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Maria DelCegno prior to the live event at maria.delcegno@millermeded.com FEE inForMation There is no fee for attending this educational activity.

PRE-REGISTER AT https://courses.elseviercme.com/aes2017 Pre-registration does not guarantee seating. on-site registration may be available, space permitting. Opinions presented during Satellite CME Symposia are those of the speakers and the ACCME-accredited provider and are not a reflection of American Epilepsy Society (AES) opinions, nor are they supported, sponsored, or endorsed by the AES.

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

This live activity is supported by an independent educational grant from Zogenix, Inc.

VISIT BOOTH #505 TO LEARN MORE

A FORCE FOR REDUCTION ONFI® (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Concomitant use of benodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Indications and Usage ONFI is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Important Safety Information WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS See full Prescribing Information for complete boxed warning. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. • Limit dosages and durations to the minimum required. • Follow patients for signs and symptoms of respiratory depression and sedation. Contraindication: Hypersensitivity ONFI is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions have included serious dermatological reactions. Risks from Concomitant Use with Opioids (see Boxed Warning) Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe ONFI concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use. Advise both patients and caregivers about the risks of respiratory depression and sedation when ONFI is used with opioids. Potentiation of Sedation from Concomitant Use with Central Nervous System (CNS) Depressants ONFI has a CNS depressant effect. Caution patients or their caregivers against simultaneous use with other CNS depressant drugs or alcohol and that the effects of other CNS depressant drugs or alcohol may be potentiated. Somnolence or Sedation ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Monitor patients for somnolence and sedation, particularly with concomitant use of other CNS depressants. Caution patients against engaging in hazardous activities that require mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known.

Physical and Psychological Dependence Carefully monitor patients with a history of substance abuse when receiving ONFI or other psychotropic agents because of the predisposition of such patients to habituation and dependence. In clinical trials, cases of dependency were reported following abrupt discontinuation of ONFI. The risk of dependence increases with increasing dose and duration of treatment. Suicidal Behavior and Ideation AEDs, including ONFI, increase the risk of suicidal thoughts or behavior in patients. Inform patients, their caregivers, and families of the risk and advise them to monitor and report any emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts of self-harm. If these symptoms occur, consider whether it may be related to the AED or illness, because epilepsy itself can increase these risks. Pregnancy, Registry and Nursing Mothers • Based on animal data, ONFI may cause fetal harm and should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. º Encourage patients to call the toll-free number 1-888-233-2334 to enroll in the Pregnancy Registry or visit http://www.aedpregnancyregistry.org/. • ONFI is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from ONFI, discontinue nursing or discontinue the drug. Adverse Reactions The most commonly observed adverse reactions reported in an LGS randomized, double-blind, placebo-controlled, parallel group clinical trial of patients who received clobazam as adjunctive therapy (≥10% in any treatment group and at least 5% greater than placebo, respectively) were somnolence or sedation (32% vs. 15%), somnolence (25% vs. 12%), pyrexia (17% vs. 3%), lethargy (15% vs. 5%), aggression (14% vs. 5%), drooling (14% vs. 3%), irritability (11% vs. 5%), ataxia (10% vs. 3%), and constipation (10% vs. 0%).

Please see Brief Summary of Prescribing Information, including Boxed Warning for risks from concomitant use with opioids, on the following pages. For more information, please see the full Prescribing Information, Medication Guide, and Instructions for Use, available at ONFI.com.

Withdrawal Symptoms As with all antiepileptic drugs (AEDs), withdraw ONFI gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms occurred following abrupt discontinuation of ONFI; the risk of withdrawal symptoms is greater with higher doses. Serious Dermatological Reactions Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period. Discontinue ONFI at the first sign of rash, unless the rash is clearly not drug-related.

ONFI® (clobazam) tablets, for oral use, CIV ONFI® (clobazam) oral suspension, CIV Brief Summary of Prescribing Information (See package insert for full Prescribing Information or visit www.ONFI.com) Rx Only WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS See full Prescribing Information for complete boxed warning. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. • Limit dosages and durations to the minimum required. • Follow patients for signs and symptoms of respiratory depression and sedation. INDICATIONS AND USAGE – ONFI® (clobazam) CIV is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. CONTRAINDICATIONS – ONFI is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions have included serious dermatological reactions [see Warnings and Precautions in full PI]. WARNINGS AND PRECAUTIONS – Risks from Concomitant Use with Opioids: Concomitant use of benzodiazepines, including ONFI, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drugrelated mortality compared to use of opioids alone. If a decision is made to prescribe ONFI concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when ONFI is used with opioids [see Drug Interactions in full PI]. Potentiation of Sedation from Concomitant Use with Central Nervous System Depressants: Since ONFI has a central nervous system (CNS) depressant effect, patients or their caregivers should be cautioned against simultaneous use with other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated [see Drug Interactions in full PI]. Somnolence or Sedation: ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central nervous system depressants. Prescribers should caution patients against engaging in hazardous activities requiring mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known. Withdrawal Symptoms: Abrupt discontinuation of ONFI should be avoided. ONFI should be tapered by decreasing the dose every week by 5-10 mg/day until discontinuation. Withdrawal symptoms occurred following abrupt discontinuation of ONFI; the risk of withdrawal symptoms is greater with higher doses. As with all antiepileptic drugs, ONFI should be withdrawn gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines. The more severe withdrawal symptoms have usually been limited to patients who received excessive doses over an extended period of time, followed by an abrupt discontinuation. Generally milder withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic doses for several months [see Dosage and Administration and Warnings and Precautions in full PI]. Serious Dermatological Reactions: Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period. Patients should be closely monitored for signs or symptoms of SJS/TEN, especially during the first 8 weeks of treatment initiation or when re-introducing therapy. ONFI should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered [see Contraindications in full PI]. Physical and Psychological Dependence: Patients with a history of substance abuse should be under careful surveillance when receiving ONFI or other psychotropic agents because of the predisposition of such patients to habituation and dependence [see Drug Abuse and Dependence in full PI]. Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including ONFI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing ONFI or any other AED must balance the risk

of suicidal thoughts or behavior with the risk of untreated illness. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers [see Warnings and Precautions in full PI]. ADVERSE REACTIONS – Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. During its development for the adjunctive treatment of seizures associated with LGS, ONFI was administered to 333 healthy volunteers and 300 patients with a current or prior diagnosis of LGS, including 197 patients treated for 12 months or more. The conditions and duration of exposure varied greatly and included single- and multiple-dose clinical pharmacology studies in healthy volunteers and two double-blind studies in patients with LGS (Study 1 and 2) [see Clinical Studies in full PI]. Only Study 1 included a placebo group, allowing comparison of adverse reaction rates on ONFI at several doses to placebo. Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1): The adverse reactions associated with ONFI treatment discontinuation in ≥1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia. Most Common Adverse Reactions in an LGS Placebo Controlled Clinical Trial (Study 1): Table 3 lists the adverse reactions that occurred in ≥5% of ONFI-treated patients (at any dose), and at a rate greater than placebo-treated patients, in the randomized, double-blind, placebocontrolled, parallel group clinical study of adjunctive AED therapy for 15 weeks (Study 1). Table 3. Adverse Reactions Reported for ≥5% of Patients and More Frequently than Placebo in Any Treatment Group ONFI Dose Level Placebo N=59 %

Lowa N=58 %

Mediumb N=62 %

Highc N=59 %

All ONFI N=179 %

Gastrointestinal Disorders Vomiting

Constipation

Dysphagia

General Disorders and Administration Site Conditions Pyrexia

Irritability

Fatigue

Upper respiratory tract infection

Pneumonia

Infections and Infestations

Urinary tract infection

Bronchitis

Metabolism and Nutrition Disorders Decreased appetite

Increased appetite

Nervous System Disorders Somnolence or Sedation

Somnolence

Sedation

5 10

Lethargy

Drooling

Ataxia

Psychomotor hyperactivity

Dysarthria

Psychiatric Disorders Aggression

Insomnia

Respiratory Disorders Cough

a Maximum daily dose of 5 mg for ≤30 kg body weight; 10 mg for >30 kg body weight b Maximum daily dose of 10 mg for ≤30 kg body weight; 20 mg for >30 kg body weight c Maximum daily dose of 20 mg for ≤30 kg body weight; 40 mg for >30 kg body weight

DRUG INTERACTIONS – Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation [see Warnings and Precautions in full PI]. CNS Depressants and Alcohol: Concomitant use of ONFI with other CNS depressants may increase the risk of sedation and somnolence. Alcohol, as a CNS depressant, will interact with ONFI in a similar way and also increases clobazam’s maximum plasma exposure by approximately 50%. Therefore, caution patients or their caregivers against simultaneous use with other CNS depressant drugs or alcohol, and caution that the effects of other CNS depressant drugs or alcohol may be potentiated [see Warnings and Precautions in full PI]. Effect of ONFI on Other Drugs: Hormonal Contraceptives: ONFI is a weak CYP3A4 inducer. As some hormonal contraceptives are metabolized by CYP3A4, their effectiveness may be diminished when given with ONFI. Additional non-hormonal forms of contraception are recommended when using ONFI [see Clinical Pharmacology and Patient Counseling Information in full PI]. Drugs Metabolized by CYP2D6: ONFI inhibits CYP2D6. Dose adjustment of drugs metabolized by CYP2D6 may be necessary [see Clinical Pharmacology in full PI]. Effect of Other Drugs on ONFI: Strong and moderate inhibitors of CYP2C19: Strong and moderate inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam, the active metabolite of clobazam. This may increase the risk of dose-related adverse reactions. Dosage adjustment of ONFI may be necessary when coadministered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole) [see Clinical Pharmacology in full PI]. USE IN SPECIFIC POPULATIONS – Pregnancy: Pregnancy Category C. Risk Summary: There are no adequate and well-controlled studies of ONFI in pregnant women. In animal studies, administration of clobazam during pregnancy resulted in developmental toxicity, including increased incidences of fetal malformations, at plasma exposures for clobazam and its major active metabolite, N-desmethylclobazam, below those expected at therapeutic doses in patients. ONFI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Available human data on the risk of teratogenicity associated with benzodiazepines are inconclusive. There is insufficient evidence in humans to assess the effect of benzodiazepine exposure during pregnancy on neurodevelopment. Administration of benzodiazepines immediately prior to or during childbirth can result in a syndrome of hypothermia, hypotonia, respiratory depression, and difficulty feeding. In addition, infants born to mothers who have taken benzodiazepines during the later stages of pregnancy can develop dependence, and subsequently withdrawal, during the postnatal period. Data for other benzodiazepines suggest the possibility of adverse developmental effects (including long-term effects on neurobehavioral and immunological function) in animals following prenatal exposure to benzodiazepines at clinically relevant doses. Data: Animal: In a study in which clobazam (150, 450, or 750 mg/kg/day) was orally administered to pregnant rats throughout the period of organogenesis, embryofetal mortality and incidences of fetal skeletal variations were increased at all doses. The low-effect dose for embryofetal developmental toxicity in rats (150 mg/kg/day) was associated with plasma exposures (AUC) for clobazam and its major active metabolite, N-desmethylclobazam, lower than those in humans at the maximum recommended human dose (MRHD) of 40 mg/day. Oral administration of clobazam (10, 30, or 75 mg/kg/day) to pregnant rabbits throughout the period of organogenesis resulted in decreased fetal body weights, and increased incidences of fetal malformations (visceral and skeletal) at the mid and high doses, and an increase in embryofetal mortality at the high dose. Incidences of fetal variations were increased at all doses. The highest dose tested was associated with maternal toxicity (ataxia and decreased activity). The low-effect dose for embryofetal developmental toxicity in rabbits (10 mg/kg/day) was associated with plasma exposures for clobazam and N-desmethylclobazam lower than those in humans at the MRHD. Oral administration of clobazam (50, 350, or 750 mg/kg/day) to rats throughout pregnancy and lactation resulted in increased embryofetal mortality at the high dose, decreased pup survival at the mid and high doses and alterations in offspring behavior (locomotor activity) at all doses. The low-effect dose for adverse effects on pre- and postnatal development in rats (50 mg/kg/day) was associated with plasma exposures for clobazam and N-desmethylclobazam lower than those in humans at the MRHD. Pregnancy Registry: To provide information regarding the effects of in utero exposure to ONFI, physicians are advised to recommend that pregnant patients taking ONFI enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves or their caregiver. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/. Nursing Mothers: ONFI is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from ONFI, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in patients less than 2 years of age have not been established. In a study in which clobazam (4, 36, or 120 mg/kg/day) was orally administered to rats during the juvenile period of development (postnatal days 14 to 48), adverse effects on growth (decreased bone density and bone length) and behavior (altered motor activity and auditory startle response; learning deficit) were observed at the high dose. The effect on bone density, but not on behavior, was reversible when drug was discontinued. The no-effect level for juvenile toxicity (36 mg/kg/day) was associated with plasma exposures (AUC) to clobazam and its major active metabolite, N-desmethylclobazam, less than those expected at therapeutic doses in pediatric patients. Geriatric Use: Clinical studies of ONFI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly subjects appear to eliminate clobazam more slowly than younger subjects based on population pharmacokinetic analysis. For these reasons, the initial dose in elderly patients should be 5 mg/day. Patients should be titrated initially to 10-20 mg/day. Patients may be titrated further to a maximum daily dose of 40 mg if tolerated [see Dosage and Administration and Clinical Pharmacology in full PI]. CYP2C19 Poor Metabolizers: Concentrations of clobazam’s active metabolite, N-desmethylclobazam, are higher in CYP2C19 poor metabolizers than in extensive metabolizers. For this reason, dosage modification is recommended [see Dosage and Administration and Clinical Pharmacology in full PI]. Renal Impairment: The pharmacokinetics of ONFI were evaluated in patients with mild and moderate renal impairment. There were no significant differences in systemic exposure (AUC and Cmax) between patients with mild or moderate renal impairment and healthy subjects. No dose adjustment is required for patients with mild and moderate renal impairment. There is essentially no experience with ONFI in patients with severe renal impairment or ESRD. It is not known if clobazam or its active metabolite, N-desmethylclobazam, is dialyzable [see Dosage and Administration and Clinical Pharmacology in full PI]. Hepatic Impairment: ONFI is hepatically metabolized; however, there are limited data to characterize the effect of hepatic impairment on the pharmacokinetics of ONFI. For this reason, dosage adjustment is recommended in patients with mild to moderate hepatic impairment (Child-Pugh score 5-9). There is inadequate information about metabolism of ONFI in patients with severe hepatic impairment [see Dosage and Administration and Clinical Pharmacology in full PI]. DRUG ABUSE AND DEPENDENCE – Controlled Substance: ONFI contains clobazam which is a Schedule IV controlled substance. Abuse: ONFI can be abused in a similar manner as other benzodiazepines, such as diazepam. The pharmacological profile of ONFI is similar to that of other benzodiazepines listed in Schedule IV of the Controlled Substance Act, particularly in its potentiation of GABAergic transmission through its action on GABAA receptors, which leads to sedation and somnolence. The World Health Organization epidemiology database contains reports of drug abuse, misuse, and overdoses associated with clobazam [see Drug Abuse and Dependence in full PI]. Dependence: Dependence: In clinical trials, cases of dependency were reported following abrupt discontinuation of ONFI. The risk of dependence is present even with use of ONFI at the recommended dose range over periods of only a few weeks. The risk of dependence increases with increasing dose and duration of treatment. The risk of dependence is increased in patients with a history of alcohol or drug abuse [see Drug Abuse and Dependence in full PI]. Withdrawal: Abrupt discontinuation of ONFI causes withdrawal symptoms. As with other benzodiazepines, ONFI should be withdrawn gradually. In ONFI clinical pharmacology trials in healthy volunteers, the most common withdrawal symptoms after abrupt discontinuation were headache, tremor, insomnia, anxiety, irritability, drug withdrawal syndrome, palpitations, and diarrhea. Other withdrawal reactions to clobazam reported in the literature include restlessness, panic attacks, profuse sweating, difficulty in concentrating, nausea and dry retching, weight loss, blurred vision, photophobia, and muscle pain and stiffness. In general, benzodiazepine withdrawal may cause seizures, psychosis, and hallucinations [see Dosage and Administration and Warnings and Precautions in full PI]. OVERDOSAGE – Signs and Symptoms of Overdosage: Overdose and intoxication with benzodiazepines, including ONFI, may lead to CNS depression, associated with drowsiness, confusion and lethargy, possibly progressing to ataxia, respiratory depression, hypotension, and, rarely, coma or death. The risk of a fatal outcome is increased in cases of combined poisoning with other CNS depressants, including alcohol. Management of Overdosage: The management of ONFI overdose may include gastric lavage and/or administration of activated charcoal, intravenous fluid replenishment, early control of airway and general supportive measures, in addition to monitoring level of consciousness and vital signs. Hypotension can be treated by replenishment with plasma substitutes and, if necessary, with sympathomimetic agents. The efficacy of supplementary administration of physostigmine (a cholinergic agent) or of flumazenil (a benzodiazepine antagonist) in ONFI overdose has not been assessed. The administration of flumazenil in cases of benzodiazepine overdose can lead to withdrawal and adverse reactions. Its use in patients with epilepsy is typically not recommended. Lundbeck Deerfield, IL 60015, U.S.A. ONFI is a registered trademark of Lundbeck. December 2016 CLB-L-00016c

LUNDBECK LOGO COLOR BREAK: 1-Color Black Usage Starfish Shadow prints 75% screen of black

Lundbeck Name prints 100% Black

55%

75%

100%

Starfish Shadow prints 55% screen of black

PMS

Post Marketing Experience: These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class. Blood Disorders: Anemia, eosinophilia, leukopenia, thrombocytopenia; Eye Disorders: Diplopia, vision blurred; Gastrointestinal Disorders: Abdominal distention; General Disorders and Administration Site Conditions: Hypothermia; Investigations: Hepatic enzyme increased; Musculoskeletal: Muscle spasms; Psychiatric Disorders: Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination; Renal and Urinary Disorders: Urinary retention; Respiratory Disorders: Aspiration, respiratory depression; Skin and Subcutaneous Tissue Disorders: Rash, urticaria, angioedema, and facial and lip edema.

BLACK

FYCOMPA® (perampanel) tablets, for oral use, CIII FYCOMPA® (perampanel) oral suspension, CIII Initial U.S. Approval: 2012 Brief Summary of Full Prescribing Information dated July 2017 WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS • Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA. • These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression. • Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA. • Closely monitor patients particularly during the titration period and at higher doses • FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening. WARNINGS AND PRECAUTIONS Serious Psychiatric and Behavioral Reactions In the controlled partial-onset seizure clinical trials, hostilityand aggression-related adverse reactions occurred in 12% and 20% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. FYCOMPA-treated patients experienced more hostility- and aggression-related adverse reactions that were serious, severe, and led to dose reduction, interruption, and discontinuation more frequently than placebo-treated patients. In general, in placebo-controlled partial-onset seizure clinical trials, neuropsychiatric events were reported more frequently in patients being treated with FYCOMPA than in patients taking placebo. These events included irritability, aggression, anger, and anxiety, which occurred in 2% or greater of FYCOMPA-treated patients and twice as frequently as in placebo-treated patients. Other symptoms that occurred with FYCOMPA and were more common than with placebo included belligerence, affect lability, agitation, and physical assault. Some of these events were reported as serious and life-threatening. Homicidal ideation and/or threat were exhibited in 0.1% of 4,368 FYCOMPA-treated patients in controlled and open label trials, including non-epilepsy trials. Homicidal ideation and/or threat have also been reported postmarketing in patients treated with FYCOMPA. In the partial-onset seizure clinical trials, these events occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression. Some patients experienced worsening of their pre-existing psychiatric conditions. Patients with active psychotic disorders and unstable recurrent affective disorders were excluded from the clinical trials. The combination of alcohol and FYCOMPA significantly worsened mood and increased anger. Patients taking FYCOMPA should avoid the use of alcohol. Similar serious psychiatric and behavioral events were observed in the primary generalized tonic-clonic seizure clinical trial. In healthy volunteers taking FYCOMPA, observed psychiatric events included paranoia, euphoric mood, agitation, anger, mental status changes, and disorientation/confusional state. In the non-epilepsy trials, psychiatric events that occurred in perampanel-treated patients more often than placebo-treated patients included disorientation, delusion, and paranoia. Patients, their caregivers, and families should be informed that FYCOMPA may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least 1 month after the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases. Dose of FYCOMPA should be reduced if these symptoms occur. Permanently discontinue FYCOMPA for persistent severe or worsening psychiatric symptoms or behaviors and refer for psychiatric evaluation. Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including FYCOMPA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 1 shows absolute and relative risk by indication for all evaluated AEDs. Table 1. Risk by indication for antiepileptic drugs in the pooled analysis Indication

Placebo Patients with Events per 1000 Patients

Drug Patients with Events per 1000 Patients

Epilepsy Psychiatric Other Total

1.0 5.7 1.0 2.4

3.4 8.5 1.8 4.3

Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients 3.5 1.5 1.9 1.8

Risk Difference: Additional Drug Patients with Events per 1000 Patients 2.4 2.9 0.9 1.9

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Neurologic Effects Dizziness and Gait Disturbance FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination. In the controlled partial-onset seizure clinical trials, dizziness and vertigo were reported in 35% and 47% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 10% of placebo-treated patients. The gait disturbance related events (including ataxia, gait disturbance, balance disorder, and abnormal coordination) were reported in 12% and 16% of patients randomized to

receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 2% of placebo-treated patients. Elderly patients had an increased risk of these adverse reactions compared to younger adults and pediatric patients. These adverse reactions occurred mostly during the titration phase and led to discontinuation in 3% of FYCOMPA-treated patients compared to 1% of placebo-treated patients. These adverse reactions were also observed in the primary generalized tonic-clonic seizure clinical trial. Somnolence and Fatigue FYCOMPA caused dose-dependent increases in somnolence and fatigue-related events (including fatigue, asthenia, and lethargy). In the controlled partial-onset seizure clinical trials, 16% and 18% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, reported somnolence compared to 7% of placebo patients. In the controlled partial-onset seizure clinical trials, 12% and 15% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, reported fatigue-related events compared to 5% of placebo patients. Somnolence or fatigue-related events led to discontinuation in 2% of FYCOMPA-treated patients and 0.5% of placebo-treated patients. Elderly patients had an increased risk of these adverse reactions compared to younger adults and pediatric patients. In the controlled partial-onset seizure clinical trials, these adverse reactions occurred mostly during the titration phase. These adverse reactions were also observed in the primary generalized tonic-clonic seizure clinical trial. Risk Amelioration Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of FYCOMPA is known. Falls An increased risk of falls, in some cases leading to serious injuries including head injuries and bone fracture, occurred in patients being treated with FYCOMPA (with and without concurrent seizures). In the controlled partial-onset seizure clinical trials, falls were reported in 5% and 10% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 3% of placebo-treated patients. Falls were reported as serious and led to discontinuation more frequently in FYCOMPA-treated patients than placebo-treated patients. Elderly patients had an increased risk of falls compared to younger adults and pediatric patients. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including FYCOMPA. DRESS may be fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. FYCOMPA should be discontinued if an alternative etiology for the signs or symptoms cannot be established. Withdrawal of Antiepileptic Drugs There is the potential of increased seizure frequency in patients with seizure disorders when antiepileptic drugs are withdrawn abruptly. FYCOMPA has a half-life of approximately 105 hours so that even after abrupt cessation, blood levels fall gradually. In epilepsy clinical trials FYCOMPA was withdrawn without down-titration. Although a small number of patients exhibited seizures following discontinuation, the data were not sufficient to allow any recommendations regarding appropriate withdrawal regimens. A gradual withdrawal is generally recommended with antiepileptic drugs, but if withdrawal is a response to adverse events, prompt withdrawal can be considered. ADVERSE REACTIONS Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Partial-Onset Seizures A total of 1,038 patients receiving FYCOMPA (2, 4, 8, or 12 mg once daily) constituted the safety population in the pooled analysis of the placebo-controlled trials (Studies 1, 2, and 3) in patients with partial-onset seizures. Approximately 51% of patients were female, and the mean age was 35 years. Adverse Reactions Leading to Discontinuation In controlled clinical trials (Studies 1, 2, and 3), the rate of discontinuation as a result of an adverse reaction was 3%, 8%, and 19% in patients randomized to receive FYCOMPA at the recommended doses of 4 mg, 8 mg, and 12 mg per day, respectively, and 5% in patients randomized to receive placebo. The adverse reactions most commonly leading to discontinuation (≥1% in the 8 mg or 12 mg FYCOMPA group and greater than placebo) were dizziness, somnolence, vertigo, aggression, anger, ataxia, blurred vision, irritability, and dysarthria. Most Common Adverse Reactions Table 2 gives the incidence in the controlled clinical trials (Studies 1, 2, and 3) of the adverse reactions that occurred in ≥2% of patients with partial-onset seizures in the FYCOMPA 12 mg dose group and more frequent than placebo (in order of decreasing frequency for the 12 mg dose group). The most common dose-related adverse reactions in patients receiving FYCOMPA at doses of 8 mg or 12 mg (≥4% and occurring at least 1% higher than the placebo group) included dizziness (36%), somnolence (16%), fatigue (10%), irritability (9%), falls (7%), nausea (7%), ataxia (5%), balance disorder (4%), gait disturbance (4%), vertigo (4%), and weight gain (4%). For almost every adverse reaction, rates were higher on 12 mg and more often led to dose reduction or discontinuation. Table 2. Adverse Reactions in Pooled Placebo-Controlled Trials in Patients with Partial-Onset Seizures (Studies 1, 2, and 3) (Reactions ≥ 2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo) Placebo n=442 % Dizziness Somnolence Headache Irritability Fatigue Falls Ataxia Nausea Vertigo Back pain Dysarthria Anxiety Blurred vision Gait disturbance Weight gain Cough Upper respiratory tract infection Vomiting Hypersomnia Anger Aggression Balance disorder Diplopia Head injury Hypoaesthesia Pain in extremity Constipation

9 7 11 3 5 3 0 5 1 2 0 1 1 1 1 3 3 3 0 <1 1 1 1 1 1 1 2

4 mg n=172 % 16 9 11 4 8 2 1 3 4 2 1 2 1 1 4 1 3 2 1 0 1 0 1 1 0 0 2

FYCOMPA 8 mg n=431 % 32 16 11 7 8 5 3 6 3 2 3 3 3 4 4 1 3 3 2 1 2 5 1 1 0 2 2

12 mg n=255 % 43 18 13 12 12 10 8 8 5 5 4 4 4 4 4 4 4 4 3 3 3 3 3 3 3 3 3

Table 2. Adverse Reactions in Pooled Placebo-Controlled Trials in Patients with Partial-Onset Seizures (Studies 1, 2, and 3) (Reactions ≥ 2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo) (cont.) Myalgia Coordination abnormal Euphoric mood Confusional state Hyponatremia Limb injury Mood altered Arthralgia Asthenia Contusion Memory impairment Musculoskeletal pain Oropharyngeal pain Paraesthesia Peripheral edema Skin laceration

2 0 0 <1 <1 <1 <1 1 1 1 1 1 1 1 1 1

1 1 0 1 0 1 1 0 1 0 0 1 2 0 1 0

1 <1 <1 1 0 1 <1 3 2 2 1 1 2 1 1 2

3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

Primary Generalized Tonic-Clonic Seizures A total of 81 patients receiving FYCOMPA 8 mg once daily constituted the safety population in the placebo-controlled trial in patients with primary generalized tonic-clonic seizures (Study 4). Approximately 57% of patients were female, and the mean age was 27 years. In the controlled primary generalized tonic-clonic seizure clinical trial (Study 4), the adverse reaction profile was similar to that noted for the controlled partial-onset seizure clinical trials (Studies 1, 2, and 3). Table 3 gives the incidence of adverse reactions in patients receiving FYCOMPA 8 mg (≥4% and higher than in the placebo group) in Study 4. The most common adverse reactions in patients receiving FYCOMPA (≥10% and greater than placebo) were dizziness (32%), fatigue (15%), headache (12%), somnolence (11%), and irritability (11%). The adverse reactions most commonly leading to discontinuation in patients receiving FYCOMPA 8 mg (≥2% and greater than placebo) were vomiting (2%) and dizziness (2%). Table 3. Adverse Reactions in a Placebo-Controlled Trial in Patients with Primary Generalized Tonic-Clonic Seizures (Study 4) (Reactions ≥ 4% of Patients in FYCOMPA Group and More Frequent than Placebo)

Dizziness Fatigue Headache Somnolence Irritability Vertigo Vomiting Weight gain Contusion Nausea Abdominal pain Anxiety Urinary tract infection Ligament sprain Balance disorder Rash

Placebo n=82 % 6 6 10 4 2 2 2 4 4 5 1 4 1 0 1 1

FYCOMPA 8 mg n=81 % 32 15 12 11 11 9 9 7 6 6 5 5 4 4 4 4

Weight Gain Weight gain has occurred with FYCOMPA. In controlled partial-onset seizure clinical trials, FYCOMPA-treated adults gained an average of 1.1 kg (2.5 lbs) compared to an average of 0.3 kg (0.7 lbs) in placebo-treated adults with a median exposure of 19 weeks. The percentages of adults who gained at least 7% and 15% of their baseline body weight in FYCOMPA-treated patients were 9.1% and 0.9%, respectively, as compared to 4.5% and 0.2% of placebo-treated patients, respectively. Clinical monitoring of weight is recommended. Similar increases in weight were also observed in adult and pediatric patients treated with FYCOMPA in the primary generalized tonic-clonic seizure clinical trial. Elevated triglycerides Increases in triglycerides have occurred with FYCOMPA use. Comparison of Sex and Race No significant sex differences were noted in the incidence of adverse reactions. Although there were few non-Caucasian patients, no differences in the incidence of adverse reactions compared to Caucasian patients were observed. Postmarketing Experience The following adverse reactions have been identified during post approval use of FYCOMPA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Dermatologic: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Psychiatric: Acute psychosis, hallucinations, delusions, paranoia, delirium, confusional state, disorientation, memory impairment. DRUG INTERACTIONS Contraceptives With concomitant use, FYCOMPA at a dose of 12 mg per day reduced levonorgestrel exposure by approximately 40%. Use of FYCOMPA with contraceptives containing levonorgestrel may render them less effective. Additional non-hormonal forms of contraception are recommended. Moderate and Strong CYP3A4 Inducers The concomitant use of known moderate and strong CYP3A4 inducers including carbamazepine, phenytoin, or oxcarbazepine with FYCOMPA decreased the plasma levels of perampanel by approximately 50-67%. The starting doses for FYCOMPA should be increased in the presence of moderate or strong CYP3A4 inducers. When these moderate or strong CYP3A4 inducers are introduced or withdrawn from a patient’s treatment regimen, the patient should be closely monitored for clinical response and tolerability. Dose adjustment of FYCOMPA may be necessary. Alcohol and Other CNS Depressants The concomitant use of FYCOMPA and CNS depressants including alcohol may increase CNS depression. A pharmacodynamic interaction study in healthy subjects found that the effects of FYCOMPA on complex tasks such as driving ability were additive or supra-additive to the impairment effects of alcohol. Multiple dosing of FYCOMPA 12 mg per day also enhanced the effects of alcohol to interfere with vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when FYCOMPA is used in combination with other CNS depressants. Care should be taken when administering FYCOMPA with these agents. Patients should limit activity until they have experience with concomitant use of CNS depressants (e.g., benzodiazepines, narcotics, barbiturates, sedating antihistamines). Advise patients not to drive or operate machinery until they have gained sufficient experience on FYCOMPA to gauge whether it adversely affects these activities. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as FYCOMPA, during pregnancy. Encourage women who are taking FYCOMPA during pregnancy to enroll in the North American Antiepileptic Drug

(NAAED) Pregnancy Registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org. Risk summary There are no adequate data on the developmental risk associated with use in pregnant women. In animal studies, perampanel induced developmental toxicity in pregnant rat and rabbit at clinically relevant doses. In the U.S. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Oral administration of perampanel (1, 3, or 10 mg/kg/day) to pregnant rats throughout organogenesis resulted in an increase in visceral abnormalities (diverticulum of the intestine) at all doses tested; maternal toxicity was observed at the mid and high doses. In a dose-ranging study at higher oral doses (10, 30, or 60 mg/kg/day), embryo lethality and reduced fetal body weight were observed at the mid and high doses tested. The lowest dose tested (1 mg/kg/day) is similar to a human dose of 8 mg per day based on body surface area (mg/m2). Upon oral administration of perampanel (1, 3, or 10 mg/kg per day) to pregnant rabbits throughout organogenesis, embryo lethality was observed at the mid and high doses tested; the no-effect dose for embryo-fetal developmental toxicity in rabbit (1 mg/kg/day) is approximately 2 times a human dose of 8 mg per day based on body surface area (mg/m2). Oral administration of perampanel (1, 3, or 10 mg/kg per day) to rats throughout gestation and lactation resulted in fetal and pup deaths at the mid and high doses (associated with maternal toxicity) and delayed sexual maturation in males and females at the highest dose tested. No effects were observed on measures of neurobehavioral or reproductive function in the offspring. The no-effect dose for pre- and postnatal developmental toxicity in rat (1 mg/kg/day) is similar to a human dose of 8 mg per day based on body surface area (mg/m2). Lactation Risk summary There are no data on the presence of perampanel in human milk, the effects on the breastfed child, or the effects of the drug on milk production. Perampanel and/or its metabolites are excreted in rat milk, and are detected at concentrations higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FYCOMPA and any potential adverse effects on the breastfed child from FYCOMPA or from the underlying maternal condition. Females and Males of Reproductive Potential Contraception Use of FYCOMPA may reduce the efficacy of hormonal contraceptives containing levonorgestrel. Advise women taking FYCOMPA who are using a levonorgestrel-containing contraceptive to use an additional non-hormonal form of contraception while using FYCOMPA and for a month after discontinuation. Pediatric Use The safety and efficacy of FYCOMPA for the treatment of partial-onset seizures in pediatric patients 12 years of age and older was established by three randomized double-blind, placebo-controlled, multicenter studies, which included 72 pediatric patients between 12 and 16 years of age exposed to FYCOMPA. The safety and efficacy of FYCOMPA for the adjunctive therapy of primary generalized tonic-clonic seizures in pediatric patients 12 years of age and older was established in a single randomized double-blind, placebo-controlled, multicenter trial (n=164), which included 11 pediatric patients 12 to 16 years of age exposed to FYCOMPA; an additional 6 patients were treated with FYCOMPA in the open label extension of the study. The safety and effectiveness of FYCOMPA in pediatric patients less than 12 years of age have not been established. Juvenile Animal Data Oral administration of perampanel (1, 3, 3/10/30 mg/kg/day; high dose increased on postnatal days [PND] 28 and 56) to young rats for 12 weeks starting on PND 7 resulted in reduced body weight, reduced growth, neurobehavioral impairment (water maze performance and auditory startle habituation) at the mid and high doses, and delayed sexual maturation at the high doses. CNS signs (reduced activity, incoordination, excessive grooming/scratching), pup death, decreased hindlimb splay, and decreased hindlimb grip strength were observed at all doses. Effects on pup body weight, pup growth, hindlimb splay, impairment in the water maze performance, and auditory startle persisted after dosing was stopped. A no-effect dose for postnatal developmental toxicity was not identified in this study. Oral administration of perampanel (1, 5,5/10 mg/kg/day; high dose increased on PND 56) to juvenile dogs for 33 weeks, starting on PND 42, resulted in CNS signs (incoordination, excessive grooming/licking/scratching, spatial disorientation, and/or ataxic gait) at all doses tested. Geriatric Use Clinical studies of FYCOMPA did not include sufficient numbers of patients aged 65 and over to determine the safety and efficacy of FYCOMPA in the elderly population. Because of increased likelihood for adverse reactions in the elderly, dosing titration should proceed slowly in patients aged 65 years and older. Hepatic Impairment Use of FYCOMPA in patients with severe hepatic impairment is not recommended, and dosage adjustments are recommended in patients with mild or moderate hepatic impairment. Renal Impairment Dose adjustment is not required in patients with mild renal impairment. FYCOMPA should be used with caution in patients with moderate renal impairment, and slower titration may be considered. Use in patients with severe renal impairment or patients undergoing hemodialysis is not recommended. DRUG ABUSE AND DEPENDENCE Controlled Substance FYCOMPA contains perampanel and is listed as a Schedule III controlled substance. Abuse Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological or physiological effects. Drug addiction, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and drug addiction are separate and distinct from physical dependence (for example, abuse may not be accompanied by physical dependence). Studies of human abuse potential were performed to evaluate the abuse potential of FYCOMPA (8 mg, 24 mg, and 36 mg) as compared to alprazolam C-IV (1.5 mg and 3 mg), and oral ketamine C-III (100 mg) in recreational polydrug users. Supra-therapeutic doses of FYCOMPA 24 and 36 mg produced responses for “Euphoria” that were similar to ketamine 100 mg and alprazolam 3 mg. For “High,” FYCOMPA 24 mg and 36 mg produced responses comparable to ketamine 100 mg and significantly higher than both doses of alprazolam on a visual analog scale (VAS). “Drug Liking,” “Overall Drug Liking,” and “Take Drug Again” for FYCOMPA were each statistically lower than ketamine 100 mg. In addition, for “Bad Drug Effects,” FYCOMPA 24 mg and 36 mg produced responses significantly higher than ketamine 100 mg. For “Sedation,” FYCOMPA 24 and 36 mg produced responses similar to alprazolam 3 mg and higher than ketamine 100 mg. Additionally, on VAS measures related to dissociative phenomena such as “Floating,” “Spaced Out,” and “Detached,” FYCOMPA at supra-therapeutic doses produced responses similar to ketamine 100 mg and greater than both doses of alprazolam tested. Of note, due to somnolence a number of subjects had missing data around Tmax of FYCOMPA. The above described data might represent an underestimate of FYCOMPA’s effects. The duration of effects of higher doses of FYCOMPA on the majority of measures was much greater than alprazolam 3 mg and ketamine 100 mg. In this study, the incidence of euphoria following FYCOMPA administration 8 mg, 24 mg, and 36 mg was 37%, 46%, 46%, respectively, which was higher than alprazolam 3 mg (13%) but lower than ketamine 100 mg (89%). Dependence Physical dependence is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. The potential for FYCOMPA to produce withdrawal symptoms has not been adequately evaluated. OVERDOSAGE There is limited clinical experience with FYCOMPA overdose. The highest reported overdose (approximately 264 mg) was intentional. This patient experienced serious adverse reactions of altered mental status, agitation, and aggressive behavior and recovered without sequelae. In general, the adverse reactions associated with overdoses were similar to the reactions at therapeutic doses with dizziness reported most frequently. There were no reported sequelae. There is no available specific antidote to the overdose reactions of FYCOMPA. In the event of overdose, standard medical practice for the management of any overdose should be used. An adequate airway, oxygenation, and ventilation should be ensured; monitoring of cardiac rhythm and vital sign measurement is recommended. A certified poison control center should be contacted for updated information on the management of overdose with FYCOMPA. Due to its long half-life, the reactions caused by FYCOMPA could be prolonged.

IMPORTANT SAFETY INFORMATION WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS • Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA • These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression • Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA • Closely monitor patients particularly during the titration period and at higher doses • FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening

SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS

SOMNOLENCE AND FATIGUE FYCOMPA caused dose-dependent increases in somnolence and fatiguerelated events. Somnolence was reported in 16% and 18% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 7% of placebotreated patients. Fatigue-related events were reported in 12% and 15% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 5% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase. These adverse reactions were also observed in the PGTC seizure clinical trial. Patients should be advised against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of FYCOMPA is known.

FALLS Falls were reported in 5% and 10% of patients in the partial-onset seizure clinical trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 3% of placebo-treated patients.

DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS)

In the partial-onset seizures clinical trials, hostility- and aggression-related adverse reactions occurred in 12% and 20% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. These effects in FYCOMPA-treated patients led to dose reduction, interruption, and discontinuation more frequently than placebo-treated patients. Homicidal ideation and/or threat have also been reported postmarketing in patients treated with FYCOMPA. The combination of alcohol and FYCOMPA significantly worsened mood and increased anger. Patients taking FYCOMPA should avoid the use of alcohol. Patients, their caregivers, and families should be informed that FYCOMPA may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least one month after the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases. Similar serious psychiatric and behavioral events were observed in the primary generalized tonic-clonic (PGTC) seizure clinical trial.

DRESS, also known as multiorgan hypersensitivity, has been reported in patients taking AEDs, including FYCOMPA. DRESS may be fatal or lifethreatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement. If signs or symptoms are present, immediately evaluate the patient and discontinue FYCOMPA if an alternative etiology for signs or symptoms cannot be established.

SUICIDAL BEHAVIOR AND IDEATION

FYCOMPA may decrease the efficacy of contraceptives containing levonorgestrel. Plasma levels of FYCOMPA were decreased when administered with moderate and strong CYP3A4 inducers, including, carbamazepine, phenytoin, or oxcarbazepine. Multiple dosing of FYCOMPA 12 mg per day enhanced the effects of alcohol on vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when FYCOMPA is used in combination with other CNS depressants.

Antiepileptic drugs (AEDs), including FYCOMPA, increase the risk of suicidal thoughts or behavior in patients. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, their caregivers, and families should be informed of the risk and advised to monitor and immediately report the emergence or worsening of depression, suicidal thoughts or behavior, thoughts about self-harm and/or any unusual changes in mood or behavior. Should suicidal thoughts and behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

DIZZINESS AND GAIT DISTURBANCE FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination. Dizziness and vertigo were reported in 35% and 47% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 10% of placebo-treated patients. Gait disturbance related events were reported in 12% and 16% of patients in the partial-onset seizure clinical trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 2% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase. These adverse reactions were also observed in the PGTC seizure clinical trial.

WITHDRAWAL OF AEDs A gradual withdrawal is generally recommended with AEDs to minimize the potential of increased seizure frequency, but if withdrawal is a response to adverse events, prompt withdrawal can be considered.

MOST COMMON ADVERSE REACTIONS The most common adverse reactions in patients receiving FYCOMPA (≥5% and ≥1% higher than placebo) include dizziness, somnolence, fatigue, irritability, falls, nausea, weight gain, vertigo, ataxia, headache, vomiting, contusion, abdominal pain, and anxiety.

DRUG INTERACTIONS

PREGNANCY AND LACTATION Physicians are advised to recommend that pregnant patients taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. Caution should be exercised when FYCOMPA is administered to pregnant or nursing women as there are no adequate data on the developmental risk associated with use in pregnant women, and no data on the presence of perampanel in human milk, the effects on the breastfed child, or the effects of the drug on milk production.

HEPATIC AND RENAL IMPAIRMENT Use in patients with severe hepatic or severe renal impairment is not recommended. Dosage adjustments are recommended in patients with mild or moderate hepatic impairment. Use with caution in patients with moderate renal impairment.

DRUG ABUSE AND DEPENDENCE FYCOMPA is a Schedule III controlled substance and has the potential to be abused and lead to drug dependence.

REFERENCE: 1. Data on file. Eisai Inc. Woodcliff Lake, NJ.

Please see Brief Summary of Prescribing Information on following pages. FYCOMPA® is a registered trademark of Eisai R&D Management Co., Ltd., licensed to Eisai Inc. ©2017 Eisai Inc. FYCO-US1140(1) October 2017

NOW APPROVED

FOR USE AS

MONOTHERAPY IN PARTIAL-ONSET SEIZURES

For patients with epilepsy 12 years of age and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures and adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures

NOW YOU CAN

HELP QUIET THE NOISE OF CONVULSIVE SEIZURES

FOR MORE OF YOUR PATIENTS

Prescribed for

100,000 PATIENTS1*†

Approved in

Available in

COUNTRIES1†

FORMULATIONS

Find out more at BOOTH 301 OR VISIT FYCOMPA.COM/HCP

Please see Important Safety Information, including a Boxed WARNING for Serious Psychiatric and Behavioral Reactions, on adjacent page. Please see Brief Summary of Prescribing Information on following pages.

* Worldwide figure for FYCOMPA® from 2012 through July 2017. Nearly 20,000 patients prescribed FYCOMPA in the United States. †Across different indications.

SPINE.qxp_Layout 1 10/31

AMERICAN EPILEPSY SOCIETY | 71ST ANNUAL MEETING | DECEMBER 1-5, 2017 | AESNET.ORG